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One of the pathological hallmarks of motor neuron death in Amyotrophic Lateral 
Sclerosis (ALS) is the abnormal accumulations of phosphorylated neurofilaments 
in the neuronal cell body. Previous reports suggested that Pin1, a prolyl-isomerase 
that catalyses the cis-trans isomerisation of the phosphorylated serine/threonine-
proline motifs, may be responsible for the aberrant accumulations of 
phosphorylated neurofilament heavy chain (p-NF-H) in neurons, which are 
observed during neurotoxicity. The aim of this thesis is to investigate the 
reduction of aberrant p-NF-H accumulations through knockdown of Pin1 activity 
using recombinant adeno-associated virus (AAV)-mediated transduction of Pin1 
shRNA in vivo in the G93A SOD1 ALS mouse model. This was achieved using 
the Pin1 shRNA construct, which showed effective and stable knockdown of Pin1 
in HEK 293T/17 cells and in primary neuronal cultures. To produce an in vivo 
gene delivery system into the spinal motor neurons by intramuscular route of 
administration, the transduction efficiencies of AAV serotypes 1, 2, 5, 6, 8 and 9 
were compared. AAV9 yielded the highest level of motor neuron transduction in 
the spinal cord and was used for Pin1 shRNA gene delivery. Accumulations of p-
NF-H in the spinal motor neurons of G93A SOD1 transgenic mice were observed 
prior to motor neuron cell death, astrocyte activation and behavioural deficits. 
This suggested that early prevention of p-NF-H accumulations may be beneficial. 
The spinal motor neurons transduced with AAV9-Pin1 shRNA showed significant 
reduction in aberrant p-NF-H accumulations indicating the Pin1 knockdown 
strategy may be of therapeutic potential in reducing the neurotoxic accumulations 
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Chapter 1 introduction 
 
1.1 PEPTIDYL-PROLYL ISOMERASE PIN1 
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) belongs to the 
parvulin subfamily of peptidyl-prolyl isomerases (PPIases) and has been reported 
to only specifically recognize phosphorylated Serine/Threonine-Proline 
(pSer/Thr-Pro) peptide sequences (Ranganathan et al., 1997; Yaffe et al., 1997). 
Serine or threonine residues that precede proline (Ser/Thr-Pro) are a major 
regulatory phosphorylation motif in cells, due to the unique stereochemistry of 
proline that enables the isomerisation of the peptidyl-prolyl peptide bonds into 
two completely different conformational states (Figure 1.1.1). The peptide bond 
of the prolyl residue in relation to an adjacent phosphorylated site in a native 
protein is able to adopt either the cis or trans state of the backbone torsion angle, 
due to its unique five-carbonyl ring structure in the peptide backbone (Lu and 
Zhou, 2007).  
 
PPIases are ubiquitously expressed enzymes that catalyse the cis/trans 
isomerisation of certain peptidyl-prolyl peptide bonds. The human PPIase, Pin1 
was originally identified in 1996 by its ability to interact with and attenuate the 
mitosis-promoting activity of Never-In-Mitosis A (NIMA), a mitotic kinase that is 
phosphorylated on multiple Ser/Thr-Pro motifs during mitosis (Lu et al., 1996). 
The human Pin1 protein is a nuclear polypeptide of 163 amino acid residues in 
length with a molecular weight of 18,000 Daltons (Lu et al., 1996). Pin1 has been 
reported to be highly evolutionarily conserved with the human Pin1 amino acid 
sequence sharing 95% similarity to the respective mouse homologue, 89% 
homology to Xenopus Pin1 and 53% homology to the plant Pin1 At (Fujimori et 
al., 1999; Landrieu et al., 2000; Winkler et al., 2000; Lu et al., 1996). Pin1 
contains two domains: the N-terminal WW domain acts as the phosphoprotein-
binding module, which targets Pin1 to the specific pSer/Thr-Pro motifs of its 
substrates in different sub-cellular compartments, and a C-terminal catalytic 
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(PPIase) domain that isomerizes specific pSer/Thr-Pro motifs to regulate protein 
function of a defined subset of phosphoproteins by controlling their 
conformations (Lu et al., 1999a; Yaffe et al., 1997; Zhou et al., 2000).  
 
1.1.1 CHARACTERIZATION OF PIN1 ACTIVITY 
Typically, though the pSer/Thr-Pro peptide bond is preferentially in the more 
stable trans conformation, the energetically less favourable cis conformation 
exists at a level of ~10-20% physiologically, as a result of spontaneous 
isomerisation (Zhou et al., 2000; Schutkowski et al., 1998). Rotation around 
prolyl peptide bond is energetically unfavourable due to the partial double-bond 
character, which requires a ~22 kcal/mol energy barrier for rotation (Ranganathan 
et al., 1997). Regulation of the signalling cascades of many proline-directed 
kinases and phosphatases is critically dependent on the conformational state of the 
prolyl-peptide bond (Brown et al., 1999; Weiwad et al., 2000). For many 
biological processes, the cis and trans isomer inter-conversion is a major rate-
limiting step, which would require many minutes without a PPIase. Additionally, 
phosphorylation of the Ser/Thr-Pro bonds causes the prolyl-peptide bond to be 
resistant to the conventional PPIases as well as further delays the isomerisation 
rate of the Ser/Thr-Pro bonds (Lu and Zhou 2007; Yaffe et al., 1997). For the 
regulation of dynamic biological processes on the millisecond timescale, Pin1 
function is required to maintain the cis and trans isomer equilibrium of the 
pSer/Thr-Pro peptide bond in the targeted proteins (Lu and Zhou 2007). 
 
Given the tight regulation of Pro-directed phosphorylation signalling and the 
diverse cellular processes that Pin1 is involved in, it is regulated firstly by the 
availability of its substrates, where Pin1 recognizes only specific pSer/Thr-Pro 
motifs with a ~1300 fold preferential selectivity compared to non-phosphorylated 
peptides (Yaffe et al., 1997; Lu and Zhou, 2007). Pin1 is also regulated at the 
transcriptional and post-translational levels, where at the transcriptional level, 
Pin1 expression is mediated by the transcription factor E2F and enhanced by c-
Neu and Ha-Ras via E2F (Ryo et al., 2002). Multiple post-translational 
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modifications also tightly regulate Pin1, for e.g. phosphorylation on Ser16 in the 
Pin1 WW domain disrupts Pin1 substrate interaction, phosphorylation of Pin1 on 
Ser71 by Death-associated protein kinase 1 (DAPK1) fully inactivates Pin1 
catalytic activity and inhibits its nuclear location, while phosphorylation on Ser65 
in Pin1 by Polo-like kinase 1 (PLK1) would reduce its ubiquitylation hence 
increasing Pin1 protein stability (Lu et al., 2002; Lee et al., 2011b; Eckerdt et al., 
2005).  
 
Pin1 activity has to be tightly regulated as its deregulation has been reported to 
contribute to a variety of human diseases such as cancer, aging, 
neurodegeneration, autoimmune, microbial infections (Lu and Zhou 2007; Lee et 




Figure 1.1.1 Cis-Trans isomerisation of pSer/Thr-Pro peptide bonds by the 
PPIase, Pin1. Pin1 contains a WW and a catalytic domain enabling it to bind to 
target proteins with phosphorylated Ser/Thr-Pro sites causing the cis and trans 
isomerization of the prolyl bond resulting in altered function, stability and/or 
intracellular localization. 
 
1.1.2 BIOLOGICAL FUNCTIONS OF PIN1 
The diverse interaction of Pin1 with a variety of key proteins revealed that it 
regulates a spectrum of activities such as the cell growth, telomere regulation and 
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aging, cellular stress, immune responses, microbial infections, germ cell 
development as well as neuronal function and survival, (Lu and Zhou 2007; Liou 
et al., 2011; Lu 2004). Unlike other PPIases, Pin1 only acts when the substrate is 
phosphorylated and accelerates its cis/trans isomerisation. Therefore Pin1 activity 
is crucial in the regulation of many proline-directed kinases and phosphatases 
which are conformation-specific to the trans conformation (Rudrabhatla et al., 
2008). 
 
1.1.2.1 Pin1 and the coordination of the cell cycle 
Driving of cells through the different cell cycle phases is tightly controlled by the 
timely activation and inactivation of various Ser/Thr-Pro directed cylin-dependent 
kinases (Lu and Zhou 2007; Nigg 2001). The function of Pin1 as the PPIase 
targeting pSer/Thr-Pro sites, has garnered much attention due to its role in the cell 
cycle progression. Pin1 has been suggested to modulate the G2/M transition of the 
cell cycle, where it has been reported to suppress premature mitotic entry induced 
by the NIMA kinase, and that overexpression of Pin1 in HeLa cells induces G2 
arrest (Lu et al., 1996). Phosphorylated mitotic regulators, including Cdc25, 
Myelin transcription factor 1 (Myt1), Wee1, PLK1, and Cdc27, have been 
recognized as Pin1-binding substrates  (Shen et al., 1998).  Pin1 has been reported 
to inhibit or increase the activity of Cdc25, which is the activating phosphatase of 
the Cdc2-Cyclin B complex that is required for the entry into the mitotic phase 
depending on the phosphorylation state of Cdc25 (Shen et al., 1998; Stukenberg 
and Kirschner, 2001). Pin1 may control the cell cycle checkpoint by modulation 
of Cdc25 activity, which regulates the Cdc2-Cyclin B activation, a key regulator 
of mitosis (Winkler et al., 2000). In Xenopus laevis, Pin1 has been shown to bind 
to Wee1, the inhibitory kinase of Cdc2-Cyclin B, resulting in the Wee1 catalytic 
inactivation at M phase of the mitotic cell cycle (Okamoto and Sagata, 2007). 
Furthermore, Pin1 has been reported to protect Early mitotic inhibitor-1 (Emi1) 
from degradation by inhibiting its association with Skp1-Cul1-Fbox protein 
(SCF)βtrcp, thus inducing the S phase and M phase entry by driving Cyclin A and 
Cyclin B accumulation (Bernis et al., 2007). Evidence has been shown that the 
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Pin1 localization to chromatin is elevated in the G2-M phase and this correlates 
with the presence of several mitotic phosphoproteins, such as Topoisomerase 2 
and the condensin complex on the chromosome which play central roles in 
chromosome condensation (Xu and Manley, 2007).  The authors suggested that 
since Pin1 enhances Topoisomerase 2 phosphorylation by Cdc2-Cyclin B, it 
likely changes the functional specificity of TopoII from S phase DNA 
replication and/or transcription to G2/M phase DNA binding and chromosome 
condensation indicating that Pin1 plays an important role in mitotic chromosome 
condensation (Xu and Manley, 2007). 
 
One of the initial studies on the role of Pin1 in cell cycle entry revealed that 
Pin1−/− mouse embryonic fibroblasts (MEF)  cells were defective in re-entering 
the cell cycle after G0 arrest (Fujimori et al., 1999). Since then, many other 
studies have collectively reported the crucial role of Pin1 in the modulation of the 
G0/G1‐S transition during cell cycle. The Cyclin E/Cyclin dependent kinase 
(Cdk)-2 complex plays a crucial role in the G1-S phase transition, where it 
promotes entry into the S phase, and deregulation of Cyclin E has been reported 
to impair DNA synthesis and the progression of the cell cycle through the S phase 
(Ekholm-Reed et al., 2004). Pin1 regulates the turnover of Cyclin E, where Pin1-/- 
MEF showed higher levels of Cyclin E resulting in the impairment of the 
progression through the G1-S phase as well as a longer cell doubling time (Yeh et 
al., 2006). The enhanced transcription and stability of the key regulator of the G1-
S phase, Cyclin D1 is regulated by Pin1 through various mechanisms, e.g. 
activation of the -catenin/T-cell transcription factor (TCF) signalling pathway, 
cooperation with Ras or c-Jun N-terminal kinase (JNK) signalling to increase c-
Jun transcriptional activity and enhancement of nuclear factor (NF)-B 
transcription activity (Hinz et al., 1999; Ryo et al., 2001; Wulf et al., 2001; Ryo et 
al., 2003). In addition, Pin1 positively regulates Cyclin D1 by directly binding to 
it, thereby indicating the essential role of Pin1 in cell proliferation and modulation 
of Cyclin D1 function (Liou et al. 2002; Lu and Zhou 2007). In fact, Pin1−/− mice 
were reported to have significantly reduced Cyclin D1 levels as well as 
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phenotypes resembling that of Cyclin D1−/− mice, such as mammary gland 
impairment during pregnancy, decreased body weight and retinal atrophies (Fantl 
et al., 1995; Liou et al., 2002). 
 
1.1.2.2 Pin1 role in oncogenesis 
Many of the proteins involved in the cell cycle have also been investigated for 
tumourigenic properties.  For example, Cyclin D1, one of the binding substrates 
of Pin1, upon deregulation has been linked to the development and progression of 
cancer (Biliran et al., 2005; Alao, 2007). Similarly, the role of Pin1 in 
oncogenesis has been widely studied in order to further understand its role in 
cancer, as well as for the development of tumour suppressor therapy. Pin1 
upregulation has been reported in various human cancers, such as prostate, lung, 
ovary, cervical, brain tumours, melanoma, liver and breast cancers, thereby 
indicating the pivotal role of Pin1 in multiple oncogenic signal pathways (Lu and 
Zhou 2007; Bao et al., 2004; Wulf et al., 2001; Ryo et al. 2001; Ryo et al. 2003; 
Ayala et al., 2003; Pang et al., 2004). The deregulation of the E2F/Rb pathway 
has been reported in many cancers, due to its role in controlling cell growth 
(Nevins, 2001). Pin1 expression is mediated by E2F and enhanced by oncogenic 
Neu and Ras signalling, therefore resulting in the transformed phenotype on 
mammary epithelial cells (Ryo et al. 2002). Interestingly, inhibition of Pin1 
suppresses the transformed phenotypes of mammary epithelial cells induced by 
Neu and Ras, which can be reversed by overexpression of Cyclin D1. Pin1 
ablation was able to prevent oncogenic Neu or Ras from inducing Cyclin D1 and 
breast cancer in the Pin1−/− mice (Wulf et al., 2004). The results indicate the 
specificity of Pin1 action in oncogenic pathways, where Pin1 mediates Neu/Ras 
signalling through the activation of Cyclin D1 during breast cancer formation 
(Ryo et al. 2002; Nevins 2001). Pin1-mediated regulation of the Neu/Ras 
signalling pathway can lead to the activation of various downstream genes that 
promote oncogenic transformation. For example, Pin1 is required for the 
recycling of Raf1, the downstream effector of Ras signalling cascade which is 
involved in oncogenic transformation (Stanton et al., 1989; Heidecker et al., 1990; 
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Dougherty et al., 2005). Recently it was reported that induction of the HER-2 
oncogene, which is overexpressed in many cancers, is regulated by Pin1 via its 
interaction with Mitogen-activated protein kinase (MAPK)/Extracellular signal-
regulated kinase (ERK) protein kinase 1 (MEK1) (Khanal et al., 2010). MEK1 is 
part of the Ras-Raf-MEK-ERK pathway, which is involved in malignant 
phenotypes that include abnormal cell growth, invasion, and angiogenesis 
(Khanal et al. 2010; Thompson and Lyons 2005).  
 
Upregulation of Pin1 by oncogenes results in a signalling cascade for the 
progression of downstream cell cycle events that would lead to malignant cell 
growth (Suizu et al., 2006; Lu and Zhou, 2007). Pin1 overexpression is associated 
with centrosome amplification in human breast cancer tissue and that Pin1 
overexpression in MEF cells, results in chromosome misaggregation, aneuploidy, 
and transformation (Suizu et al., 2006). However there have been discrepancies 
with regards to the role of Pin1 in oncogenesis, which might be attributed to the 
different models used or cancer types investigated. This is likely due to the 
diverse repertoire of substrates that interact with Pin1; therefore, its ability to 
enhance or inhibit tumour formation depends on various conditions or the genetic 
modifiers involved. For example, although Pin1 was found to be upregulated in 
breast tumours and its overexpression enhanced the transformation of mammary 
epithelial cells, however Pin1 expression was under-expressed in certain cancers 
such as kidney cancer and restoration of Pin1 in renal cell carcinoma attenuated 
cell growth (Ryo et al., 2002; Teng et al., 2011; Bao et al., 2004). In in vitro 
studies involving breast, prostate and liver cancer cells, Pin1 overexpression was 
shown to stabilize -catenin, hence increasing the transcription of several -
catenin target genes including those encoding Cyclin D1 and c-myc, which are 
critical for the development of cell transformation and cancer (Ryo et al., 2001; 
Pang et al., 2004; Chen et al., 2006; Lu and Zhou, 2007). However in Pin1-/- 
studies, the c-myc and Cyclin E1 levels were found to be stabilized in Pin1-/- MEF 
cells, which led to cell cycle defects resulting in the sensitized immortalized Pin1-
/- cells to more extensive and aggressive transformation and tumourigenesis 
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induced by the Ras oncogene (Yeh et al., 2004; Yeh et al., 2006; Lu and Zhou, 
2007). Therefore the role of Pin1 as a tumour suppressor requires critical analysis 
on its role in both in vitro and in vivo in specific cancer models as well as 
investigation on the effect of its inhibition on the various Pin1 substrates 
involved. 
 
1.1.2.3 Pin1 regulation of cellular stress 
Several of the key proteins involved during cellular stress responses have been 
shown to be regulated by Pin1 (Lu and Zhou 2007). One such example is the 
regulation of p53, which plays a crucial role in the DNA damage-induced 
checkpoint pathway (Liou et al 2011). The tumour suppressor p53 is triggered 
upon various cellular stresses resulting in either the arrest of cell cycle 
progression or apoptosis (Lakin and Jackson, 1999). p53 stability and activity 
have been shown to be regulated by post-translational modifications and 
associations with other proteins (Sionov and Haupt, 1999; Zacchi et al., 2002). 
During DNA damage, Pin1 binding of p53 is enhanced resulting in increased p53 
stability, increased DNA-binding activity and transactivation function of p53, 
thereby promoting cell cycle arrest and apoptosis (Wulf et al., 2002; Zacchi et al., 
2002; Zheng et al., 2002; Mantovani et al., 2007). UV-treated Pin1-/- cells failed 
to efficiently stabilize p53, which was unable to effectively dissociate from the 
MdmM2 and was then able to escape cell cycle arrest and apoptotic responses 
(Zacchi et al., 2002; Zheng et al., 2002). Another report found that upon 
phosphorylation of p53 at Ser46 triggered by cytotoxic stimuli, Pin1 mediates the 
dissociation of p53 from the apoptosis inhibitor: Inhibitory member of the 
apoptosis-stimulating proteins of the p53 Family (iASPP), thereby promoting 
cellular apoptosis (Mantovani et al., 2007). Pin1 has also been reported to regulate 
the mitochondrial translocation of growth factor adaptor Shc (p66Shc) in response 
to oxidative damage (Pinton et al., 2007). p66Shc is involved in the translation of 
oxidative damage into cell death via the production of reactive oxygen species 
within mitochondria, as well as in the regulation of stress apoptotic responses and 
life span (Migliaccio et al., 1999). Under oxidative conditions in the cell, protein 
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kinase C  is activated and induces phosphorylation of p66Shc (Pinton et al., 
2007). Pin1 binds with phosphorylated p66Shc and triggers its mitochondrial 
accumulation resulting in alterations of the mitochondrial three-dimensional 
structure and Ca2+ responses, thus inducing apoptosis (Pinton et al., 2007). 
 
1.1.2.4 Pin1 in germ cell development 
Initial reports on the Pin1-/- mice showed that Pin1 is highly expressed in the testis 
and that the mice developed age-dependent testicular atrophy and fertility defects, 
indicating that Pin1 may have a role in spermatogenesis (Liou et al., 2002). The 
role of Pin1 in the development of germ cells was previously confirmed, whereby 
a progressive and age-dependent degeneration of the spermatogenic cells was 
observed in Pin1−/− testis (Atchison and Means, 2003). It has since been reported 
that the male and female Pin1-/- mice are born with reduced gonocytes and 
oocytes, which have been attributed to the prolonged cell cycle of their primordial 
germ cells (Atchison et al., 2003). Therefore Pin1 is not only required for normal 
fertility, but also for primordial germ cell development during mouse 
embryogenesis (Atchison et al. 2003). 
 
1.1.2.5 Role of Pin1 in telomere regulation and ageing 
Telomeres consist of repetitive nucleotide sequences that cap the ends of 
eukaryotic chromosomes, thereby protecting the ends of the chromosome from 
degradation and end fusion with neighbouring chromosomes (Rodier et al., 2005). 
Telomeres are crucial for maintaining the cellular proliferative capacity and 
telomere shortening that has been shown in ageing and in a number of age-related 
pathologies for e.g. atherosclerosis and Alzheimer’s disease (Samani et al., 2001; 
Cawthon et al., 2003; Panossian et al., 2003; Blasco, 2007). One of the major 
contributors to telomere length preservation is the telomere DNA-binding protein, 
Telomeric Repeat-Binding Factor 1 (TRF1) (Lee et al., 2009). Pin1 interacts with 
the conserved phosphorylated Thr149-Pro motif in TRF1 and regulates its 
stability, whereby Pin1 inhibition renders TRF1 resistant to protein degradation, 
enhances TRF1 binding on telomeres, leading to gradual telomere shortening and 
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a range of premature aging phenotypes in the Pin1−/− mice (Lee et al., 2009). 
These findings indicate that Pin1 plays a role in regulating the TRF1 stability, 
telomere maintenance and ageing (Lee et al., 2009).  
 
1.1.2.6 Pin1 modulation of the immune response 
One of the key players in the T cell activation, Nuclear factor of activated T cells 
(NFAT) is negatively regulated by Pin1, which inhibits the dephosphorylation of 
NFAT by calcineurin and thus possibly affecting the activation state and the 
subcellular localization of NFAT (Liu et al., 2001). Furthermore, it has been 
reported that Pin1 mediated the post-transcriptional regulation of Th1 cytokines 
by activated T cells and that ablation of Pin1 greatly attenuated Interferon (IFN)-
c, Interleukin-2 (IL-2) and C-X-C motif chemokine (CXCL)-10 mRNA stability, 
accumulation and protein expression after cell activation (Esnault et al., 2007b). 
Additionally, Pin1 has also been shown to be involved in B cell development and 
maturation by negatively regulating the turnover of Bruton Tyrosine Kinase 
(BTK), a non‐receptor tyrosine kinase expressed in B-lymphocytes (Yu et al., 
2006). It has been noted that during genotoxic stress, Pin1 is crucial for the 
degradation of the anti-apoptotic B-cell lymphoma protein (BCL)-6, a 
transcription factor required for the formation of germinal center B cells (Phan et 
al., 2007).  
 
Several studies have investigated the role of Pin1 in regulating activation and 
survival of eosinophil granulocytes, important mediators of allergic responses and 
asthma pathogenesis (Esnault et al., 2007a; Shen et al., 2008; Shen et al., 2009). 
Two publications have both reported that blockade of Pin1 in a rat asthma model 
selectively reduced eosinophilic pulmonary allergic inflammation (Esnault et al., 
2007; Shen et al., 2008). Pin1 inhibition was reported to attenuate the production 
of Granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-5, which 
are responsible for eosinophil survival, maturation and function (Esnault et al., 
2007b). Transforming growth factor (TGF)-β1, a critical determinant of 
pulmonary immunity and fibrosis is effectively inhibited when Pin1 levels are 
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reduced thereby attenuating airway fibrosis in allergen-challenged animals (Shen 
et al., 2008). In the absence of GM-CSF or IL-5, the pro-apoptotic BCL-2-
associated X protein (BAX) spontaneously undergoes activation and initiates 
mitochondrial disruption (Shen et al., 2009). Pin1 was reported to inhibit BAX 
activity downstream of cytokine signalling, thereby facilitating cytokine-induced 
survival of eosinophils that occurs after allergen challenge (Shen et al., 2009). 
 
1.1.3 Role of Pin1 in neurons 
Pin1 is highly expressed in neurons, where it mainly localizes to neuronal nuclei 
in normal human neurons and its expression increases during neuronal 
differentiation (Lu et al., 1999b; Hamdane et al., 2006). In fact, Pin1 regulates 
several proteins that are crucial for neuronal function and survival such as Pin1-
induced conformational changes on gephyrin to promote its binding to 
components of motor protein complexes, facilitating the delivery of glycine 
receptors to the cell surface (Zita et al., 2007). Pin1 has been described to promote 
the neuronal mitochondrial apoptotic machinery (Becker and Bonni, 2007; 
Behrens et al., 2009). Pin1 interacts with the JNK scaffold protein, JNK-
interacting protein 3 (JIP3) in the mitochondrial membrane of neurons and upon 
activation of the JNK signalling, Pin1 dissociates from JIP3 and binds to the 
phosphorylated BCL-2 mediator of cell death-extra long (BimEL), which results 
in the stabilisation of BimEL and activation of apoptosis indicating the 
importance of Pin1 in neuronal survival (Becker and Bonni, 2006). Furthermore, 
upregulation of Pin1 was found to positively regulate caspase-dependent death of 
nerve growth factor (NGF)-maintained neurons that is associated with an 
accumulation of Ser (63)-phosphorylated c-Jun in neuronal nuclei and is partially 
dependent on BAX. However, reduction of Pin1 prior to NGF withdrawal 
suppresses the accumulation of phosphorylated c-Jun, inhibits the release of 






1.1.4 Pin1 in neurodegeneration 
There have been many studies that have reported the role of Pin1 in age-
dependent neurodegeneration in diseases such as Alzheimer’s Disease (AD), 
Parkinson’s Disease (PD) and more recently in Amyotrophic Lateral Sclerosis 
(ALS).  
 
1.1.4.1 Alzheimer’s Disease 
AD is the most common cause of dementia, accounting for 60-80% of cases. The 
clinical features of AD include significant loss of cognitive function, such as, 
impairment of memory, language, judgment, perception and reasoning as well as 
disorientation, behavioural changes and difficulty in execution of motor activities. 
Neuropathological hallmarks of AD consist of the intracellular neurofibrillary 
tangles and extracellular senile plaques that comprised amyloid  (A peptides, 
which are derived from amyloid precursor protein (APP) (Serrano-Pozo et al., 
2011). Neurofibrillary tangles consist of the hyperphosphorylated microtubule-
associated protein tau, whereas phosphorylation of APP on the Thr668-Pro motif 
was found increased in AD brains suggesting that abnormal phosphorylation as 
one of the common features between the neuropathologies (Morishima-
Kawashima et al., 1995; Lee et al., 2001; Lee et al., 2003; Lee and Tsai, 2003; Lu 
and Zhou, 2007). Since proline-directed phosphorylation has been identified as a 
common link in both tangle and plaque pathology, the role of Pin1 in AD has 
been extensively investigated (Figure 1.1.2) (Lu et al., 2003a; Lu and Zhou, 
2007). Additionally, a late-onset familial AD gene has been located on 
chromosome 19p13.2, where the Pin1 gene is also located (Campbell et al., 1997; 
Wijsman et al., 2004; Lu and Zhou, 2007). The neurofibrillary pathology in AD 
has been shown to have differential vulnerabilities to neurons in different 
subregions of the hippocampus and neocortex (Davies et al., 1992; Liou et al., 
2003). Pin1 expression was found inversely correlated with the predicted neuronal 
vulnerability and actual neuronal degeneration in AD, i.e. subregions with low 
expression of Pin1 were known to be prone to neurofibrillary degeneration in AD 
(Liou et al., 2003). Pin1 downregulation in vulnerable brain regions found in AD 
13 
 
could be a result of Pin1 inactivation by oxidative modification, since Pin1 
activity is susceptible to oxidation during the early stages of AD or as a result of 
Pin1 sequestration in the neurofibrillary tangles (Lu et al., 1999b; Butterfield et 
al., 2006; Sultana et al., 2006; Lu and Zhou, 2007). The tau- and A- pathologies 
observed in the Pin1−/− mice resemble many aspects of neuropathology observed 
in human AD (Liou et al. 2011). Pin1-/- mice show progressive age-dependent 
neuropathy, characterized by motor and behavioural deficits as well as 
pathologically by neurofibrillary tangle (NFT) formation, neuronal degeneration, 
increased amyloidogenic APP processing and elevated insoluble A42 levels 
(Liou et al., 2003; Pastorino et al., 2006).  
(Lu and Zhou, 2007). 
 
 
Figure 1.1.2 Pin1 regulation of tau function and APP processing in healthy 
and AD neurons. Pin1 promotes the normal neuronal function by controlling the 
function of the target proteins that are phosphorylated at the Ser/Thr-Pro sites by 
protein kinases (PK). In healthy neurons (blue region), Pin1 catalyzes the 
isomerisation of cis to trans conformation of these phosphorylation sites in APP 
and tau thus promoting non-amyloidogenic APP processing and reduction of Aβ 
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production, as well as promote tau dephosphorylation and restoration of tau 
function. However in AD, the loss of Pin1 function (red region) could possibly 
lead to the accumulation of the cis-pSer/Thr-Pro motifs in APP resulting in 
amyloidogenic processing of APP, build-up of amyloid β‑42 (Aβ42) and 
eventually the formation of amyloid plaques. Additionally cis-pSer/Thr-Pro 
motifs in tau would lead to hyperphosphorylation of tau, which is resistant to 
dephosphorylation by phosphatases (PPases) and results in a loss of microtubule 
(MT) binding, which then induces the formation of neurofibrillary tangles. The 
formation of tangles and plaques might then further inhibit Pin1 function by 
sequestering Pin1 and inducing its oxidative modifications, hence leading to a 
positive feedback loop. Therefore, Pin1 deregulation might act via multiple 
mechanisms in neurodegeneration. 
 
Pin1 has been proposed to regulate APP processing, whereby Pin1 was found to 
bind to the phosphorylated Thr668-Pro motif in APP and accelerated its 
isomerisation, regulating the APP intracellular domain between two 
conformations (Pastorino et al., 2006). Phosphorylation has been shown to act as 
a conformational switch by shifting the APP trans to cis form due to local 
structural constraints (Ramelot and Nicholson, 2001). One report hypothesized 
that phosphorylation of Thr668-Pro acts as a conformational switch to the cis 
form that may favour amyloidogenic APP processing, whereas Pin1 isomerisation 
of APP to the trans conformation may favour non-amyloidogenic APP 
processing, therefore reducing A production (Pastorino et al., 2006). Pin1 
overexpression has been reported to reduce A secretion in cell cultures, whereas 
Pin1−/− cells secrete higher A secretion (Pastorino et al., 2006). Pin1−/− mice 
alone or crossed with APP overexpressing mutant mice was reported to have 
increased amyloidogenic APP processing and age-dependent selective increase in 
insoluble A42 (Pastorino et al., 2006). The inactivation of Pin1 as mentioned 
above, could render Pin1 unavailable to catalyze the isomerisation of APP, 
resulting in amyloidogenic APP processing and Asecretion (Lu and Zhou, 
2007). However, a study conducted using a “knock-in” mice, in which the Thr668 
in the wild-type (WT) APP protein was substituted with a non-phosphorylatable 
alanine residue replacing the threonine residue present, resulted in no significant 
changes in APP or A levels and subcellular distributions indicating that 
phosphorylation at Thr668 may not be the only site responsible for the regulation 
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of Alevels  (Sano et al., 2006). Recently it was published that Pin1 promotes 
APP turnover by inhibiting glycogen synthase kinase-3 (GSK3) activity (Ma et 
al., 2012). In AD brains and other tauopathies, Pin1 was found to be sequestered 
to the neurofibrillary tangles, resulting in depletion of soluble Pin1 (Lu et al., 
1999b; Thorpe et al., 2001; Ramakrishnan et al., 2003). Pin1 was reported to 
catalyze the isomerisation of the pThr231-Pro motif in tau to facilitate 
dephosphorylation by protein phosphatase 2 A (PP2A) (Zhou et al., 2000). 
Additionally overexpression of Pin1 promotes degradation of WT tau, while 
ablation of Pin1 increases protein stability and accumulation of tau i.e. enhancing 
the possibility of tau hyperphosphorylation and accumulation (Liou et al 2011; 
Lim et al., 2008). One study suggested that Pin1 plays a role in promoting tau 
binding to microtubules, thus restoring the function of hyperphosphorylated tau 
and permitting polymerization of tubulin into microtubules (Lu et al., 1999b). A 
recent publication showed that Pin1 binds and stimulates dephosphorylation of tau 
at the hyperphosphorylated Cdk5-mediated Alzheimer phosphorylation sites 
(Kimura et al., 2013). Additionally, the authors had reported that Tau carrying the 
Frontotemporal dementia with parkinsonism-17 (FTDP-17) mutation P301L or 
R406W had slightly weaker binding to Pin1 than WT tau, suggesting that FTDP-
17 mutations induced tau hyperphosphorylation by impairment of its interaction 
with Pin1 (Kimura et al., 2013). From the studies on the role of Pin1 in AD, it 
appears that Pin1 is neuroprotective against the disease pathology and 
progression. 
 
1.1.4.2 Parkinson’s Disease 
PD is a relatively common neurodegenerative disorder with early symptoms 
showing motor impairment such as, tremors, rigidity, postural instability, 
bradykinesia and akinesia. Other non-motor related clinical features include 
autonomic dysfunction, dementia, neuro-psychiatric problems, sleep and sensory 
abnormalities. PD is characterized by the preferential loss of dopaminergic 
neurons in the substantia nigra as well as the formation of Lewy bodies and 
cytoplasmic inclusions containing aggregates of -synuclein in the surviving 
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neurons (Lotharius and Brundin, 2002; Liou et al., 2011). Pin1 was shown to 
localize to the Lewy bodies in PD brain tissue and it binds to synphilin-1, 
enhancing the interaction between synphilin-1 and -synuclein thus facilitating 
the formation of -synuclein inclusions, indicating that Pin1 activity could be 
responsible for the pathogenic mechanisms in PD (Ryo et al., 2006).  
 
1.1.4.3 Amyotrophic Lateral Sclerosis  
ALS is a motor neuron disease with the defining pathology of motor neuron death 
in the motor cortex of the brain, the brain stem, and the spinal cord. A previous 
study had described that in ALS spinal cords, Pin1 co-localises with 
phosphorylated neurofilament heavy chain (p-NF-H) in the ventral horn region 
and that in a cellular excitotoxic model, knockdown of Pin1 levels could reduce 
the p-NF-H accumulations (Kesavapany et al., 2007). The authors then 
hypothesized that the presence of Pin1 facilitates the accumulation of p-NF-H in 
the spinal cord of ALS patients, which is one of the key pathological events in 
ALS (Kesavapany et al., 2007; Manetto et al., 1988; Mizusawa et al., 1989; 
Munoz et al., 1988). The role of Pin1 in p-NF-H accumulations is further 
described in Section 1.3.2.3. However, the role of Pin1 in ALS has not been 
widely studied since and whether it promotes or inhibits disease progression had 














1.2 AMYOTROPHIC LATERAL SCLEROSIS 
ALS, also known as Lou Gehrig’s disease and motor neuron disease, is a 
progressive and lethal neurodegenerative disorder that is characterized by the 
death of lower motor neurons in the brainstem and spinal cord, and the upper 
motor neurons in the motor cortex, leading to paralysis of voluntary muscles 
(Ferraiuolo et al., 2011a). The muscles that control eye movement and the urinary 
sphincters are however, not affected, and death is caused by respiratory failure 
which occurs within five years of diagnosis (Pasinelli and Brown, 2006). The 
worldwide incidence of ALS is approximately two per 100,000 individuals with 
the mean age of disease onset at 55-60 years old (Ferraiuolo et al., 2011a). There 
is currently no primary therapy for ALS, and the current available drug is rizuole 
which only mildly prolongs survival without any improvement in symptoms. The 
pathological hallmark for ALS includes atrophy of motor neurons, swelling of the 
perikarya and proximal axons, accumulation of phosphorylated neurofilaments, 
Bunina bodies and Lewy body-like inclusions, and the deposition of inclusions 
(spheroids) and strands of ubiquitinated material in the axons. Other pathological 
hallmarks include activation and proliferation of astrocytes and microglia 
(Pasinelli and Brown, 2006). Though the motor neurons tend to be affected the 
earliest and most severely, a previous report demonstrated degeneration in the 
substantia nigra and pathological changes in the hippocampal dentate granule 
cells, therefore ALS may be regarded as a multisystem disorder (Ota et al., 2005; 
Ferraiuolo et al., 2011a).  
 
1.2.1 FAMILIAL ALS 
Most ALS cases are classified as sporadic ALS (sALS), with no apparent genetic 
linkage, while 5-10% of cases of autosomal dominant inheritance, also known as 
familial ALS (fALS). In fALS, there have been several gene defects that have 
been reported: superoxide dismutase (SOD1), alsin, senataxin (SETX), 
synaptobrevin/vesicle-associated membrane protein (VAMP)-associated protein B 
(VAPB) and dynactin (Rosen, 1993; Chance et al., 1998; Hadano et al., 2001; 
Yang et al., 2001; Puls et al., 2003; Chen et al., 2004; Nishimura et al., 2004; 
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Pasinelli and Brown, 2006). SOD1 mutations account for approximately 20-25% 
of fALS cases and more than 150 mutations have been identified (Pasinelli and 
Brown, 2006). Most SOD1 mutations are dominantly inherited, where mutation in 
a single copy of the gene is sufficient to cause the disease. The SOD1 enzyme is 
crucial in the conversion of superoxide, a by-product of mitochondrial respiration, 
to water and hydrogen peroxide. Each subunit of SOD1 binds to one zinc and one 
copper atom, which it requires to facilitate the dismutase function. Since the 
clinical and pathological profiles of sALS and fALS are rather similar, models 
representing fALS (in particular with the SOD1 mutations), are widely used to 
investigate the pathology of sALS. Early studies showed that in fALS patients, 
there is a loss of SOD1 enzymatic activity (Deng et al., 1995; Orrell et al., 1995). 
However, contrary to earlier studies, it was reported that despite having normal 
SOD1 activity, the expression of the ALS-associated mutant SOD1 protein in the 
transgenic mice resulted in the progression of ALS disease pathology, indicating 
that the neurodegenerative disorder does not result from a diminution of SOD1 
activity but represents a dominant "gain-of-function" mutation (Gurney et al., 
1994; Ripps et al., 1995; Bruijn et al., 1997b). This was supported in a study that 
had shown normal development with no motor deficits or pathology in SOD1 
deficient mice (Reaume et al., 1996). Recently, there have been several studies 
that have demonstrated that there are several genes involved in sALS as well, 
such as, inositol 1,4,5-triphosphate receptor 2 (ITPR2) and dipeptidyl peptidase 6 
(DPP6) (van Es et al., 2007; van Es et al., 2008; Ferraiuolo et al., 2011a). The 
association of sALS has been shown with single nucleotide polymorphisms on 
chromosome 9p21, the susceptibility locus for fALS and frontotemporal dementia 
(Dunckley et al., 2007). Additionally, intermediate-length polyglutamine 
expansions in ataxin-1 were identified as a risk factor for sALS (Elden et al. 
2010). 
 
1.2.2 MOLECULAR PATHWAYS IN ALS PATHOGENESIS 
There are at least seven primary mechanisms that have been associated with the 
disease pathology observed in ALS: oxidative damage (attributed to the SOD1 
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mutations), repetitive motor neuron firing and subsequent excitotoxic death, 
mitochondrial dysfunction leading to apoptosis, toxicity from intracellular 
aggregates, endoplasmic reticulum (ER) stress, impaired axonal transport 
resulting in axonal strangulations and non-cell autonomous glia and microglia 
signalling of inflammatory and degenerative cellular pathways (Figure 1.2.1) 
(Cleveland and Rothstein, 2001). 
 
 
Figure 1.2.1 Possible molecular mechanisms involved in ALS pathogenesis. 
The disease mechanism in ALS is complex and involves the activation of several 
cellular pathways in motor neurons, and dysregulated interaction with 
neighbouring glial cells. Motor neurons may undergo transcriptional 
dysregulation and abnormal RNA processing which, together with overproduction 
of reactive oxygen species (ROS), contribute to aberrant protein folding and 
accumulation of protein aggregates, thus leading to proteasome impairment and 
ER stress. Other mechanisms involved include mitochondrial dysfunction, 
dysregulation of calcium handling leading to excitotoxicity, as well as impaired 
axonal transport that would activate the autophagy and apoptotic pathways 
observed in ALS. Motor neurons can secrete complement subunits to signal 
cellular stress to neighbouring cells. Glia cells also contribute to the pathology by 
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activation of an inflammatory cascade via secretion of cytokines, release of 
inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2), 
reduced lactate release; and activation of pro-NGF–p75 receptor signalling. 
 
1.2.2.1 Oxidative damage in ALS 
Oxidative stress arises from the disruption of the reactive oxygen species (ROS) 
homeostasis i.e. imbalance between the generation and removal of ROS, which 
then causes structural damage and changes in redox regulation (Ferraiuolo et al., 
2011a). Oxidative stress has been shown to account for 20% of fALS cases, due 
to mutations in SOD1, a major antioxidant protein (Rosen, 1993; Ferraiuolo et al., 
2011a). Oxidative stress has been known to aggravate other pathophysiological 
processes in ALS such as excitotoxicity, mitochondria dysfunction, protein 
inclusions, ER stress as well as modifications in signalling from astrocytes and 
microglia (Rao and Weiss, 2004; Wood et al., 2003; Kanekura et al., 2009; 
Blackburn et al., 2009; Duffy et al., 2011; Sargsyan et al., 2005; Ferraiuolo et al., 
2011a). There have been various reports that support the involvement of oxidative 
damage in ALS with evidence of elevated free radical damage in the urine, serum 
and cerebrospinal fluid (CSF) samples of ALS patients (Smith et al., 1998; 
Simpson et al., 2004; Mitsumoto et al., 2008).  
 
There are several hypotheses proposed for the mechanisms involved in the 
oxidative damage mediated by the catalytic function of mutant SOD1. The first 
hypothesis is that mutant SOD1 improperly binds to copper resulting in the use of 
peroxynitrite (formed by the spontaneous combination of superoxide and nitric 
oxide) to catalyse the nitration of tyrosine residues (Cleveland and Rothstein, 
2001). There are elevated levels of nitrotyrosine in both the mutant SOD1 
transgenic mice as well as in fALS and sALS patients (Beal et al., 1997; Ferrante 
et al., 1997). The second hypothesis states that the aberrantly reduced SOD1-Cu1+ 
form uses hydrogen peroxide as the substrate, and catalyses the formation of 
reactive hydroxyl radicals leading to a cascade of peroxidation (Cleveland and 
Rothstein, 2001). The third hypothesis involves the inability of the mutant SOD1 
to bind to zinc properly, allowing a rapid reduction of the mutant SOD1 to the 
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SOD1-Cu1+ form which then results in a reverse catalysis, whereby superoxide 
anions are produced from oxygen rather than dismutation (Cleveland and 
Rothstein, 2001). The superoxide anions would then combine with freely 
diffusing nitric oxide to produce peroxynitrite (Cleveland and Rothstein, 2001).  
 
However, there have been contradictory reports that mutant SOD1 induces 
aberrant oxyradical reactions. Though there has been evidence of increased levels 
of oxidative markers found in the G93A SOD1 transgenic mice, this was not 
observed in the G37R SOD1 transgenic mice (Bruijn et al., 1997a; Andrus et al., 
1998; Hall et al., 1998b; Pasinelli and Brown, 2006). The overexpression of 
G93A, L126Z and A4V SOD1 in mice was shown to accelerate the ALS-like 
phenotype and shorten the lifespan, yet in the G85R SOD1 mice, neither ablation 
nor upregulation of WT SOD1 had any effect on the age of onset and the survival 
or the rate of disease progression (Bruijn et al., 1998; Jaarsma et al., 2000; Deng 
et al., 2006; Pasinelli and Brown, 2006).  Additionally, transgenic mice that lack 
the copper chaperone for superoxide dismutase (CCS) protein for the 
incorporation of copper into SOD1 was reported to develop motor neuron disease, 
despite the reduction of SOD1 activity in these mice (Wong et al., 2000). Another 
report demonstrated that transgenic mice with copper-binding-site-null SOD1 
with loss of dismutase activity; also developed the ALS-like phenotype (Wang et 
al., 2003). The discrepancies in the observed findings could mean that the 
aberrant copper-mediated oxyradical chemistry of the mutant SOD1 is not 
required for the ALS pathology, and that oxidative stress might be induced by the 
mutant SOD1 via other mechanisms beyond its catalytic function. One report 
showed that NADPH oxidase (NOX) expression is increased in the mutant SOD1 
mice as well as in the central nervous system (CNS) of ALS patients (Wu et al., 
2006). The mutant SOD1 increased NOX-dependent superoxide production and 
ablation of NOX1 or NOX2 genes resulted in the improved survival of G93A 
SOD1 mice with slowed rate of disease progression (Wu et al., 2006; Marden et 
al., 2007; Ferraiuolo et al., 2011a). Another example is the transcription factor, 
nuclear erythroid 2-related factor 2 (Nrf2), which regulates the expression of 
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antioxidant response element (ARE) genes that are upregulated during oxidative 
stress (Kirby et al. 2005). In cells expressing the mutant SOD1 and in tissue 
samples from ALS patients, Nrf2-ARE signalling is dysregulated with a reduction 
in the Nrf2 expression indicating an alternative mutant SOD1 signalling cascade 
for chronic motor neuron degeneration (Sarlette et al., 2008; Kirby et al., 2005; 
Ferraiuolo et al., 2011a). 
 
1.2.2.2 Excitotoxicity  
Glutamate is the main excitatory neurotransmitter in the CNS that is involved in 
the stimulation of postsynaptic receptors. The excessive activation of glutamate 
receptors has been shown as one of the components in neurodegenerative 
diseases, which could be caused by increased synaptic levels of glutamate and/or 
increased sensitivity of the postsynaptic neuron to glutamate (Ferraiuolo et al., 
2011a; Van Damme et al., 2005). The excessive glutamate-induced stimulation 
activates an influx of calcium that would disrupt the intracellular calcium 
homeostasis and lead to subsequent excitotoxicity, where apoptosis is initiated by 
cleaved caspase processing, perturbation of mitochondrial function and adenosine 
triphosphate (ATP) production as well as dysregulation of the ROS-generating 
enzyme systems resulting in ROS release (Ferraiuolo et al., 2011a; Arundine and 
Tymianski, 2003). The termination of glutamate-induced excitatory signal by the 
removal of glutamate from the neuronal synapse is facilitated by the excitatory 
amino acid transporter (EAAT) 2 (Ferraiuolo et al., 2011a). There have been 
published reports on the inactivation of EAAT2 in the spinal cord of ALS 
transgenic rodents (Bruijn et al., 1997b; Howland et al., 2002). Inactivation of 
EAAT2 has been reported to be facilitated by several possible mechanisms; such 
as the cleavage of EAAT2 by caspase-3, oxidation of EAAT2 by mutant SOD1 
and/or inactivation of EAAT2 by splicing errors that include intron-retention and 
exon-skipping that were identified in a subset of sALS patients (Lin et al., 1998; 
Trotti et al., 1999; Boston-Howes et al., 2006; Pasinelli and Brown, 2006). The 
role of excitotoxicity in ALS has also been proven in sALS patients, where the 
loss in EAAT2 levels as well as increase in glutamate levels in the CSF of ALS 
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patients have been shown (Rothstein et al., 1990; Rothstein et al., 1995; Pasinelli 
and Brown, 2006). The higher sensitivity of motor neurons to elevations of 
calcium during excitotoxicity could be a reason for the selective death of motor 
neurons observed during ALS. Motor neurons have increased vulnerability to 
calcium deregulation, due to the lack of calcium-binding proteins such as, 
calbindin and parvalbumin as well as the absence of the GluR2 subunit of the 2-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptors, 
which is calcium impermeable thus indicating motor neurons express calcium-
permeable AMPA receptors unlike most neuronal groups in the human CNS 
(Alexianu et al., 1994; Williams et al., 1997; Pasinelli and Brown, 2006). 
 
1.2.2.3 Mitochondrial dysfunction 
Mitochondria play a critical role in the cell by providing the energy supply of 
ATP, maintaining the calcium homeostasis and control of cell apoptosis 
(Ferraiuolo et al., 2011a). Mitochondria dysfunction has been cited as one of the 
main causes for the ALS pathogenesis, with various studies reporting strong 
evidence on its role in the disease. For example, interventions to improve 
mitochondrial function such as creatine, which inhibits opening of the 
mitochondrial transition pore, and minocycline, which blocks the mitochondrial 
permeability-transition-mediated cytochrome c release, resulted in delayed 
disease progression in ALS transgenic mice (Klivenyi et al., 1999; Zhu et al., 
2002; Pasinelli and Brown, 2006). In mutant SOD1 models, it was previously 
reported that misfolded SOD1 is both restricted to spinal cord and is selective for 
mitochondrial membranes (Vande Velde et al., 2008). Several studies have 
reported that mitochondrial vacuolation and damage are early events during the 
pre-symptomatic stage in the mutant SOD1 transgenic ALS mice and that the 
vacuolation increases in number and volume as the disease progresses (Kong and 
Xu, 1998; Bendotti et al., 2001; Sasaki et al., 2005). There have been several 
hypotheses on how mutant SOD1 impairs mitochondrial function. One study 
revealed that mutant SOD1 induces the extension and leakage of the outer 
mitochondrial membrane as well as the expansion of the intermembrane space 
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(Higgins et al., 2003). This could result in the release of pro-apoptotic molecules 
normally residing in the intermembrane space and initiate motor neuron 
degeneration (Higgins et al., 2003). Therefore, mutant SOD1 could be involved in 
fusing the peroxisomes and the outer mitochondrial membrane, a process that 
could form pores in the mitochondrial membrane allowing the release of 
cytochrome c and the initiation of an apoptotic cascade (Pasinelli and Brown, 
2006). The second hypothesis proposes that mutant SOD1 is selectively recruited 
to the outer mitochondrial membrane to form aggregates that impair the protein 
translocation machinery of the mitochondria (Pasinelli and Brown, 2006). It has 
been reported that there is preferential association of the mutant SOD1 with the 
spinal cord mitochondria and this results in mutant SOD1 aggregates in the 
mitochondria, which then cross-links onto integral membrane components on the 
cytoplasmic face of the mitochondria (Liu et al., 2004). There have been 
numerous reports showing defects in the mitochondria in ALS patients and G93A 
SOD1 mice, which result in disruption of the mitochondrial respiration, electron 
transfer chain and ATP synthesis, as well as oxidative damage to nucleic acids, 
proteins and lipids by the dysregulation of ROS release in ALS (Ferrante et al., 
1997; Andrus et al., 1998; Liu et al., 1999; Jung et al., 2002; Mattiazzi et al., 
2002; Wiedemann et al., 2002). One report revealed that there was increased 
modification of proteins by 4-hydroxynonenal (HNE), a product of membrane 
lipid peroxidation, in the lumbar spinal cord of sALS patients. One of the 
modified proteins is EAAT2, which results in the impairment of glutamate 
transport, and excitotoxic motor neuron degeneration in ALS (Pedersen et al., 
1998). The dysregulated energy metabolism is hypothesized to contribute to 
motor neuron dysfunction in ALS (Ferraiuolo et al., 2011a). Expression of mutant 
SOD1 in in vitro and in vivo studies resulted in depolarized mitochondria, 
impaired calcium homeostasis and reduced ATP production (Jung et al., 2002; 
Menzies et al., 2002; Damiano et al., 2006; Pasinelli and Brown, 2006; Rizzardini 
et al., 2006). Therefore, mitochondrial dysfunction is also related to impairment 
of calcium homeostasis in ALS. One study revealed that even prior to disease 
onset in the G93A SOD1 mice, there was significant decrease in mitochondrial 
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Ca2+ loading capacity in brain and spinal cord (Damiano et al., 2006). The 
mitochondria-dependent apoptotic pathway has been revealed to contribute to the 
motor neuron cell death observed in ALS, via the activation of caspases-9, -3 and 
-8 by mutant SOD1 (Sathasivam et al., 2005). Localization of mutant SOD1 in the 
mitochondria has been revealed to form intra-mitochondrial aggregates that 
trigger the release of mitochondrial cytochrome c followed by the activation of 
caspase-dependent cell death cascade in a fALS model (Takeuchi et al., 2002).  
The release of cytochrome c results in the binding of caspase-9 and Apaf-1, which 
leads to subsequent cleavage and activation of caspase-3 (Li et al., 1997). 
Previously, it has been demonstrated that expression of mutant SOD1 resulted in 
the cleavage and inhibition of EAAT2 by caspase-3, which suggests another 
possible mechanism involved in the impairment of glutamate uptake in ALS 
(Boston-Howes et al., 2006). At end-stage of the mutant SOD1-linked ALS, the 
downstream caspase-7 is activated and the anti-apoptosis protein, X chromosome-
linked inhibitor of apoptosis protein (XIAP) is cleaved (Guegan et al., 2001). This 
suggests that in ALS, there is possibly a sequential recruitment of the components 
involved in the mitochondrial-dependent apoptotic pathway, beginning from the 
cytochrome c translocation into the cytosol leading to the activation of caspase-9, 
followed by the subsequent caspase-3 and caspase-7 activation. Several studies 
also showed that in mutant SOD1, there is an initial activation of caspase-1, which 
occurs prior to disease onset and acts slowly as a chronic cell death initiator, after 
which caspase-3 acts as the final effector of cell death (Pasinelli et al., 2000; 
Vukosavic et al., 2000). The activation of caspase-1 has been proposed to be 
involved in chronic neural inflammation involving activation of astrocytes and 
microglia in the mutant SOD1 mice, thus initiating the slow progressive cell death 
pathology in the ALS motor neurons (Pasinelli and Brown, 2006).  
 
1.2.2.4 Protein aggregation 
Protein aggregation is one of the key pathological features in many 
neurodegenerative diseases, for example neurofibrillary tangles and plaques in 
AD and -synuclein in Lewy bodies in PD. Misfolded SOD1 inclusions were 
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identified in the motor neurons of both sALS and fALS patients as well as in 
rodent models expressing mutant SOD1 (Shibata et al., 1994; Rakhit et al., 2007; 
Bosco et al., 2010; Johnston et al., 2000; Wang et al., 2002a; Ferraiuolo et al., 
2011a). One hypothesis on the role of protein aggregates in ALS is that they 
sequester the mutant proteins to confer self-protection against the disease. A 
recent study conducted showed that the soluble mutant SOD1 proteins are the 
most toxic and that aggregation of mutant SOD1 is a form of cellular protection, 
whereby increased solubility of the mutant SOD1 aggregates increased cellular 
toxicity (Brotherton et al., 2013). Contrary to this however, the mutant SOD1 
inclusions have been proposed to enhance the disease pathogenesis by inhibition 
of chaperone and/or proteasomal function, with subsequent misfolding and 
insufficient clearance of numerous proteins, as well as sequestration, inactivation 
or enhancement of toxicity of other proteins crucial for cellular processes 
(Pasinelli and Brown, 2006). One such example is BCL-2, which has been 
described to bind to the mutant SOD1 aggregates in the spinal cord, indicating the 
entrapment of BCL-2 in the aggregates and depletion of the anti-apoptotic protein 
in the motor neurons (Pasinelli et al., 2004). In fact, overexpression of BCL-2 in 
the SOD1 transgenic mice was reported to attenuate neurodegeneration and delay 
activation of the caspases (Vukosavic et al., 2000). Additionally, there was an 
observed significant decrease in chaperone activity in tissues from mice 
expressing ALS-linked mutant SOD1 prior to phenotype onset (Tummala et al., 
2005). The toxic effect of SOD1 aggregates was also supported by a study which 
suggested that the constant proteolysis of mutant SOD1 proteins overloads the 
proteasomes and results in motor neuron death (Urushitani et al., 2002). One 
study reported that though the SOD1 inclusions have been found in the spinal 
cord of fALS cases, there was lack of evidence supporting that SOD1 inclusions 
were also found in all sALS cases indicating the possibility of different 
mechanisms involved between sALS and fALS (Liu et al., 2009). 
 
Cytoplasmic inclusions containing TAR DNA binding protein-43 (TDP-43) and 
mutant fused in sarcoma (FUS) protein have been described in ALS patients (Arai 
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et al., 2006; Neumann et al., 2006; Groen et al., 2010; Hewitt et al., 2010). Both 
TDP-43 and FUS are DNA/RNA binding proteins located in the nucleus and are 
involved in multiple aspects of RNA processing such as transcriptional regulation, 
alternative splicing and mRNA transport (Ferraiuolo et al., 2011a). However, 
TDP-43 inclusions are not found in mutant FUS ALS cases implying that the FUS 
disease pathway is independent of TDP-43 aggregation (Vance et al., 2009). The 
delocalisation, accumulation and ubiquitination of TDP-43 in the cytoplasmic 
inclusions in motor neurons have been found in the early pathogenic event in ALS 
that lead to motor neuron degeneration (Giordana et al., 2010). Mutations in the 
gene encoding TDP-43, TARDBP were discovered in several sALS and fALS 
cases (Sreedharan et al., 2008). Additionally, TDP-43 immunopositive inclusions 
were found in sALS as well as fALS cases carrying A4T or I113T mutations in 
SOD1 (Robertson et al., 2007). Disease-linked mutations of TDP-43 in cell 
culture were shown to increase TDP-43 inclusion formation in response to 
stressful stimuli (Liu-Yesucevitz et al., 2010). FUS mutations have been reported 
in FUS-related fALS patients and neuropathology in these cases revealed that 
there were neuronal and/or glial cytoplasmic inclusions positive for the FUS/TLS 
protein (Groen et al., 2010; Hewitt et al., 2010). The majority of fALS-associated 
mutations impair the nuclear import of FUS by interference with the transportin-
mediated transport pathway, thus resulting in the cytoplasmic redistribution and 
recruitment of FUS into stress granules (Dormann et al., 2010; Ito et al., 2011). 
 
1.2.2.5 Endoplasmic reticulum stress 
The intracellular inclusions observed during ALS are related to the accumulation 
of misfolded proteins. Protein misfolding and aberrant accumulations elicit the 
ER stress response pathway that induces the following cellular responses: the 
unfolded protein response (UPR), ER-associated degradation, and apoptosis. 
During ER stress, there is upregulation of ER-resident chaperones that facilitate 
the correct protein folding or there is enhanced degradation of the misfolded 
protein (Kaufman, 2002; Ferraiuolo et al., 2011a). Though these mechanisms are 
initially protective, long-term ER stress triggers the apoptotic signal as shown by 
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activation of caspases during ER stress-induced apoptosis (Imaizumi et al., 2001; 
Hitomi et al., 2004). Deficiency of X-box-binding protein-1 (XBP-1), a key UPR 
transcription factor that regulates genes involved in protein folding and quality 
control deficiency, resulted in a dramatic decrease in cellular toxicity with higher 
levels of autophagy in motor neurons and reduced accumulation of mutant SOD1 
aggregates (Hetz et al., 2009; Matus et al., 2009). There have been various 
publications that associate ER stress as an early pathology of motor neuron 
degeneration in ALS. Proteomic analysis of the spinal cord of the transgenic 
G93A SOD1 ALS model revealed upregulation of the UPR chaperone, protein-
disulfide isomerase (PDI), and its recruitment to the mutant SOD1 inclusions 
(Atkin et al., 2006). PDI and other UPR-induced proteins were reported to be 
upregulated prior to the onset of symptoms in the mutant SOD1 rodents, 
suggesting that ER stress has an early role in the ALS pathogenesis (Atkin et al., 
2008). PDI was found in the CSF and was widely distributed and aggregated 
throughout the motor neurons of sALS patients (Atkin et al., 2008).  
 
1.2.2.6 Impaired axonal transport 
Disruption of axonal transport is one of the main pathologies in ALS, and hence it 
would be critical to determine the mechanisms underlying this dysfunction in the 
disease. The axonal transport of molecules and organelles is crucial for the 
development, function and survival of neurons. Motor neurons are among the 
largest neurons and are highly polarised with long axons, therefore axonal 
transport-mediated delivery of cellular components is essential, such as, 
anterograde transport of RNA, protein and organelles that are synthesised in the 
cell body to the synapses and neuromuscular junctions (NMJ), whereas retrograde 
transport mediates delivery of trophic factors and other constituents to the cell 
body (Ferraiuolo et al., 2011a). The principal molecular machinery for axonal 
transport are kinesin and the dynein-dynactin complexes for anterograde and 
retrograde transport respectively (Pasinelli and Brown, 2006). Evidence of 
impairment of the axonal transport has been described in ALS patients as well as 
in transgenic ALS mice (Pasinelli and Brown, 2006; Sasaki and Iwata 1996; 
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Sasaki et al., 2005). Defective axonal transport has been demonstrated as an early 
key pathogenic event in ALS that was observed in pre-symptomatic transgenic 
ALS mice and that these deficits were found to be aggravated with disease 
progression (Bilsland et al., 2010; Williamson and Cleveland, 1999; Borchelt et 
al., 1998; Zhang et al., 1997). The disruption of axonal transport could be a result 
of the cascade of the ALS disease pathology, for example, mitochondrial 
dysfunction was shown to impair the axonal mitochondria transport, which in turn 
could compromise the axonal transport of other components because of the 
energy requirement of axonal transport (Ferraiuolo et al., 2011a; De Vos et al., 
2007). The impairment of axonal transport is affected by the mislocalisation and 
disruption of the molecular motors, kinesin and dynein (Pasinelli and Brown, 
2006). One study reported that dynein associated with the aggregates of mutant 
SOD1 resulting in the altered cellular localization of dynein, which could inhibit 
the dynein/dynactin function, while another report described that crossing of the 
G93A SOD1 mice with transgenic mice that have mutations in the motor protein 
dynein resulted in delayed disease progression and significantly increased the life 
span of the mice (Kieran et al., 2005; Ligon et al., 2005). Genome-wide single-
nucleotide polymorphism (SNP) analysis in sALS cases showed that the 
decreased KIFAP3 (encodes a kinesin-associated protein) expression correlated 
with increased survival in sALS (Landers et al., 2009). There have been 
contradictory results stating that though dynein-mediated retrograde transport is 
slowed in the transgenic ALS mice, mutant SOD1 does not interact with 
anterograde transport motors of the kinesin-1 family and there is no decrease in 
KIF5A-mediated anterograde transport (Shi et al., 2010). There is elevation of the 
tumour necrosis factor (TNF)- in mutant SOD1 mice, which has been shown that 
to impair kinesin function via hyperphosphorylation by p38 MAPK indicating a 
possibility that the disruption of kinesin in ALS could be through a different 
pathway (De Vos et al., 2000; Kiaei et al., 2007; Ferraiuolo et al., 2011a). 
Another possibility is that in ALS, the binding of the axonal components to the 
motor proteins is disrupted, for example; hyperphosphorylation of neurofilaments 
by MAPK and Cdk5 could impede axonal transport (Tortarolo et al., 2003; 
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Ackerley et al., 2000; Guidato et al., 1996; Ferraiuolo et al., 2011a). 
Excitotoxicity, which has been shown to contribute to ALS pathogenesis, has 
been reported to reduce the axonal transport of neurofilaments by activation of 
protein kinases (Ackerley et al., 2000). The aggregations of neurofilaments at the 
proximal axons might physically impede the axonal transport especially the 
anterograde traffic (Pasinelli and Brown, 2006; Sasaki et al., 2005). Additional 
evidence showed a polymorphism in the C-terminal tail domain of the human NF-
H in ALS patients (Figlewicz et al., 1994). In addition to neurofilaments, the 
neuronal intermediate filament peripherin has also been implicated in the ALS 
pathology, whereby a neurotoxic peripherin splice variant (Per 61) associated 
with the pathological aggregates in ALS transgenic mice expressing G37R SOD1 
as well as in fALS patients (Robertson et al., 2003). Overexpression of peripherin 
in mice was reported to impair axonal transport of neurofilament proteins prior to 
the appearance of the axonal spheroids, which suggests that aberrant expression of 
peripherin could be involved in the progressive formation of ALS-like spheroids 
in axons (Millecamps et al., 2006). 
 
1.2.2.7 Non–cell autonomous toxicity in ALS 
There have been recent advances in the role of neighbouring cells mediating 
motor neuron death in ALS. The involvement of non-neuronal cells in the disease 
pathology has been reported, where the activation of astrocytes and microglia was 
described as one of the early pathology of the disease in ALS (Ince et al., 1996). 
Further evidence showed that in the ALS mice expressing the mutant SOD1 in 
specific cell types, when motor neurons expressing the mutant SOD1 were 
adjacent to non-neuronal cells without the mutant protein, there was extended 
survival of the mice with delayed degeneration. Conversely, mice that had WT 
motor neurons surrounded by non-neuronal cells expressing the mutant SOD1 
transgene resulted in the disease pathology (Clement et al., 2003). Glial cells 
carrying an ALS-causing mutation in the SOD1 gene were reported to induce 
neural degeneration in human stem cell-derived and mouse embryonic stem cell-
derived motor neurons (Di Giorgio et al., 2007; Nagai et al., 2007; Marchetto et 
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al., 2008). Previous studies reported that the toxic effect from the mutant SOD1 
glia cells specifically affected the motor neurons, while interneurons, GABAergic 
or dorsal root ganglion neurons remained unaffected which could explain the 
selective vulnerability of motor neurons in ALS (Nagai et al., 2007; Di Giorgio et 
al., 2008). The non-cell autonomous toxicity was also found expressed by specific 
cell types, for example, media conditioned with astrocytes expressing mutant 
SOD1 when cultured with motor neurons, resulted in neuronal death while 
conditioned media from skeletal myocytes, spinal cord microglia, cerebral cortical 
neurons or skin fibroblasts expressing the mutant SOD1 did not cause the similar 
toxicity to the motor neurons (Nagai et al., 2007). The non-cell autonomous 
astrocytes toxicity on motor neurons could be attributed to the impairment of the 
astrocyte lactate efflux transporter, with resultant decreases of spinal cord lactate 
levels as well as increases in pro-NGF-p75 receptor signalling (Ferraiuolo et al., 
2011b). Additionally, the mutant SOD1 expressing astrocytes were shown to 
activate NOX2 superoxide production, which was reported to be involved in the 
oxidative damage of the motor neurons in ALS (Marchetto et al., 2008). The 
authors had also noted the increased pro-inflammatory activity of the induced 
nitric oxide synthase enzyme (iNOS), which could be due to the release of ROS 
via the NOX pathway (Pawate et al., 2004; Marchetto et al., 2008).  
 
The role of neuroinflammation during ALS pathology showed elevations of 
Monocyte chemoattractant protein-1 (MCP-1) and IL-8 inflammatory chemokines 
in the CSF of ALS patients and that biochemical indices of immune-response 
activation were present in the blood (Kuhle et al., 2009; Mantovani et al., 2009; 
Ferraiuolo et al., 2011a). The astrocytes from G93A SOD1 mice showed 
significant elevations of prostaglandin E2 (PGE2), leukotriene B4 (LTB4) as well 
as higher iNOS expression and NO synthesis during basal or TNFα-stimulated 
conditions (Hensley et al., 2006). Double transgenic mice with mutant SOD1 and 
ablated functional T cells or CD4+ T cells were shown to have a more aggressive 
form of motor neuron disease, accompanied by attenuation of gliosis, increased 
mRNA levels for pro-inflammatory cytokines and NOX2, as well as reduced 
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trophic factors and glial glutamate transporters (Beers et al., 2008). Rescue of the 
disease phenotype with improvement of survival, cytotoxicity suppression and 
restoration of glia activation was observed when bone marrow transplants 






























1.3 NEUROFILAMENTS  
The neuronal cytoskeleton consists of abundant proteins, which include 
microtubules, actin and neurofilaments that are transported along the length of 
axons. Neurofilaments are part of the largest family of cytoskeletal proteins, 
intermediate filaments (IFs) and are classified as type IV IFs (Holmgren et al. 
2012). Neurofilaments are the most abundant cytoskeletal proteins in the adult 
axonal cytoskeleton (Holmgren et al., 2012). The neuronal IFs consists of the 
neurofilament triplet proteins; that are classified based on the length of their tail 
domain and are found in most terminally differentiated neurons; neurofilament 
light chain (NF-L; 68 kDa), middle chain (NF-M; 145-160 kDa), and heavy chain 
(NF-H; 160-200 kDa) as well as the two other related IFs: a-internexin (expressed 
in the developing and adult nervous system) and peripherin (found mostly in 
lower motor, autonomic and sensory neurons) (Holmgren et al., 2012).  
  
1.3.1 MOLECULAR BIOLOGY OF NEUROFILAMENTS  
1.3.1.1 Structure and assembly of neurofilaments  
All IFs have a similar structural organization, a highly conserved central α-helical 
core or rod domain, an amino-terminal head domain and a carboxyl-terminal or 
tail domain (Figure 1.3.1) (Holmgren et al., 2012). The assembly of the IFs into 
10-nm fibers is regulated by the head domain, while the central rod domain 
facilitates the formation of coiled-coil oligomers and the carboxy-terminal tail 
domain forms the side arms that project from the filaments and which appear as 
the structural component of crossbridges to form interconnections between 
neurofilaments, microtubules and other organelles establishing a proper filament 
network (Gill et al., 1990; Nakagawa et al., 1995; Ching and Liem, 1998; Chen et 
al., 2000; Holmgren et al., 2012). It has been reported that IFs lengthen by end-to-
end annealing of assembled filaments and are able to incorporate subunits along 
their length by dissociation of the tetramer subunits and reinsertion within the 
polymer wall without compromising the structural integrity, a process termed 




Figure 1.3.1 Representative diagram of neurofilament protein subunits The 
domains and structures of the three neurofilament subunit proteins: NF-L, NF-M, 
and NF-H.  (Barry et al., 2007). 
 
1.3.1.2 Transport of neurofilaments  
Axonal transport has been classified as either fast axonal transport for delivery of 
vesicular cargos necessary for synaptic activity or slow axonal transport, which is 
the transport of axonal cytoskeleton and cytosolic proteins (Hoffman and Lasek, 
1975; Grafstein and Forman, 1980; Barry et al., 2007). The transport of the 
vesicular cargoes and membrane organelles occur at a fast transport rate of 50-400 
mm per day, while the slow axonal transport of cytoskeletal and other soluble 
protein complexes is at a rate of 0.2-8 mm per day (Lasek et al., 1984; Muresan, 
2000). The transport of axoplasmic proteins was first visualized by using pulse-
chase radioactive labelling in neurons (Lasek, 1967). By using radiolabelled 
cytoskeletal proteins, analysis of the distance travelled by the label after set 
periods of time allowed calculation of the average rate of transport, which was 
determined to be 0.1 – 3 mm day each day and the rate of fast axonal transport of 
vesicular movement about 0.1 μm per second (Baas and Brown, 1997; Hirokawa 
et al., 1997; Nixon, 1998; Miller et al., 2002). Neurofilaments are classified as 
part of the slow axonal transport as demonstrated by the use of GFP tagged NF-H 
and NF-M transfected into neurons, which revealed that the slow axonal transport 
of neurofilaments occurs at fast axonal rates but is interrupted by prolonged 
pauses (Roy et al., 2000; Wang et al., 2000; Grierson and Miller, 2011). The 
transport of neurofilaments was also reported to occur bi-directionally at 
approximately 1 μm per second along the axon (Prahlad et al., 2000; Shah et al., 
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2000; Wang et al., 2000). The published reports indicated that the slow axonal 
transport of neurofilaments is mediated by the anterograde and retrograde motor 
proteins utilized for fast axonal transport: kinesin and dynein/dynactin 
respectively, which would explain the bi-directional transport of neurofilament 
(Grierson and Miller, 2011; Prahlad et al., 2000; Shah et al., 2000; Yabe et al., 
1999; Yabe et al., 2000). Though the precise molecular motors for neurofilament 
transport are unknown, it has been previously reported that using conditional 
knockout mice lacking the neuronal-specific conventional kinesin heavy chain, 
KIF5A, there was age-dependent sensory neuron degeneration, an accumulation 
of neurofilaments in cell bodies, reduced neurofilaments in axons, loss of large 
caliber axons, and hind limb paralysis (Xia et al., 2003). However another study 
revealed that inhibition of dynein but not kinesin activity can foster aberrant 
accumulation of neurofilaments within neurites (Motil et al., 2007). Disruption of 
dynein in mice overexpressing dynamitin resulted in the proximal accumulation 
of neurofilaments due to the specific defect in the dynein/dynactin-mediated 
transport, while the kinesin anterograde transport was still functional (LaMonte et 
al., 2002). The transport of neurofilament proteins as either disassembled subunits 
(small oligomers) or as intact filaments (polymers) is uncertain (Miller et al., 
2002). It has been reported that some degree of neurofilament disassembly occurs 
prior to transport (Miller et al., 2002; Yabe et al., 1999; Yabe et al., 2001). 
However, there were also published reports that revealed the movement of intact 
neurofilaments (Shah et al., 2000; Wang et al., 2000; Roy et al., 2000). Since a 
small proportion of neurofilaments are transported at any one time, there may be 
some disassembly of neurofilaments to permit disassociation from the rest of the 
neurofilament matrix and transport through the axon (Miller et al., 2002; Al-








1.3.2 NEUROFILAMENT FUNCTION  
1.3.2.1 Biological function of neurofilaments 
One of the main functions of neurofilaments is the regulation of axonal calibre 
and diameter, which is crucial since the speed of conductivity of an impulse along 
the axon is proportional to its calibre (Friede and Samorajski, 1970; Sakaguchi et 
al., 1993; Al-Chalabi and Miller, 2003). Neurofilaments are abundant in neurons 
with large-diameter axons such as motor neurons, where fast conduction 
velocities are essential (Grierson and Miller, 2011). The role of neurofilaments in 
maintaining the axonal caliber was reported using neurofilament-deficient quails, 
which showed reduced axonal diameter and conduction velocity in the axons 
(Ohara et al., 1993; Sakaguchi et al., 1993). This observation was confirmed in 
transgenic mice lacking functional NF-H, which resulted in the development of 
only small calibre neurons (Eyer and Peterson, 1994). Additionally, 
neurofilaments are also involved in neuronal differentiation, axonal outgrowth 
and regeneration (Holmgren et al., 2012).  
 
1.3.2.2 Function of neurofilaments is regulated by phosphorylation 
There are multiple Ser and Thr phosphorylation sites in the head and tail domains 
of neurofilaments that can be phosphorylated by a variety of kinases (Holmgren et 
al., 2012). The phosphorylation of neurofilaments on the head domain has been 
implicated in neurofilament assembly, for example, polymerization of NF-L in 
vitro was inhibited by phosphorylation by protein kinase N (PKN), while 
phosphorylation of the head domain of the neurofilament subunits by cAMP-
dependent protein kinase (A-kinase) resulted in the fragmentation of the 
neurofilaments through a process of “thinning” and Rho-associated kinase (Rho-
kinase) phosphorylation of NF-L resulted in its disassembly (Hisanaga et al., 
1994; Mukai et al., 1996; Hashimoto et al., 1998). Neurofilaments are the most 
extensively phosphorylated proteins in the nervous system due to the tail domains 
of NF-M and NF-H which contain multiple Ser/Thr-Pro phosphorylation motifs, 
with the number of sites depending on the species, for example, rat NF-H contains 
52 repeats (Elhanany et al., 1994; Pant and Veeranna, 1995; Pant et al., 2000; 
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Holmgren et al., 2012).  Ser/Thr kinases implicated in the phosphorylation of KSP 
repeats on neurofilament tail domains include Cdk5, MAPKs such as ERKs, 
JNKs  and p38 kinases; and additional kinases, including GSK3β, Cdc2 and 115 
kDa NF kinase (Roder et al., 1993; Shetty et al., 1993; Xiao and Monteiro, 1994; 
Giasson and Mushynski, 1997; Ackerley et al., 2000; Veeranna et al., 2008). 
Neurofilament phosphorylation begins as the neurofilaments enter the axon 
hillock and continues in a gradient fashion along the axon (Nixon and Shea, 1992; 
Nixon et al., 1994; Grant and Pant, 2000). One study showed that the transient 
phosphorylation of the NF-M head domain at protein kinase A (PKA)-specific 
sites occurs in the cell bodies after neurofilament subunit synthesis (Zheng et al., 
2003). The authors then revealed that the transient phosphorylation of head 
domains inhibits tail domain phosphorylation, suggesting this as one of several 
mechanisms underlying topographic regulation of neurofilaments (Zheng et al., 
2003). It is possible that deregulation of this process could be responsible for the 
pathological accumulations of phosphorylated neurofilaments observed in the 
neuronal perikarya in neurodegenerative disorders (Zheng et al., 2003). The 
increased charge of the neurofilaments caused by heavy phosphorylation has been 
suggested to influence the properties of the tail domain and thus the neurofilament 
function (Miller et al., 2002). The degree of phosphorylation of the NF-M and 
NF-H tail domains was found to regulate the overall conduction velocity of 
neurofilaments (Archer et al., 1994; Nixon et al., 1994). It has been reported that 
ablation of the NF-H gene increased the transport velocity of the NF-M and NF-L 
subunits, while overexpression of NF-H inhibited neurofilament axonal transport 
(Collard et al., 1995; Marszalek et al., 1996; Zhu et al., 1998). This was further 
supported by a study that demonstrated when the Ser/Thr-Pro motifs in NF-H 
were mutated to alanine or aspartate residues, there was significantly faster 
transportation of the non-phosphorylated NF-H alanine mutant while the 
permanently phosphorylated aspartate NF-H mutant was transported significantly 




Additionally, phosphorylation of neurofilaments may promote interaction 
between neurofilaments resulting in the bundling of the filaments that coincides 
with its reduced motility (Leterrier et al., 1996; Yabe et al., 2001). However, this 
is contrary to published reports that found that the extensive phosphorylation of 
the neurofilament tail domains increases negative repulsive electrostatic charges 
hence increasing the spacing between individual neurofilaments, which would 
then expand the axon diameter (Carden et al., 1987; Kumar and Hoh, 2004). One 
report suggested that phosphorylation may not regulate the axonal diameter 
directly through electrorepulsive charges but possibly through indirect 
mechanisms, such as the slowing of neurofilament transport and the formation of 
a stationary cytoskeletal lattice (Pijak et al., 1996). This was supported by 
evidence showing that attachment of neurofilaments to the motor proteins, such as 
kinesin and dynein are negatively regulated by the phosphorylation of the tail 
domains (Shah et al., 2000; Yabe et al., 2000). Therefore, phosphorylation of 
neurofilaments regulates the assembly of the neuronal skeleton to form a stable 
network that determines conduction velocity and preserves the axon calibre. 
 
Phosphorylation of neurofilaments depends on a dynamic equilibrium regulated 
by kinases and phosphatases (Grant and Pant, 2000). Inhibition of protein 
phosphatase 1 (PP1) and PP2A by addition of okadaic acid to dorsal root ganglion 
cells enhances the kinase phosphorylation of NF-L and NF-M as well as disrupts 
the neurofilament networks by disassembling and fragmenting the neurofilaments 
(Sacher et al., 1992). Furthermore, dephosphorylation by PP2A has been reported 
to preserve the assembly of NF-L into the filamentous form in neurons (Saito et 
al., 1995). These results indicate that phosphatases may be crucial in facilitating 
neurofilament assembly in the cell bodies prior to entering the axon hillock for 
axonal transport (Grant and Pant, 2000). Since one of the functions of 
neurofilaments is to stabilize the axon, the disruption of the neurofilament 
network has also been proposed to contribute to the destruction of the axon, as 
observed when addition of phosphatase inhibitors results in the preferential 
destruction of axons (Merrick et al., 1997). Another study revealed that PP2A also 
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inhibits aberrant phosphorylation of neurofilaments in the perikarya, whereby 
ablation of PP2A results in the accumulation of hyperphosphorylated 
neurofilaments in the neuronal cell body (Rudrabhatla et al., 2009). Additionally, 
another study reported that dephosphorylation of neurofilaments is also involved 
in promoting its turnover by calpain degradation (Pant, 1988).  
 
1.3.3 NEUROFILAMENTS AND NEUROLOGICAL DISEASES 
A common pathology of neurodegenerative diseases such as AD, PD, ALS and 
Charcot-Marie-Tooth (CMT) is the accumulation of phosphorylated 
neurofilaments.  Phosphorylation of the tail domains of neurofilaments usually 
occurs in the axonal compartment and not in the cell body or perikaryal. However 
in disease pathology, the accumulation of neurofilaments was observed in the cell 
body (Sternberger et al., 1985; Lee et al., 1988; Julien and Mushynski, 1998). 
This phenomenon could be due to various defects including mutations, 
deregulation of neurofilament protein synthesis, perturbed axonal transport and 
abnormal phosphorylation/glycosylation/oxidation (Liu et al., 2011).  
 
1.3.3.1 Charcot-Marie-Tooth 
CMT is an inherited peripheral neurological disease that is divided into 4 main 
types, CMT1-4. There have been various reports on several mutations on NFL 
that have been associated with CMT2, indicating the involvement of 
neurofilaments in the disease (Mersiyanova et al., 2000; Yoshihara et al., 2002; 
Jordanova et al., 2003; Grierson and Miller, 2011). The multisynthetase complex 
p43 (MSC p43) was found to interact with NF-L and maintain the normal 
phosphorylation levels in neurofilaments, therefore essential for neurofilaments 
assembly and axon maintenance (Zhu et al., 2009). Ablation of MSC p43 resulted 
in similar phenotypic pathology as CMT2, such as, axonal degeneration in motor 
neurons, disorganization of the axonal neurofilaments network, defective NMJ, 
muscular atrophy and motor dysfunction (Zhu et al., 2002). CMT mutations in the 
NF-L subunit and small heat-shock protein B1 (HSPB1) was reported to cause 
disruption of the neurofilament network and aggregation of NF-L in primary 
40 
 
cultured motor neurons. However, co-expression of WT HSPB1 could remediate 
the progressive degeneration and loss of neuronal viability found in the CMT 
mutant NFL and likewise, deletion of NF-L markedly reduced degeneration and 
loss of motor neuron viability induced by the mutant HSPB1 (Zhai et al., 2007). 
One possible mechanism for the neurofilament accumulation observed in CMT is 
an alteration in the motor proteins associated with neurofilaments, whereby 
CMT2A patients were reported to contain a loss-of-function mutation in the 
motor domain of the KIF1B gene and heterozygous KIF1B mutant mice have a 
defect in transporting synaptic vesicle precursors and suffer from progressive 
peripheral neuropathy similar to CMT human pathology (Zhao et al., 2001).  
 
1.3.3.2 Alzheimer’s Disease 
One of the main pathologies observed in AD, neurofibrillary tangles have been 
reported to contain extensively phosphorylated neurofilament proteins, suggesting 
the possible role of neurofilaments in the formation of tangles (Liu et al., 2011; 
Haugh et al., 1986; Sternberger et al., 1985). There were elevated levels of total 
and phosphorylated neurofilaments in the CSF of AD patients, suggesting that 
neurofilament levels in the CSF could be used as a marker for AD patients (Hu et 
al., 2002). Additionally, oxidative marker trans-HNE adducts, which has been 
shown to be immunoreactive in AD brain samples, was detected on p-NF-H and 
to a lesser extent, phosphorylated NF-M (p-NF-M) (Montine et al., 1997; Wataya 
et al., 2002). In AD brains, the observed decrease of O-GlcNAcylation is 
accompanied by an increase in p-NF-M, which suggests that the 
hyperphosphorylation and accumulation of NF-M in AD brain could be due to the 
impaired brain glucose uptake/metabolism via down-regulation of NF-M O-
GlcNAcylation (Deng et al., 2008; Liu et al., 2011).  
 
1.3.3.3 Parkinson’s Disease 
In PD, the Lewy bodies found in the degenerating neurons have been shown to 
consist of α-synuclein, the three neurofilament subunits, ubiquitin and proteasome 
subunits, torsinA and parkin (Liu et al., 2011; Galloway et al., 1992; Trimmer et 
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al., 2004). The accumulated NF-H and NF-M in Lewy bodies are altered and 
highly phosphorylated at the core of the substantia nigra (Hill et al., 1991; Forno 
et al., 1986). The NF-L and NF-M levels were reduced in substantia nigra 
specimens from PD patients while another study demonstrated that the mRNA 
levels of NF-H and NF-L were reduced in PD (Hill et al., 1993; Basso et al., 
2004). This indicates that the neurofilaments are sequestered into the Lewy bodies 
and that the lack of neurofilaments in the axon could result in neuronal death (Hill 
et al., 1993). Neurofilament levels in the CSF are also higher in patients with 
multiple system atrophy predominated by parkinsonism (MSA-P), suggesting that 
CSF neurofilament levels can be used as a biomarker for PD (Abdo et al., 2007).  
 
1.3.3.4 Amyotrophic Lateral Sclerosis 
Motor neuron cell bodies of ALS patients have been shown to contain 
neurofilament accumulations, suggesting that a disruption in their axonal transport 
(Hirano et al., 1984; Manetto et al., 1988; Munoz et al., 1988; Leigh et al., 1989; 
Murayama et al., 1992; Rouleau et al., 1996). The ALS transgenic SOD1 mutant 
mice have shown accumulations of neurofilaments similar to that in ALS patients, 
which has been demonstrated to be an early pathological hallmark due to the 
impaired axonal transport of neurofilaments (Zhang et al., 1997; Williamson and 
Cleveland, 1999; Collard et al., 1995). The role of neurofilaments in ALS have 
been supported by other studies, which have reported that single overexpression 
of any of the three neurofilament subunits (NF-L, NF-M and NF-H) resulted in 
progressive muscle dysfunction associated with neurofilament accumulations and 
axonal loss that were reminiscent of motor neuron disease (Cote et al., 1993; Xu 
et al., 1993; Gama Sosa et al., 2003). There have been contradictory reports 
however, that demonstrated crossing of mutant SOD1 transgenic mice with mice 
overexpressing mouse NF-L or NF-H subunits resulted in the delay of disease 
onset and improvement of the survival of these mice suggesting that 
neurofilament accumulation may be protective in certain circumstances 




In ALS, the neuronal cell body accumulations of neurofilaments have been 
labelled by antibodies that detect the phosphorylated tail domains of NF-M and 
NF-H, indicating that aberrant phosphorylation of NF-H and NF-M could be 
related to the disrupted axonal transport of neurofilaments in the disease state 
(Manetto et al., 1988; Munoz et al., 1988). However mass spectrometry analysis 
of purified and characterized NF-H from the cervical spinal cords of ALS patients 
and controls revealed that there were no significant differences in the 
physicochemical properties of normal and ALS NF-H, yet this does not exclude 
the possibility that neurofilament phosphorylation was altered topographically in 
disease (Strong et al., 2001; Miller et al., 2002). Previous published reports have 
described that phosphorylation of the tail domain of neurofilaments by Cdk5/p35 
activity results in the impairment of axonal transport, while inhibition of the Cdk5 
kinase activity reduces neurofilament phosphorylation and enhances 
neurofilament axonal transport (Ackerley et al., 2000; Shea et al., 2004). 
Additionally, deletions and mutations of the Ser/Thr-Pro motif in the tail domain 
in NF-H have been found in a number of sALS patients (Figlewicz et al., 1994; 
Al-Chalabi et al., 1999; Barry et al., 2007). Elimination of the tail domains in NF-
H and NF-M (and the known phosphorylation sites) in mice carrying a G37R 
SOD1 mutant resulted in the delay of disease onset, with more surviving neurons 
and extended survival of the ALS mice (Lobsiger et al., 2005). Interestingly, 
truncation of both NF-M and NF-H carboxy-termini resulted in an additive effect 
of better survival and delay of onset compared to truncation of the carboxy-
terminus from a single neurofilament species (Lobsiger et al., 2005; Dale and 
Garcia, 2012). Recent advancements in the development of ALS biomarkers have 
suggested the use of NF-H levels in the CSF as a measure to indicate the disease 
state. There was a five-fold increase in the NF-H levels in the CSF of ALS 
patients and the elevated NF-H levels in ALS patients was also detected in the 
plasma, serum and CSF, thereby further opening the field to neurofilament-based 




The prolyl isomerase, Pin1 was found to associate with p-NF-H and co-localise 
with p-NF-H in ALS-affected spinal cord neuronal inclusions (Kesavapany et al., 
2007). The authors also showed that Pin1 is involved in the modulation of 
oxidative stress-induced NF-H phosphorylation, whereby inhibition of Pin1 
rescues neurons from aberrant NF-H phosphorylation and cell death (Kesavapany 
et al., 2007; Rudrabhatla et al., 2008). Under normal conditions, neurofilament 
proteins are found to be phosphorylated in the axonal compartment. However, in 
neurological disorders such as ALS, there is an aberrant accumulation of 
hyperphosphorylated neurofilaments within the neuronal cell bodies. This 
aberrant hyperphosphorylation of neurofilaments could be attributed to an 
increase in kinase activity, a decrease of phosphatase activity, or both 
(Rudrabhatla et al., 2009).  
 
Oxidative stress has been described in in vitro studies to inhibit axonal transport 
and induce aberrant accumulation of neurofilaments in the neuronal cell body via 
influx of Ca2+ through the glutamate receptors, which then activates kinases such 
as MAPK/SAPK, ERK or p38 that phosphorylate the neurofilament tail domains 
(Ackerley et al., 2000; Stevenson et al., 2009). During oxidative stress, Pin1 
elevates the phosphorylation of NF-H by modulating the activity of Pro-directed 
kinases such as Cdk5, MAPK, and c-Jun N-terminal protein kinase 3 (JNK3), 
likely by stabilizing the trans conformation of the pSer/Thr-Pro sites in the tail 
domain of neurofilaments to permit accessibility to the other Ser/Thr-Pro sites 
along the tail domain (Rudrabhatla et al., 2008). However, the authors had also 
showed that in ALS lumbar spinal cord and AD brain, there was a reduction in 
phosphatase PP2A activity and hypothesized that this reduction could be the 
underlying cause for the Pin1 induced aberrant p-NF-M/H accumulation in the 
cell bodies (Rudrabhatla et al., 2009). PP2A has been reported to be highly 
expressed in the cell body of neurons and that ablation of its activity by PP2A 
inhibitors leads to perikarya accumulation of hyperphosphorylated 
neurofilaments, indicating that PP2A activity could be the regulator of the 
topographic phosphorylation of neurofilaments (Rudrabhatla et al., 2009). 
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Additionally, dephosphorylation of purified rat phosphorylated neurofilaments 
from spinal cord and sciatic nerve by PP2A was inhibited by addition of 
increasing amounts of Pin1 (Rudrabhatla et al., 2009). Previous findings indicated 
that interactions with Schwann cells modulate regional phosphorylation of 
neurofilament within the ensheathed axonal segments and that interaction of 
myelin-associated glycoprotein (MAG) with axonal receptor(s) regulates 
expression of neurofilaments and their phosphorylation by the Pro-directed 
protein kinases (Hsieh et al., 1994; Dashiell et al., 2002). From the published 
reports, it seemed that the aberrant hyperphosphorylation of neurofilaments 
during oxidative stress could be attributed to both the increase in kinase activity 
and decrease of phosphatase activity. The authors then proposed that Pin1 acts as 
a regulatory mechanism on the phosphorylation of NF-M/H, whereby under 
normal conditions the higher PP2A activity in the cell body of neurons inhibits 
the phosphorylation of Ser/Thr-Pro sites in NF-M/H in the perikarya. This 
prevents the formation of pSer/Thr-Pro peptide sequences for Pin1 isomerisation, 
though Pin1 is also localised in the cell body. However, as the neurofilaments are 
transported down the axon, the Ser/Thr kinases are activated by axonal-glial 
interaction and some of the Ser/Thr-Pro residues along the tail domain of NF-M/H 
proteins are phosphorylated. Though phosphorylation results in the Ser/Thr-Pro 
motif in the cis conformation and blocks additional phosphorylation, binding of 
Pin1 to neurofilaments catalyses the cis to trans isomerisation thus inhibiting the 
dephosphorylation by PP2A and increases the accessibility of the other Ser/Thr-
Pro sites to effect further phosphorylation. This phenomenon together with the 
already reduced PP2A activity found in ALS would then lead to the aberrant 
hyperphosphorylation of NF-M/H in the cell body. The p-NF-M/H proteins then 
accumulate in the neuronal cell bodies hence impairing the axonal transport 
(Figure 1.3.2).  Based on the results, by selectively reducing Pin1 levels, it is 







Figure 1.3.2 Role of Pin1 in phosphorylation of NF-M/H. The top diagram 
represents normal neurons, where the higher PP2A activity in the cell body 
prevents neurofilament (NF) phosphorylation. The phosphorylation of 
neurofilaments are selective to the axonal compartment, where axonal–glial 
interaction activates the Pro-directed kinases and phosphorylates some of KSP 
sites, which is stabilized to the trans isomer by Pin1 to increase the accessibility 
of other pSer/Thr-Pro sites for phosphorylation. The bottom diagram represents 
the diseased state, whereby PP2A activity is inhibited in the cell body and there is 
high influx of calcium ions that activate proline-directed kinases, thus leading to 
phosphorylation of NF. Pin1 stabilises the phosphorylated NF to the trans isomer 
thus facilitating further phosphorylation and aberrant phospho-NF accumulation 
in the cell bodies. This then impairs the axonal transport in the neurons and leads 











1.4 RNA INTERFERENCE THERAPEUTICS 
RNA interference (RNAi) is a viable method for the silencing of specific gene 
expression in mammalian cells due to its potency as well as high specificity and 
selectivity. Therefore RNAi is an attractive choice for therapeutics involving 
cancers, control of disease-associated genes and viral infections. In several 
examples, RNAi has been shown to be selective of only the mutant transcripts, 
leaving WT transcripts intact (Aagaard and Rossi, 2007). One study reported that 
RNAi was able to distinguish between the WT and mutant alleles of two disease 
genes: the SOD1 gene and the huntingtin (HTT) gene, indicating that single 
nucleotide polymorphisms are sufficient to induce RNAi targeted silencing of 
mutant alleles (Schwarz et al., 2006).  
 
1.4.1 RNAi PATHWAY 
Early applications of RNAi exploited the small interfering RNAs (siRNAs) for 
gene expression knockdown, where the 21-bp RNA duplexes are integrated into 
the RNA-interfering silencing complex (RISC) and the antisense strand of the 
siRNA binds to the complementary target mRNA for degradation. Though the use 
of siRNA is simple and results in potent gene silencing, its effect is transient 
whereby once the siRNA or its precursors are degraded, repeated treatments 
would be required (Aagaard and Rossi, 2007). Another method of RNAi is using 
short hairpin RNA (shRNA), which has a tight hairpin stem and loop structure of 
complementary RNA base pairing. Introduction of the short hairpin RNA into the 
cell would result in its translocation into the nucleus and integration for synthesis 
of the shRNA by the cellular machinery ensuring stable, long-term target gene 
knockdown, which is required for the purpose of this study. The synthesized 
shRNA is then initially cleaved by Drosha, an RNase III to produce the processed 
primary transcript, which is exported to the cytoplasm by exportin-5. After which, 
the pre-shRNA binds to Dicer, an RNase III endonuclease which further cleaves 
the shRNA to produce a double-stranded siRNA. The siRNA is then transferred to 
RISC, followed by unwinding of the double stranded RNA to produce the primed 
RISC with the target antisense RNA strand, to bind to the complementary mRNA 
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for degradation (Rao et al., 2009). The mechanism of action of shRNA is 
summarized in Figure 1.4.1. shRNA is stably expressed in cells and would permit 
stable knockdown of the target gene, therefore ideal for long term gene therapy 
treatment. However, due to the negative charge of the shRNA, it is unable to 
readily cross the membrane and therefore requires the use of vector-based shRNA 
systems to deliver the shRNA into the cell (Aagaard and Rossi, 2007). Several 
strategies are available using non-viral vehicles and viral vectors, such as 
retrovirus/lentivirus, adenovirus and adeno-associated virus (AAV) for efficient 
delivery of the shRNA. Though non-viral vectors have better safety profiles, the 
transduction efficiency is generally lower than the viral vectors (Rao et al., 2009).  
 
 
Figure 1.4.1. Mechanism of action of shRNA-mediated interference pathway 
Once the shRNA expression vector is delivered into the cytoplasm, it is 
transported into the nucleus for transcription. The pre-shRNA transcript produced 
from cleavage by the Drosha/DGCR8 complex is transported by exportin-5 into 
the cytoplasm to be loaded onto the Dicer/Tat-RNA-binding protein (TRBP)/ 
PKR activating protein (PACT) complex to be processed into mature shRNA. 
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Mature shRNA in the Dicer/TRBP/PACT complex associates with the Argonaute 
protein containing RISC, which is primed to cause RNA interference of the target 
gene by degrading the complementary mRNA or translational suppression via p-
bodies. (Rao et al., 2009). 
 
Previous publications have also shown that the use of shRNA was capable of 
mitigating the disease progression in several neurodegenerative diseases. One 
such example was that the intraspinal injection of lentiviral SOD1 shRNA in the 
G93A SOD1 mice substantially slowed down both the onset and the progression 
rate of the disease (Raoul et al., 2005). Another example showed that 
administration of the herpes simplex virus vector containing the amyloid 
precursor protein (APP) shRNA to the mutant mouse model overexpressing a 
mutant form of APP in the hippocampus, resulted in the inhibition of A 
accumulation in these mice (Hong et al., 2006). For the purpose of this study, 
Pin1 shRNA is to be used for stable Pin1 knockdown in order to determine its 
neuroprotective effects against p-NF-H accumulation in the ALS mouse model 















1.5 ADENO-ASSOCIATED VIRUS 
Adeno-associated virus (AAV) is a single-stranded DNA-containing virus that 
belongs to the Parvoviridae family, with non-enveloped, icosahedral capsids with 
a 20mm diameter. The small capsid size of AAV permits a packaging limit of 
only 4.8kb of foreign DNA and it contains two open reading frames: Rep 
(encodes non-structural proteins involved in viral genome replication, 
transcriptional control, integration and encapsidation of the AAV genomes) and 
Cap (encodes the three capsid proteins VP1, VP2 and VP3), as well as the 
inverted terminal repeats (ITRs) that are involved in the primase-independent 
synthesis of the second DNA strand and the packaging of the AAV genome into 
the capsid (Buning et al., 2008). AAV depends on a co-infection with a helper 
virus to facilitate its productive infection. There are twelve human AAV serotypes 
(AAV1 to AAV12) and more than 100 serotypes from non-human primates 
discovered (Daya and Berns, 2008). AAV2 was the first discovered and the most 
studied serotype. The AAV vectors are attractive tools for gene therapy treatment 
such as neurological diseases which usually require the transduction into post-
mitotic cells with sustained, long-term gene expression to treat the disease 
(Chtarto et al., 2013). 
 
1.5.1. AAV VECTOR DELIVERY OF shRNA 
An ideal vector system for shRNA expression has several requirements; 
transduction efficiency into the target cells, safety, stable shRNA expression and 
easy manufacture of the vector (Grimm et al., 2005). AAV vectors are able to 
transduce a broad range of cell types: both dividing and non-dividing cells. The 
percentage of cells transduced depends on the mode of delivery and the AAV 
serotypes used. Due to variations in the capsid protein sequences, the receptors 
used for cell entry may differ between serotypes resulting in different preferential 
tissue tropism (Buning et al., 2008). This was supported by a study that examined 
transgene expression and biodistribution of AAV serotypes 1 to 9 after tail vein 
injection (Zincarelli et al., 2008). The authors discovered that the tissue 
distribution and the kinetics (onset, duration of expression, and elimination) of 
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AAV vectors vary between the different AAV serotypes (Zincarelli et al., 2008). 
Therefore, experimental protocols can be modified to use the particular serotypes 
that significantly improve transduction efficiency in certain tissue. Additionally, 
the feasibility to cross package a given AAV vector construct into capsids from 
other serotypes allows a broader host range (Grimm et al., 2005). For example, a 
clinical trial was conducted on Duchenne muscular dystrophy (DMD) patients 
using a chimeric adeno-associated virus capsid variant, AAV2.5 derived from 
AAV2 capsid with five mutations from AAV1. The chimeric vector has the 
improved muscle transduction capacity of AAV1 while keeping the AAV2 
receptor binding resulting in reduced antigenic cross-reactivity (Bowles et al., 
2012). Moreover, the use of different serotypes or capsid sequences to avoid the 
formation of antibodies against a specific serotype allows re-administration of the 
AAV particles (Grimm et al., 2005). The mode of delivery of the AAV particles 
also determines the target cell transduced. Several papers have published that 
intramuscular injections of AAV effectively transduces the motor neurons of the 
spinal cord (Kaspar et al., 2003; Lu et al., 2003b; Towne et al., 2010). Intravenous 
injections of AAV have been shown to transduce the neurons in the CNS (Iwata et 
al., 2013, Fu et al., 2011; Duque et al., 2009). However, there have been several 
reports that besides neuronal cells in the CNS, a percentage of glia cells are also 
transduced by AAV (Gray et al., 2011; Howard et al., 2008; Foust et al., 2009). 
Secondly, AAV have a good safety profile which is partly due to the non-
malignant WT AAV as compared to the other viral vectors such as lentivirus and 
adenovirus (Tenenbaum et al., 2003; Grimm et al., 2005). A study conducted 
using DNA microarray to identify and compare the genes modulated during AAV 
or adenovirus infection indicates that the AAV infection elicited a non-pathogenic 
response, while the adenovirus infection induced immune and stress-response 
genes associated with pathogenic effects (Stilwell and Samulski, 2004). Another 
study demonstrated that when AAV was used to transduce the hepatocytes in 
mice, it is the extrachromosomal AAV, not the integrated form, which is major 
form of AAV in the liver and the primary source of AAV-mediated gene 
expression, indicating a lower risk of vector-related insertional mutagenesis 
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(Nakai et al., 2001). Insertional mutagenesis may risk inadvertent oncogene 
activation, which is especially deleterious in CNS delivery (Chtarto et al., 2013). 
Furthermore, in its extrachromosomal form, AAV is able to stably express in the 
infected cell therefore preventing not only insertional mutagenesis but also 
enabling high and stable expression of the transgene. Another benefit of using the 
AAV vector system is the ease at which recombinant particles can be produced at 
bulk amounts, whereby medium-scale AAV preparations typically produces in the 
range of 1012 recombinant particles (Grimm et al., 2005). Using AAV as the gene 
delivery tool in this study, Pin1 shRNA is to be delivered into the motor neurons 
of the ALS mouse spinal cord with stable and efficient transduction. 
 
1.5.2. CLINICAL TRIALS USING AAV 
AAV-mediated gene transfer has been explored in the past decade and many 
studies have progressed to the use of AAV in human clinical trials especially in 
neurological disease. The administration of 1 x 1012 vector genomes (vg) per 
subject by intracranial infusions showed no evidence of AAV2 neutralizing 
antibody titers in serum for the majority of subjects tested while a small subset (3 
out of 10 patients) demonstrated low to moderately high levels of AAV2 
neutralizing antibody with respect to baseline, indicating the safety and 
tolerability of the AAV vector delivery into the brain (McPhee et al., 2006). 
Another study reported that when patients with moderate to advanced PD 
received bilateral infusion of a low dose of the AAV-human aromatic l-amino 
acid decarboxylase (hAADC) into the putamen, there was a modest improvement 
observed in the patients (Eberling et al., 2008).The results from positron emission 
tomography (PET) imaging with fluoro-L-m-tyrosine tracer used for evaluation of 
AADC expression indicated that the AAV-mediated hAADC application persisted 
four years after vector delivery and was well tolerated. The data collected 
indicated improvements in the Unified Parkinson’s Disease Rating Scale 
(UPDRS) in all patients during the first 12 months following treatment but 




1.6 OBJECTIVE OF STUDY  
The initial data on the role of Pin1 in the accumulation of p-NF-H was indeed 
promising, however the exact outcome of Pin1 knockdown in disease pathology 
such as in ALS, had not been elucidated. The main objective of this study is to 
determine if reduction of Pin1 expression in an ALS model is able to rescue the 
disease pathology of aberrant accumulations of p-NF-H. The proceeding chapters 
discuss the validation of Pin1 knockdown using the Pin1 shRNA construct in vitro 
in cortical neurons and HEK293T/17 cells, followed by, the use of AAV as the 
gene delivery methodology to ensure delivery of Pin1 to the spinal cord of the 
ALS transgenic mice. The final chapter investigates the administration of AAV-
Pin1 shRNA to determine its effect on the reduction of the neurotoxic p-NF-H 
accumulations. Following the reduction of the aberrant p-NF-H accumulation, the 
final chapter additionally investigates into the effect of Pin1 knockdown on the 
















CHAPTER 2 – MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 PREPARATION OF PLASMID CONSTRUCT 
 
 
Figure 2.1.1.1 – Control shRNA (blue) and Pin1 shRNA (red) sequences. 
 
Table 2.1.1.1 – Materials used and stock preparation during plasmid construct 
transformation into competent cells and plasmid purification. 
 
Item description Manufacturer Stock Preparation 
Subcloning Efficiency DH5α 
Competent Escherichia coli 
cells 
Invitrogen - 
Fast Media LB Agar Amp Fermentas Each sachet was dissolved in 
200 mL deionised distilled water 
(ddH2O) and heated until 
bubbling using the microwave. 
The solution was swirled gently 
and re-heated until dissolved. 
The solution was allowed to cool 
before pouring into plates. 
Stored at 4 °C until use. 
Ampicillin sodium salt Sigma 100 mg/mL stock prepared by 
dissolving in ddH2O. Mixture 
was sterilized filtered. Stored at -





Table 2.1.1.1 continued. 
Item description Manufacturer Stock Preparation 
Luria Bertani (LB) Broth Sigma Aldrich 20 g dissolved in 1 L ddH2O and 
autoclaved. Stored at 4 °C until 
use. 
QIAprep Miniprep Kit Qiagen - 
Glycerol Invitrogen - 
 
2.1.2 MAMMALIAN CELL CULTURES 
 
Table 2.1.2.1 – Reagents used for cell culture of primary neuronal cultures and 
cell lines. 
 
Item description Manufacturer Stock Preparation 
Poly-D-lysine (PDL) Sigma Aldrich 2 mg/mL stock prepared by dissolving 








(ethylene diamine tetra 
acetic acid) 
Invitrogen 10X Trypsin-EDTA stock was diluted 
with 1XPBS to prepare 1X Trypsin-
EDTA. Stored at -20 °C until use. 
Dulbecco's phosphate 
buffered saline (PBS) 






Sigma Aldrich 1 mg/mL stock prepared by dissolving 














Neurobasal (Invitrogen), 2% B27 supplement 
(Invitrogen), 100 IU/mL penicillin (Invitrogen), 100 




Eagle (DMEM) medium  
DMEM (Invitrogen), 10% (v/v) Fetal Bovine Serum 
(FBS) (Invitrogen), 100 IU/mL penicillin (Invitrogen), 





DMEM (Invitrogen), 10% (v/v) FBS (Invitrogen), 1.5 
g/L (w/v) sodium bicarbonate (Sigma Aldrich), 100 
IU/mL penicillin (Invitrogen), 100 μg/mL 
streptomycin (Invitrogen), 1mM sodium pyruvate 
(Invitrogen). 
HEK 293T/17 DMEM 
freezing medium 
DMEM (Invitrogen), 20% (v/v) FBS (Invitrogen), 1.5 
g/L (w/v) sodium bicarbonate (Sigma Aldrich), 100 
IU/mL penicillin (Invitrogen), 100 μg/mL 
streptomycin (Invitrogen), 1 mM sodium pyruvate 




DMEM (Invitrogen), 10% (v/v) FBS (Invitrogen) 
AAV-293 freezing 
medium 
DMEM (Invitrogen), 20% (v/v) FBS (Invitrogen), 
20% DMSO (Sigma Aldrich) 
HEK 293 DMEM 
medium 
DMEM supplemented with 10% FBS, 100 IU/mL 








2.1.3 ADENO-ASSOCIATED VIRUS (AAV) PRODUCTION  
 
Table 2.1.3.1 – List of reagents used for AAV production and purification. 
 
Item description Manufacturer Stock Preparation 
AAV Helper Free 
System 
Stratagene - 
1X TNE buffer  
50 mM Tris pH7.4 
130 mM NaCl 





For 50 mL (prepared in ddH2O);  
2.5 mL Tris pH7.4 (1M) 
1.3 mL NaCl (5M)  
100 L EDTA (0.5M) 
Mixture was filter sterilized. 
Stored at room temperature until use. 
1.5 mM Na2HPO Sigma Aldrich 
 
0.5 M stock prepared by dissolving in 
ddH2O. Stored at room temperature 
until use. 
2XHBS 
280 mM NaCl 
1.5 mM Na2HPO





For 50 mL (prepared in ddH2O);  
2.8 mL NaCl (5M)  
150 L Na2HPO
mL HEPES (1M) 
Mixture was filter sterilized.  
Stored at -20 °C until use. 
0.3M calcium chloride Sigma Aldrich Powder solid dissolved in ddH2O and 
filter sterilized. Stored at room 




Polysciences Powder solid dissolved in ddH2O to 1 
mg/mL and pH adjusted to 7.1. 
Mixture was filter sterilized.  
Benzonase  EMD 
Chemicals 
- 




Table 2.1.3.1 continued. 
Item description Manufacturer Stock Preparation 
500 mM NaCl 1st Base 5 M Stock solution was added to the 
culture supernatant to a final 
concentration of 500 mM NaCl. 
Optiprep  
 
Sigma Aldrich Stock from manufacturer: 60% (w/v) 
solution of iodixanol in water (sterile) 
PBS–35 mM NaCl Sigma Aldrich Powder solid dissolved in 1XPBS to 
35 mM NaCl.  
0.1% Pluronic F-68 Invitrogen - 
10X PBS-MK 
10X PBS 
10 mM MgCl2 





For 100 mL solution;  
100 mL of 10X PBS  
0.2 g MgCl2•6H2O 
0.19 g KCl 
PBS-MK-NaCl 
10X PBS-MK 




For 100 mL (prepared in ddH2O); 
10 mL of 10X PBS-MK 













Prepared by mixing 9 volumes of 
Optiprep (60% (w/v) iodixanol) with 
1 volume of 10X PBS-MK. 
Prepared by mixing 4 volumes of 54% 
Iodixanol with 1.4 volumes of 1X 
PBS-MK. 
Prepared by mixing 2.5 volumes of 
54% Iodixanol with 2.9 volumes of 
1X PBS-MK. 
Prepared by mixing 1.5 volumes of 
54% Iodixanol with 1.2 volumes of 




2.1.4 IMMUNOSTAINING AND BIOCHEMICAL ANALYSES 
 
Table 2.1.4.1 – Primary antibodies used for immunocytochemistry (ICC), 
immunohistochemistry (IHC) and Western blotting (WB). 
 









SC46660 Santa Cruz 1:30 ICC 
Anti-Pin1 
(rabbit polyclonal) 









1: 30000 (Transfected 
samples) WB 
1: 300 IHC 
Anti-GFP 
(rabbit polyclonal) 





1:5000 (HEK 293T/17 
samples) WB 
















Table 2.1.4.1 continued. 

















Table 2.1.4.2 – Secondary antibodies used for immunofluorescence and Western 
blotting. 
 
Antibodies Catalog No. Manufacturer Dilution Factor Used 
Alexa Fluor 488 Goat 
Anti-Mouse IgG (H+L) 
A11008 
 
Invitrogen 1:200 IHC, ICC 
Alexa Fluor 488 Goat 
Anti-Rabbit IgG (H+L) 
A11001 Invitrogen 1:200 IHC, ICC 
Alexa Fluor 594 Goat 
Anti-Mouse IgG (H+L) 
A11005 Invitrogen 1:200 IHC, ICC 
Alexa Fluor 594 Goat 
Anti-Rabbit IgG (H+L) 
A11012 Invitrogen 1:200 IHC, ICC 
ECL Anti Rabbit IgG 
HRP-linked whole 
antibody (from donkey) 
NA934V GE Healthcare 1:1000 WB 
Anti-mouse IgG 
Horseradish peroxidase 
(HRP) linked whole 
antibody (from sheep) 





Table 2.1.4.3 – Reagents used for immunostaining of cells and tissues. 
 




Calbiochem 37% Paraformaldehyde diluted with 
1X PBS to prepare 4% 
Paraformaldehyde. Stored at room 
temperature up to 2 weeks. 
Triton X-100 Sigma Aldrich Triton X-100 was diluted in 1X PBS 
to prepare 0.05% Triton X-100. Stored 
at room temperature until use. 
PBS 1st Base 10X stock solution from manufacturer 
was dissolved in ddH2O. 
FBS Invitrogen - 
4',6-diamidino-2-
phenylindole (DAPI) 
Invitrogen 5 mg/mL stock prepared by dissolving 
in deionised distilled water. Stored at 4 




Sucrose Sigma Aldrich 30%, 20% and 10% (w/v) sucrose 
solution was prepared by dissolving 









Sigma Aldrich 0.05% (w/v) stock was prepared by 
dissolving in1X TBS. Solution was 
filtered and stored at -20 °C until use. 
Xylene Sigma Aldrich - 
VECTASTAIN® 









Table 2.1.4.3 continued. 
Item description Manufacturer Stock Preparation 
VECTASTAIN® 





1X TBS (Tris buffered 
saline) 
50 mM Tris-HCl pH7.4 






For 1 L (prepared in ddH2O);  
20 mL Tris-HCl pH7.4 (1 M) 
30 mL NaCl (5 M)  
Stored at room temperature until use. 
Hydrogen Peroxide 
(H2O2) 
Sigma Aldrich - 




Table 2.1.4.4 – Kits and chemicals used for Sodium Dodecyl Sulphate (SDS)-
PAGE and Western Blotting. 
 
Item description Manufacturer Stock Preparation 
Complete, EDTA-free 




50X stock prepared by dissolving 
one tablet in 1 mL ddH2O. Stored 
at -20 °C until use. 
Lysis Buffer 
50 mM Tris pH7.0 
150 mM NaCl 
1% (v/v) Triton X-100 
1 mM NaF 
1 mM EDTA 
1 mM ethylene glycol tetra 








For 50 mL (prepared in ddH2O);  
2.5 mL Tris-HCl pH7.0 (1 M)  
1.5 mL NaCl (5 M)
500 L Triton X-100 
100 L NaF (0.5 M) 
100 L EDTA (0.5 M) 
100 L EGTA (0.5 M) 
Stored at 4 °C until use. 
Pierce bicinchoninic acid 






Table 2.1.4.4 continued. 
Item description Manufacturer Stock Preparation 
Bovine Serum Albumin 
(BSA) Standard Set 
Bio-rad - 
Novex 4-20% Tris-Glycine 
Mini Gels 1.0 mm, 10 Well  
Invitrogen - 
2X SDS sample buffer  
62.5 mM Tris-HCl pH6.8 
2% (v/v) SDS 
10% (v/v) glycerol 
0.01% (w/v) bromophenol 
blue  
5% (v/v) -mercaptoethanol 
 
1st Base                                                                                                                         





For 50 mL (prepared in ddH2O);  
3.125 mL Tris-HCl pH6.8 (1M)
10 mL SDS (10%)
mL glycerol (100%) 
mg bromophenol blue 
 
2.5 mL -mercaptoethanol (added 
just before use) 
Stored at room temperature until 
use. 
Tris Glycine- SDS Buffer 1st Base 10X stock solution from 
manufacturer was dissolved in 
ddH2O. 




For 1L solution (prepared in 
ddH2O);  
100 mL Tris Glycine (10X)  
200 mL Methanol 
Ponceau S. solution 
 
Sigma Aldrich 0.1% (w/v) stock prepared by 
dissolving in 5% (v/v) acetic acid. 
Solution was mixed thoroughly 
until dissolved and stored at room 
temperature overnight before use. 
Glacial acetic acid VWR 5% (v/v) acetic acid prepared by 




Table 2.1.4.4 continued. 
Item description Manufacturer Stock Preparation 
15% resolving gel 
375 mM Tris pH 8.8 
15% (v/v) Acrylamide/Bis 
solution 
0.1% (v/v) SDS 
0.04% (w/v) APS 








For preparation of 2 gels (10 mL): 
2.5 mL Tris pH 8.8 (1.5 M) 
5 mL Acrylamide/Bis solution 
(30%) 
100 L SDS (10%) 
40 L APS (25% w/v in ddH2O) 
4 L TEMED 
ddH2O: 3.4 mL 
5% stacking gel 
125 mM Tris pH 6.8 
5% (v/v) Acrylamide/Bis 
solution 
0.1% (v/v) SDS 
0.1% (w/v) Ammonium 
persulphate (APS) 









For preparation of 2 gels (5 mL): 
630 L Tris pH 6.8 (1 M) 
830 L Acrylamide/Bis solution 
(30%) 
50 L SDS (10%) 
20 L APS (25% w/v in ddH2O) 
5 L TEMED 
ddH2O: 3.4 mL 
Skimmed Milk (Low Fat) Anlene - 
1X TBST 
50 mM Tris-HCl pH7.4 
150 mM NaCl  







For 1 L (prepared in ddH2O);  
20 mL Tris-HCl pH7.4 (1 M) 
30 mL NaCl (5 M)  
1 mL Tween 20 
Stored at room temperature until 
use. 
ECL Plus Western Blotting 
Detection 
GE Healthcare - 
SeeBlue Plus 2  Invitrogen Band sizes: 188, 98, 62, 49, 38, 




Table 2.1.4.4 continued. 
Item description Manufacturer Stock Preparation 
Stripping buffer  
62.5 mM Tris pH7.0 
2% (v/v) SDS 





For 50 mL (prepared in ddH2O);  
3.125 mL Tris-HCl pH 7.0 (1 M)  
10 mL SDS (10%)
350 L -mercaptoethanol (added 
just before use) 
Stored at room temperature until 
use. 
 
Table 2.1.4.5 – Forward and reverse primers for Real-time reverse transcription 
polymerase chain reaction (RT-PCR) for WT and G93A SOD1 mice. 
 





Forward 5’ CTGGTGAAGCACAGCCAGTC 3’ 





Human Forward 5’ ACCCACTCCTCCACCTTTG 3’ 
Reverse 5’ CTCTTGTGCTCTTGCTGGG 3’ 
Mouse Forward 5’ TGGCCTCCAAGGAGTAAGAAAC 3’ 
Reverse 5’GGGATAGGGCCTCTCTTGCT 3’ 
 
Table 2.1.4.6 – List of reagents used for Real-time RT-PCR. 
 
Item description Manufacturer Stock Preparation 
RNeasy mini kit  Qiagen - 
TRIzol® Reagent Invitrogen - 
Chloroform J.T. Baker - 
High Capacity cDNA 




Power SYBR® Green 








2.1.5 ANIMAL STUDIES 
 
Table 2.1.5.1 – Forward and reverse primers for genotyping polymerase chain 
reaction (PCR) for WT and G93A SOD1 mice. 
 
Target sequence Primer Sequence 
WT  Forward 5’ CTAGGCCACAGAATTGAAAGATCT3’ 
Reverse 5’ GTAGGTGGAAATTCTAGCATCATCC 3’ 
G93A SOD1 Forward 5’ CATCAGCCCTAATCCATCTGA 3’ 
Reverse 5’ CGCGACTAACAATCAAAGTGA 3’ 
 
Table 2.1.5.2 – Reagents used for genotyping and perfusion. 
 
Item description Manufacturer Stock Preparation 
Proteinase K Sigma Aldrich 
 
Powder solid was dissolved to 1 
mg/mL in ddH2O. 
Digestion buffer  
 
67 mM Tris-HCl pH 8.8 
17 mM Ammonium 
Sulphate ((NH4)2SO4) 
67 mM MgCl2 
1% (v/v) -
mercaptoethanol  









    
Sigma Aldrich 
Promega 
For 10 mL (prepared in 
Nuclease-free H2O);  
670 L Tris-HCl pH 8.8 (1 M) 
53.125 L (NH4)2SO4 (3.2 M) 
 
670 L MgCl2 (1 M) 
100 L -mercaptoethanol 
 
50 L Triton X-100 
0.5 g/ml Proteinase K added 
just before use 
TAE buffer  1st Base 10X stock solution from 
manufacturer was dissolved in 
ddH2O. 






Table 2.1.5.2 continued. 
Item description Manufacturer Stock Preparation 
Agarose Invitrogen Powder solution dissolved in 
1X TAE Buffer and heated until 
bubbling using the microwave. 
The solution was swirled gently 
and re-heated until dissolved. 
The solution was allowed to 
cool before pouring to make 
agarose gels.  
PCR Mastermix 
components  
1.5 mM MgCl2 





2% (v/v) DMSO 
1X Colorless GoTaq® Flexi 
Buffer1 













For 25 L reaction (prepared in 
Nuclease-free H2O): 
1.5 L MgCl2 (25mM) 
0.1 L Go Taq Flexi DNA 
polymerase (5 U/μL) 
0.5 μL dNTP (10 mM) 
 
 
0.5 μL DMSO 
2.5 μL Colorless GoTaq® Flexi 
Buffer1 (10X) 
2.5 L BlueJuice Gel Loading 
Dye (10X) 
Saline solution (0.9% 
NaCl) 
B.Braun - 
100 bp DNA ladder Promega Marker sizes: 1500 bp, 1000 bp, 
900 bp, 800 bp, 700 bp, 600 bp, 






Table 2.1.5.2 continued. 




Sigma Aldrich For 1 L preparation, 40 g of 
powder solid was dissolved in 
900 mL ddH2O. The mixture 
heated and stirred until powder 
was dissolved. pH was adjusted 
to pH 7.6 with NaOH. Once 
cooled to room temperature, 
100 mL of 10X PBS was added 
and solution was filtered. Stored 
























2.2.1 PREPARATION OF PLASMID CONSTRUCT 
2.2.1.1 Plasmid Construct 
The plasmids used in this study were Control shRNA and Pin1 shRNA, which 
were designed and cloned into the AAV vector by Vector Biolabs, PA USA 
(Appendix Figure 1). The Control shRNA encodes a missense ‘non-silencing’ 
shRNA and the Pin1 shRNA was produced to knockdown Pin1 expression levels 
(Figure 2.1.1.1).  
 
2.2.1.2 Transformation of competent cells with plasmids 
Transformation of competent cells with plasmids was performed according to the 
manufacturer’s instructions with slight modifications. Subcloning Efficiency 
DH5α Competent Escherichia coli cells were thawed on ice. 50 L of cells were 
aliquoted and gently mixed with 1 to 10 ng of plasmid DNA, after which the 
mixture was incubated on ice for 30 minutes. The cells were then heat shocked for 
20 seconds in a 42 °C water bath, following which the cells were incubated again 
on ice for 2 minutes. 950 L of pre-warmed LB Broth (without antibiotics) was 
added to the cells and then placed into a shaking incubator at 200 revolutions per 
minute (rpm) for 1 hour at 37 °C. The transformation mixture was then spread 
onto LB agar plates containing ampicillin (Fast Media LB Agar Amp) and 
incubated inverted overnight at 37 °C. Using a sterile pipette tip on the following 
day, single bacterial colonies were picked and each mixed into separate tubes (at 
least five times volume of the culture for sufficient aeration) containing 2 mL of 
LB broth supplemented 0.1 mg/mL ampicillin. The inoculated LB broth was then 
placed into a shaking incubator at 200 rpm overnight at 37 °C. After which, the 
bacterial culture was mixed with glycerol at a 1:1 ratio in a sterile 2 mL tube and 
the glycerol stocks were stored at -80 °C. 
 
2.2.1.3 Plasmid DNA purification 
A small amount of culture from the glycerol stocks of the transformed competent 
cells containing the plasmid DNA (Control shRNA and Pin1 shRNA) was 
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inoculated separately into the required amount of LB Broth containing 0.1 mg/mL 
ampicillin, prepared in conical flasks or 50 mL falcon tubes with at least five 
times volume of the culture for sufficient aeration. The flasks or tubes containing 
the LB broth culture were then placed in a shaking incubator at 200 rpm for 
overnight incubation at 37 °C. The LB broth culture was then collected on the 
following day and spun at 3000 xg for 15 minutes at 4 °C. The supernatant was 
discarded and the bacterial cell pellet was stored at -20 °C until further use. The 
plasmid DNA was purified from the cell pellet using the QIAprep Miniprep Kit 
(Qiagen, Hilden Germany) according to manufacturer’s instructions. For each 5 
mL of LB broth culture, the collected bacterial pellet was re-suspended in 250 μL 
Buffer P1 and the mixture was transferred to eppendorf tube, followed by addition 
of 250 μL Buffer P2. The tube was then inverted and mixed thoroughly. 350 μL 
Buffer N3 was then added and mixed thoroughly by inversion of the tubes, after 
which the tubes were centrifuged at 17,900 xg for 10 minutes at room temperature 
and the collected supernatant was added to the QIAprep spin column placed with 
the collection tubes. The columns were then centrifuged for one minute at 17,900 
xg and the flow through was discarded, after which 750 μL Buffer PE was added 
and the column was centrifuged for one minute at 17,900 xg. The flow through 
was discarded and the column was then centrifuged for another one minute at 
17,900 xg. The column was then placed into a new collection tube and the DNA 
was eluted with 50 μL Buffer EB by centrifugation for one minute at 17,900 xg. 
DNA was then quantified using the NanoDrop 1000 Spectrophotometer (Thermo 
Scientific, Runcorn UK). 
 
2.2.2 CELL CULTURES 
2.2.2.1 Preparation of primary cortical neuronal cultures 
Coating of cell culture surfaces with poly-D-lysine (PDL)  
Coating with PDL is required for improved growth of primary cultures as well as 
attachment of the cells onto the culture surface. The culture surfaces (either glass 
coverslips (Marienfeld Laboratory Glassware, Germany) or culture plates) were 
incubated with 0.02 mg/mL PDL (prepared in sterilized ddH2O, Atrium 611VF 
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Sartorius) overnight at room temperature. After which, the PDL solution was 
removed and the culture surfaces were washed three times with ddH2O. The 
culture vessels were left to dry completely in the Biological Safety Cabinet (BSC) 
prior to use. 
 
Preparation of cortical neurons  
Primary mouse cortical neurons were cultured using described protocol in the 
Worthington Papain Dissociation Kit with slight modifications. Embryonic day 15 
(E15) pups were surgically removed from the time-mated pregnant mice. The 
cortices were dissected from the pups and triturated in the papain/DNase solution 
(prepared according to manufacturer’s instructions) at 37 °C for 40 minutes in the 
shaking water bath. After which, the cells were triturated once more before 
centrifugation at 1,000 xg for 5 minutes at 4 °C. The supernatant was discarded 
and the cell pellet was re-suspended in albumin-ovomucoid inhibitor/DNase 
solution. After incubation at room temperature for 5 minutes, the cell suspension 
was layered on top of the discontinuous density gradient (albumin-ovomucoid 
inhibitor). The mixture was centrifuged at 800 xg for 5 minutes at 4 °C, following 
which the supernatant was discarded and the cell pellet was re-suspended in the 
cortical neuron culture medium, Neurobasal (NB) culture medium with 2% (v/v) 
B27 supplement containing 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 
mM glutamax. The cells were filtered through a 70 m Nylon cell strainer (BD 
Falcon, BD Biosciences, Franklin Lakes, NJ, USA) before a cell count was 
performed. The cell number was determined with the use of the Countess 
Automated Cell Counter (Invitrogen, Carlsbad, CA). For immunocytochemistry 
and biochemical analyses studies, cortical neurons were plated at 1 x 105 cells per 
15 mm glass coverslip placed in 12-well plates. Cortical neurons were maintained 
in a cell culture humidified incubator set at 37 °C with 5% CO2. Subsequently, 






2.2.2.2 Preparation of HEK 293T/17 cultures 
Culture of HEK 293T/17 cells 
HEK 293T/17 cells (ATCC number CRL11268) that was stored in liquid 
nitrogen, was quickly thawed in a 37 °C water bath. The cells were then added 
drop-wise to a sterile 50mL tube containing 10 volumes of the pre-warmed HEK 
293T/17 DMEM medium supplemented with 10% FBS, 1 mM sodium pyruvate, 
100 IU/mL penicillin, 100 μg/mL streptomycin and 1.5 g/L (w/v) sodium 
bicarbonate. Cells were briefly centrifuged at 200 xg for 5 minutes, after which 
the pellet was re-suspended in 20 mL of DMEM medium. The medium containing 
the cells were then transferred to a 75-cm2 culture flask. Subsequently HEK 
293T/17 DMEM culture medium was full-changed every three days.  
 
Passaging of HEK 293T/17 cells 
Culture flasks containing HEK 293T/17 cells were washed with 1X PBS twice 
before addition of 0.1% (v/v) trypsin-EDTA (prepared in 1X PBS). Flasks were 
then incubated for 5 minutes at 37 °C for cell detachment from the flask. The 
trypsinization was de-activated by addition of HEK 293T/17 DMEM medium. 
The supernatant of cells was collected and spun at 300 xg for 5 minutes. The 
supernatant was discarded and the cell pellet was re-suspended in HEK 293T/17 
DMEM medium, after which the cell number counted and cells were plated at the 
density of  between 5 x 104 cells to  1 x 105 cells per 15 mm coverslips placed in 
12-well plates and 1 x 106 cells cells/well in 6-well plates. Cells were cultured in 
HEK 293T/17 DMEM medium, which was full-changed every three days. 
 
Freezing of HEK 293T/17 cells 
The HEK 293T/17 cells were first passaged as per the protocol above and the 
supernatant of cells collected was centrifuged at 300 xg for 5 minutes. The cell 
pellet was collected and re-suspended in HEK 293T/17 DMEM medium 
containing 20% FBS. As the cell suspension was continuously mixed by swirling, 
an equal volume of the HEK 293T17 freezing medium (HEK 293T/17 DMEM 
medium supplemented with 20% FBS and 20% DMSO) was then added drop-
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wise to the re-suspended cells. The cell suspension was then immediately 
transferred to the cryovials, which were placed into the freezing container, Mr. 
Frosty (Nalgene, Thermo Scientific) for overnight incubation at -80 °C, after 
which the cryovials were then placed into the liquid nitrogen tank for long term 
storage. 
 
2.2.2.3 Cell transfections 
Cortical neurons at 4-5 days in culture (DIC) and HEK 293T/17 cells (24 hours 
after seeding) were transfected using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s protocol with slight modifications. Table 2.2.1 depicts the 
amount of reagents used for the transfection experiments according to the cell 
culture vessel used. 
 

















2000 mixture added 
per well (L) 
12-well 1000 1.6 g in  
100 L 
4.0L in 100L 200 L 
6-well 2000 4.0 g in  
250 L 
10L in 250 L 500 L 
 
The plasmid DNA was diluted with Opti-MEM Reduced Serum medium 
according to the amounts stated in Table 2.2.1. Lipofectamine 2000 was then 
diluted with Opti-MEM Reduced Serum medium (Invitrogen) (Table 2.2.1) and 
incubated at room temperature for 5 minutes. After which, the diluted plasmid 
DNA and diluted Lipofectamine 2000 were mixed together and incubated at room 
temperature for 20 minutes for the formation of the DNA-Lipofectamine 2000 
complexes. The DNA-Lipofectamine 2000 mixture was then added drop-wise to 
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each well with the cells and plating medium (respective cell culture medium). 
Following incubation of the DNA-Lipofectamine 2000 mixture with the cells for 
45 minutes and 16 hours for primary cultures and HEK 293T/17 cells 
respectively, the medium was aspirated and culture medium (conditioned medium 
for primary cultures and fresh medium for HEK 293T/17 was added to cells. Cells 
were then maintained in the cell culture humidified incubator set at 37 °C with 
5% CO2 until collection of cells for further analyses. 
 
2.2.2.4 Transduction of primary cultures and HEK 293T/17 cells 
Transduction of primary cultures (cortical neurons) and HEK 293T/17 cells were 
performed by adding vector dilutions at 1:25 to the cultures. Primary cultures 
were transduced at 4-5 DIC and the HEK 293T/17 cells at 24 hours after seeding. 
Primary cultures were incubated with the recombinant AAV (rAAV) at 1:20 
dilution factor for 9 hours in the presence of 4 g/mL of polybrene to increase the 
transduction efficiency of the cells. Incubation of the HEK 293T/17 with the 
vector was done for 6 hours. Following which, the media was replaced with fresh 
media for HEK 293T/17 cells but the primary cultures were added with 
conditioned media (without any rAAV). Cells were then maintained in the cell 















2.2.3 ADENO-ASSOCIATED VIRUS (AAV) PRODUCTION  
2.2.3.1 Production of rAAV using the AAV Helper-Free System 
Preparation of AAV-293 cultures 
The rAAV stocks were prepared using the AAV-293 cell line provided by 
Stratagene (Agilent Technologies, CA USA). The AAV-293 cells stably express 
the Adenovirus proteins E1A and E1B required for AAV-2 production. The 
AAV-293 cells stored in the liquid nitrogen was quickly thawed in a 37 °C water 
bath, after which the cells were added drop-wise to a 15 mL tube containing 10 
volumes of the pre-warmed DMEM medium (containing 4.5 g/L glucose, 110 
mg/L sodium pyruvate, and 2 mM L-glutamine) supplemented with 10% FBS in 
the cell culture humidified incubator set at 37 °C with 5% CO2. Cells were briefly 
centrifuged at 200 xg for 5 minutes, after which the pellet was re-suspended in 20 
mL of DMEM medium. The medium containing the cells were then transferred to 
a 75-cm2 culture flask. Subsequently AAV-293 DMEM culture medium was full-
changed every three days. 
 
Passaging of AAV-293 cells 
AAV-293 cells were washed with 1X PBS twice before addition of 0.1% (v/v) 
trypsin-EDTA (prepared in 1X PBS), after which flasks were incubated for 5 
minutes at 37°C. The trypsinization was de-activated by addition of AAV-293 
DMEM medium and the supernatant of cells was centrifuged at 300 xg for 5 
minutes. The cell pellet was re-suspended in AAV-293 DMEM medium and 
cultured into 175-cm2 culture flasks. Cell confluence was maintained at 50%. 
 
Freezing of AAV-293 cells 
After passaging the AAV-293 cells as per the protocol above, the supernatant of 
cells collected was centrifuged at 300 xg for 5 minutes. The cell pellet was 
collected and re-suspended in AAV-293 DMEM medium containing 20% FBS. 
An equal volume of the AAV-293 freezing medium (AAV-293 DMEM medium 
supplemented with 20% FBS and 20% DMSO) was then added drop-wise to the 
re-suspended cells, while the cell suspension was continuously mixed by swirling. 
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The cell suspension was then immediately transferred to the cryovials, which 
were placed into the freezing container, Mr. Frosty for overnight incubation at -80 
°C, after which the cryovials were then placed into the liquid nitrogen tank for 
long term storage. 
 
Plasmids 
The Control shRNA and Pin1 shRNA constructs were co-transfected with 
pHelper and pAAV-RC plasmids provided by the manufacturer. The pHelper 
plasmid contains the subset of adenovirus genes (VA, E2A and E4) necessary for 
high-titer AAV production. The pAAV-RC plasmid contains the AAV-2 rep and 
cap genes, which together encode the trans-acting factors required for AAV 
replication and the viral capsid structural proteins.  
 
Calcium Phosphate Transfection 
For production of AAV, calcium phosphate triple co-transfections were 
performed in the AAV-293 cells according to the manufacturer’s instructions. The 
AAV-293 cells were seeded 48 hours prior to transfections at 3 x 106 cells into 
100 mm tissue culture plates with 10 mL culture media. The cells were used for 
transfections at approximately 70-80% confluency. The AAV-293 cells were 
triple co-transfected with pHelper and pAAV-RC plasmids (Stratagene) together 
with the recombinant pAAV-IRES-hrGFP vector containing Control shRNA or 
Pin1 shRNA. Each plate required 10 g from each of the plasmids, which were 
mixed together and added into a conical tube. 1 mL of 0.3 M calcium chloride 
(CaCl2) was added to the plasmids and the solution was gently mixed. The 
DNA/CaCl2 mixture was then added dropwise to 1 mL of 2X HBS (280 mM 
sodium chloride (NaCl), 1.5 mM Na2HPO and 50 mM HEPES (N-2-
hydroxyethylpiperazine-N’-2ethanesulfonic acid), adjusted to pH to 7.10. The 
DNA/ CaCl2/HBS suspension was then mixed by gentle inversion, followed by 
dropwise addition of the DNA/ CaCl2/HBS suspension onto the cells in the plate. 
The cells were then returned to the incubator for 6 hours. After which, the media 
in the plate was removed and replaced with fresh DMEM growth medium. The 
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cells were then maintained for an additional 72 hours in the cell culture 
humidified incubator set at 37 °C with 5% CO2. 
 
Purification of rAAV2 particles 
Purification of AAV was done according to the manufacturer’s instructions with 
slight modifications. The transfected AAV-293 cells and medium were harvested 
at 72 post-transfection and collected into 50 mL tubes. The cell suspension was 
then subjected to four freeze–thaw cycles by alternating the tubes between the dry 
ice-ethanol bath and the 37 °C water bath for approximately 10 minutes 
incubation with each freeze and thaw. The cell suspension was vortexed briefly 
after each thaw cycle. The cellular debris was then collected by centrifugation at 
4,000 xg for 10 minutes at room temperature. The supernatant was then collected 
and filtered through a 0.45m filtering unit. The filtrate was then spun at 50,000 
xg for 150 minutes at 4°C. The pellet was then re-suspended in 1X TNE buffer 
(50 mM Tris pH 7.4, 130 mM NaCl, 1 mM EDTA) and the viral suspension was 
incubated overnight at 4°C on a shaking platform after which, it was briefly 
centrifuged at 8,000 xg for 30 seconds, aliquoted and stored at -80°C. 
 
2.2.3.2 rAAV production performed by Vector Core Lab, UPENN 
The AAV vectors used in this study for in vivo transduction into the motor 
neurons of the mouse spinal cord were purchased from and produced 
commercially in the Vector Core Lab facility, University of Pennsylvania 
(UPENN), detailed below and as described previously (Lock et al., 2010). Small 
and large-scale Polyethylenimine (PEI) transfections as well as the vector 




For the production of the rAAV by UPENN, the plasmids used for the 
transfections were: (1) cis plasmid Control shRNA or Pin1 shRNA containing an 
enhanced green fluorescent protein (eGFP) expression cassette flanked by AAV2 
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ITRs, (2) trans plasmids pAAV 2/1, pAAV 2, pAAV 2/5, pAAV 2/6, pAAV 2/8, 
and pAAV 2/9 containing the AAV 2 rep gene and capsid protein genes from 
AAV 1, 2, 5, 6, 8, and 9, respectively and (3) adenovirus helper plasmid pAdΔF6. 
15 to 50 mg lots of >90% supercoiled plasmid were obtained (Puresyn, Malvern, 
PA) and used for all transfections. 
 
Small-scale Polyethylenimine (PEI) Transfection 
PEI-based triple transfections of AAV cis, AAV trans, and adenovirus helper 
plasmids were performed in HEK 293 cells. Late-passage HEK 293 cell cultures 
were maintained in the exponential growth phase by passaging twice weekly and 
were maintained in HEK 293 DMEM supplemented with 10% FBS, 100 IU/mL 
penicillin, 100 μg/mL streptomycin. The HEK 293 cells were seeded in 6-well 
plates or in 15-cm plates at 1 × 106 cells or 1.5 × 107 cells respectively and used for 
transfections at 85–90% confluency. For the small-scale transfections in the 6-
well plates, the transfection was performed with the plasmid ratios of 2:1:1 (1.73
μg of adenovirus helper plasmid/0.86 μg of cis plasmid/0.86 μg of trans plasmid 
per well). PEI “Max” (Polysciences, PA USA) was dissolved at 1 mg/mL in water 
and pH adjusted to 7.1. For every μg of DNA transfected, 2 μg of PEI was added 
to 100 μL of serum-free DMEM and mixed by vortexing. After 15 minutes 
incubation at room temperature, the mixture was added to 1.2  mL of serum-free 
DMEM medium to replace the cell culture medium in each well. For transfections 
in the 15-cm plates, the same plasmid ratios of 2:1:1 were used but all reagent 
amounts were increased by a scale of 15X. 
 
Large-scale PEI Transfection 
Four days prior to transfection, the HEK293 cells from confluent 15-cm plates 
were split into 10-layer cell stacks (Corning, NY USA) containing 1 L of 
complete DMEM. The day before transfection, the cells in the cell stacks were 
trypsinized and re-suspended in 200 mL of medium. Once the cell clumps had 
settled, the cells were then seeded at 6.3 × 108 cells into each of six 10-layer cell 
stacks cultured in serum-free DMEM. At 75% confluency, the HEK293 cells 
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were used for the large-scale PEI-based transfections. Plasmids ratios of 2:1:1 
(1092 μg of adenovirus helper plasmid/546 μg of cis plasmid/546 μg of trans 
plasmid per cell stack) were used, with the PEI “Max”/DNA ratio at 2:1 (w/w). 
The plasmid mix and PEI were prepared separately in serum-free DMEM (total 
volume, 54 mL) for each cell stack and mixed by vortexing, prior to incubation 
for 15 minutes at room temperature. After which, the mixture was added to 1 L of 
serum-free DMEM containing 100 IU/mL penicillin and 100 μg/mL 
streptomycin. The culture medium in the stack was replaced with the DMEM–
PEI–DNA mix, and the transfections were incubated in the cell culture humidified 
incubator set at 37 °C for 72 hours. Following this, 500 mL of fresh serum-free 
DMEM was added to each cell stack and the cultures were further incubated for 
120 hours. Benzonase was then added to the culture supernatant to a final 
concentration of 25 units/mL and the stack was incubated for another 2 hours, 
after which 500 mM of NaCl was added and incubation resumed for another 2 
hours before harvesting of cells and medium separately. For quantification of cell-
associated vector, the cells were trypsinized and lysates collected from three 
sequential freeze–thaw cycles (−80 °C/37 °C).  
 
Vector Purification 
The culture medium collected from the cell stacks (one cell stack for small scale 
preparations and two cell stacks for routine scale preparations) containing the 
transfected HEK 293 cells (downstream feedstock) was left overnight at 4 °C to 
allow the samples to precipitate. The samples were then spun at 16,900 ×g, 4 °C 
for 30 minutes and the supernatant was collected. The supernatant was then 
incubated for 1 hour at 37 °C, after which the supernatant was clarified through a 
0.5-μm Profile II depth filter (Pall, NY USA) into a 10-L Allegro medium bag 
(Pall). Then the clarified feedstock was concentrated by tangential flow filtration 
(TFF), using a NovaSet-LS LHV holder with customized inner diameter of 0.25-
inch tubing and ports (TangenX Technology, MA USA) and a 0.1-m2 Sius-LS 
single-use TFF screen channel cassette with a 100-kDa molecular weight cutoff 
(MWCO) HyStream membrane (TangenX Technology). According to the 
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manufacturer's recommendations, the feedstock was concentrated by 125-fold to 
85 mL with a transmembrane pressure of 10–12 psi maintained throughout the 
procedure. After each run, the TFF filter was discarded and 0.2 N NaOH was used 
to sanitize the system between runs. The concentrated feedstock centrifuged at 
10,500 ×g, 15 °C for 20 minutes and the supernatant was collected in a new tube. 
Six iodixanol step gradients were formed as published previously with slight 
modifications (Zolotukhin et al., 1999).  
 
Increasingly dense iodixanol (OptiPrep; Sigma Aldrich, St Louis, MO) solutions 
in 1XPBS containing 10 mM magnesium chloride and 25 mM potassium were 
successively underlaid in 40 mL Quick-Seal centrifuge tubes (Beckman 
Instruments, Palo Alto, CA). The steps of the gradient were 4 mL of 15% 
iodixanol, 9 mL of 25% iodixanol, 9 mL of 40% iodixanol, and 5 mL of 54% 
iodixanol. 14 mL of the clarified feedstock was then overlaid onto the gradient 
and the tube was sealed. The tubes were centrifuged for 70 minutes at 350,000 ×g 
in a 70Ti rotor (Beckman Instruments) at 18°C and the gradients were 
fractionated through an 18-gauge needle inserted horizontally approximately 1 cm 
from the bottom of the tube. Fractions were diluted 20-fold with water into an 
ultraviolet (UV)-transparent 96-well plate (Corning, NY, USA) and the 
absorbance was measured at 340 nm. A spike in OD340 (optical density at 340 nm) 
readings indicated the presence of the major contaminating protein band and all 
fractions below this spike were collected and pooled. Pooled fractions from all six 
gradients were combined, diafiltered against 10 volumes of the final formulation 
buffer (PBS–35 mM NaCl), and concentrated 4-fold to ~10 mL by TFF according 
to the manufacturer's instructions, using a 0.01-m2 single-use Sius TFF cassette 
with a 100-kDa MWCO HyStream screen channel membrane (TangenX 
Technology) and an LV Centramate cassette holder (Pall). A transmembrane 
pressure of 10 psi was maintained throughout the process. The holdup volume of 
the apparatus was kept low, using minimal lengths of platinum-cured silicone 
tubing (inner diameter, 1.66 mm) (Masterflex, Cole Parmer Instrument, Vernon 
Hills, IL). In addition, all wettable parts were pre-treated for 2 hours with 0.1% 
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Pluronic F-68 in order to minimize binding of the vector to surfaces. The TFF 
filter was discarded after each run and the system was sanitized with 0.2 N NaOH 
between runs. Glycerol was added to the diafiltered, concentrated product to a 































2.2.4 IMMUNOSTAINING AND BIOCHEMICAL ANALYSES 
2.2.4.1 Immunocytochemistry 
Cells plated on glass coverslips were washed twice 1X PBS prior to fixation with 
4% (v/v) PFA (prepared in 1X PBS) for 20 minutes at room temperature. After 
fixation, cells were washed twice with 1X PBS followed by permeabilization with 
0.1% (v/v) Triton X-100 (prepared in 1X PBS) for 20 minutes at room 
temperature. After which, the cells were washed once with 1X PBS before 
blocking for 30 minutes at room temperature with 5% (v/v) FBS prepared in 1X 
PBS (5% FBS/PBS). Cells were then immunolabeled with the primary antibodies 
prepared in 5% FBS/PBS for one hour at room temperature. Coverslips were then 
washed three times with 1X PBS, followed by incubation for one hour at room 
temperature with the appropriate secondary antibodies. After incubation, the 
coverslips were washed three times with 1X PBS, followed by counterstaining of 
nuclei for 5 minutes at room temperature with DAPI (Sigma Aldrich) prepared at 
a dilution of 1:1000 in 1X PBS. The coverslips were then mounted onto glass 
slides using Faramount Aqueous mounting medium (Dako, Hamburg, Germany). 
The 1XPBS washes of the coverslips were done at room temperature at 5 minutes 
intervals. Fluorescent images were captured with a Carl Zeiss LSM-510 or LSM 5 
LIVE DuoScan laser-scanning confocal microscope.  
 
2.2.4.2 Immunohistochemistry 
Tissue preparation and cryosectioning 
The spinal cords collected from the cardiac perfusion (described in Section 
2.2.5.6) were post-fixed overnight in 4% PFA (pH 7.0) at 4 °C, prior to 
cryoprotection in sucrose. Spinal cords were incubated overnight at 4°C with each 
increasing step gradient of 5%, 10%, 20% and 30% sucrose prepared in 1X PBS. 
Each spinal cord was separated into the four regions: sacral, lumbar, thoracic and 
cervical. The spinal tissues were frozen embedded in the Shandon M-1 
Embedding Matrix (Thermo Scientific) and sectioned into 30 m transverse 
spinal slices using the Leica CM3050S cryostat (Leica Biosystems, Nussloch 
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Germany). The sections were placed onto Shandon Polysine Microscope slides 
(Thermo Scientific) and stored at -20 °C until further use.  
 
Immunofluorescence 
Slides containing frozen tissue slices were enclosed using nail polish as a water-
repellent barrier to keep reagents localized and prevent mixing of primary 
antibodies across the different sections on the same slide. At room temperature, 
0.1% (v/v) Triton X-100 (prepared in 1X PBS) (PBS-Tx) was added to the 
sections three times. After which, the sections were added with the blocking 
reagent, 10% FBS/PBS-Tx (10% (v/v) FBS prepared in PBS-Tx) for 30 minutes 
at room temperature. Sections were then immunolabeled overnight at 4 °C with 
the primary antibodies prepared in 5% FBS/PBS-Tx. At the following day, 
sections were then washed twice with PBS-Tx, followed by an additional wash of 
1X PBS. Sections were then incubated for one hour at room temperature with the 
appropriate secondary antibodies prepared in 5% FBS/PBS-Tx. After incubation, 
the sections were washed three times with 1X PBS, followed by counterstaining 
of nuclei for 5 minutes at room temperature with DAPI prepared at a dilution of 
1:1000 in 1X PBS. The sections were then mounted with coverglasses 
(Marienfeld Laboratory Glassware) using Faramount Aqueous mounting medium. 
The PBS-Tx or 1XPBS washes of the slides were done at room temperature at 5 
minutes intervals. Fluorescent images were captured with a Carl Zeiss LSM-510 
laser-scanning confocal microscope or Olympus BX61 with BX-UCB controller 
box. 
 
3,3'-Diaminobenzidine (DAB) staining 
The cryosections mounted onto the glass slides were enclosed using nail polish 
and were then washed with 1XPBS-Tx (0.1% Triton X-100 prepared in 1X PBS) 
three times for 5 minutes each. After which, the sections were immunostained 
using either the VECTASTAIN® EliteABC Kit-Mouse IgG or VECTASTAIN® 
EliteABC Kit-Rabbit IgG (Vector Laboratories, CA USA) for mouse or rabbit 
antibodies respectively according to manufacturer’s instructions with slight 
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modifications. The sections were added with 10% (v/v) blocking serum (from kit) 
prepared in PBS-Tx, for 30 minutes at room temperature. After which, the 
primary antibody prepared in the 5% blocking serum was added and sections were 
incubated overnight at 4°C. Sections were then washed twice with PBS-Tx, 
followed by addition of 1X PBS wash. Sections were then incubated for one hour 
at room temperature with the 0.5% (v/v) biotinylated secondary antibody 
(provided in kit) prepared in the 5% blocking serum. After incubation, the 
sections were washed three times with 1X PBS, followed by addition of 
VECTASTAIN® Elite ABC Reagent (2% Reagent A from kit added to 1X PBS, 
followed by addition of 2% Reagent B), that was prepared 30 minutes before use. 
Sections were incubated with the VECTASTAIN® Elite ABC Reagent for 30 
minutes at room temperature, followed by three washes with 1X PBS and one 
wash with 1X TBS (50 mM Tris-HCl pH7.4, 150 mM NaCl) for 10 minutes. 
Sections were then incubated with the DAB mixture (1X DAB with 0.01% (v/v) 
H2O2) prepared in 1X TBS, until the development of the desired stain intensity. 
After which, the sections were washed four times with 1X TBS (5 minutes each) 
at room temperature. Sections were then dehydrated by subsequent immersions in 
70% ethanol, 90% ethanol, absolute ethanol and xylene for 2 minutes each prior 
to mounting with coverglasses using the DPX mountant for microscopy (VWR 
BDH Prolabo, UK). The PBS-Tx or 1X PBS washes of the slides were done at 
room temperature at 5 minutes intervals. Images were captured using the 
Olympus BX61 with BX-UCB controller box. 
 
2.2.4.3 SDS-PAGE and Western Blotting 
Protein Extraction 
The HEK 293T/17 cells harvested were first washed twice with 1X PBS prior to 
lysis of cells by mixing and incubating on ice for 30 minutes with Lysis Buffer 
(50 mM Tris pH 7.0, 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM sodium 
fluoride (NaF), 1 mM EDTA, 1 mM EGTA supplemented with protease inhibitor 
cocktail tablets (Roche Diagnostics, Mannheim, Germany). The lysed cells were 
spun at 15,000 xg at 4 °C for 15 minutes to obtain the protein lysate supernatant, 
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which was then quantified using the Pierce BCA assay kit as per manufacturer’s 
instructions (described in Section 2.2.4.5). Equal volume of the 2XSDS sample 
buffer (62.5mM Tris-HCl pH6.8, 2% (v/v) SDS, 10% (v/v) glycerol, 0.01% (w/v) 
bromophenol blue and 5% (v/v) -mercaptoethanol) was added to the protein 
lysates prior to loading into the SDS-PAGE gels. For primary cortical neurons, 
the samples were scraped directly in 2X SDS sample buffer to obtain the total 
lysate samples. All protein lysates were stored at -80°C until use. 
 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were resolved by SDS-PAGE. The SDS-PAGE gels used were 
either commercially purchased continuous gels (Novex® 4-12% Bis-Tris Gels, 
Invitrogen) and/or self-cast discontinuous gels as follows; 5% stacking gels (125 
mM Tris pH 6.8, 0.1% (v/v) SDS, 5% (v/v) Acrylamide/Bis solution, 0.1% (w/v) 
APS, 0.1% (v/v) TEMED) with 15% resolving gels (375 mM Tris pH 8.8, 0.1% 
(v/v) SDS, 15% (v/v) Acrylamide/Bis solution, 0.04% (w/v) APS, 0.04% (v/v) 
TEMED). The lysates harvested with the 2X SDS sample buffer were prepared by 
heating of samples at 95 °C for 5 minutes. Samples were then centrifuged at 
15,000 xg for 5 minutes before loading of 20 g of the protein lysate (from the 
HEK 293T/17 cells) or 20 L of the total lysates (from the cortical neurons) into 
each well of the SDS-PAGE gel. The protein ladder (SeeBlue Plus 2, Invitrogen) 
was loaded as a precise size standard to determine molecular weight of protein of 
interest from the samples. The gel was run in 1X Tris Glycine-Sodium Dodecyl 
Sulphate (SDS) Buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% (v/v) SDS, pH 
8.3) at 150 V for 1.5 hours using the Bio-Rad Mini-PROTEAN 3 system (Bio-
Rad, CA, USA) run with the PowerPac™ HC High-Current Power Supply. 
 
Western Blotting 
After completion of the run, the sample proteins on the SDS-PAGE gels were 
transferred onto the Hybond ECL Nitrocellulose membrane (GE Healthcare, 
Sweden) in 1X Tris Glycine buffer (25 mM Tris-HCl, 192 mM glycine, pH 8.3) 
with 20% (v/v) methanol using the XCell II™ Blot Module (Invitrogen). The 
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transfer was done at 0.1 A for 1.5 to 2 hours. After the protein transfer, the 
nitrocellulose membrane was incubated with Ponceau S. solution for 2 to 3 
minutes to visualize the total protein bands on the membrane. The membrane was 
then washed with 1X TBST buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 
0.1% (v/v) Tween 20) to remove the Ponceau S. staining. The membrane was 
incubated in 10% blocking buffer (10% (w/v) skim milk prepared in 1X TBST) 
for 30 minutes at room temperature. After which, the membrane was incubated 
with the primary antibody prepared in 5% blocking buffer at 4 °C overnight. The 
membrane was then washed three times with 1X TBST at 5 minutes intervals 
prior to incubation for one hour at room temperature with the appropriate HRP-
conjugated secondary antibody prepared in the 5% blocking buffer. After washing 
the membrane four times at 5 minute-intervals with 1X TBST, the membrane was 
developed using the ECL Plus Western Blotting Detection system (GE 
Healthcare) as per the manufacturer’s instructions. The chemiluminescence 
signals were detected by exposure of the blots to Amersham Hyperfilm ECL, 
which was then developed using the Medical Film Processor (Konica Minolta). In 
order to re-probe the same membrane with another antibody, the membrane 
incubated with stripping buffer (62.5 mM Tris pH 7, 2% (v/v) SDS, 0.1 M -
mercaptoethanol) for 20 to 30 minutes at 55 °C. Following which, the membrane 
was washed four times with 1X TBST for 5 minutes each. The membrane was 
then re-probed using the same methodology from the blocking step onwards. 
Quantification of the bands was performed by densitometric analyses using the 
Universal Hood II Gel Imager System (Bio-Rad). 
 
2.2.4.4 Real-time reverse transcription polymerase chain reaction (RT-PCR) 
RNA extraction 
Following treatment with Control shRNA and Pin1 shRNA by transfections in 
HEK93T17 cells and AAV transductions in primary cells, the total RNA was 
extracted according to manufacturer’s instructions with slight modifications using 
the RNeasy mini kit (Qiagen). After removal of culture medium, cells were 
washed with 1X PBS twice prior to addition of 0.5 mL TRIzol® Reagent per 
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well. The cells were then scraped in the TRIzol® Reagent and collected into an 
eppendorf tube, which was stored at -80 °C until further use. The mixture was 
added with 0.1 mL of chloroform was added and the mixture was shaken 
vigorously by hand for 15 seconds. The mixture was then incubated at room 
temperature for 2-3 minutes and subsequently centrifuged at 15,000 xg for 15 
minutes at 4 °C. Following centrifugation, the mixture was observed to be 
separated into three layers; the colourless top aqueous layer, an interphase layer 
and the red bottom, phenol-chloroform layer. The upper aqueous layer was 
transferred to a fresh eppendorf tube and an equal volume of 70% ethanol was 
added to the aqueous layer. The mixture was mixed well by pipetting, followed by 
addition of 700 L (maximum volume) of the mixture to the RNeasy column 
placed in the 2 mL collection tube. The columns were spun at 10,500 xg for 15 
seconds, after which the flow through in the collection tube was discarded and 
any remaining mixture of the aqueous layer-ethanol was added to the column and 
spun again followed by removal of the flow through. The RNeasy column was 
washed with 700 L Buffer RW1 followed by centrifugation at 10,500 xg for 15 
seconds. The flow through was discarded and 500 L Buffer RPE was added to 
the column, which was subsequently centrifuged at 10,500 xg for 15 seconds and 
flow through was discarded. Another 500 L of Buffer RPE was applied to wash 
the column and to prevent any carryover of the Buffer RPE, the RNeasy column 
was centrifuged at 10,500 xg for 2 minutes. The column was then placed into a 
new collection tube and the RNA was eluted by addition of 30 L of RNase-free 
water (H2O). The RNA was then quantified using the NanoDrop 1000 
Spectrophotometer.  
 
Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City CA, USA) according to the manufacturer’s 
instructions (see Table 2.2.2) with slight modifications. The RT-PCR reaction 
mixture was prepared on ice in PCR tubes and the following program was used in 
87 
 
the Bio-Rad MyCycler Thermal Cycler; 25 °C for 10 minutes, 37 °C for 120 
minutes, 85 °C for 5 seconds and final holding at 10 °C. 
 
Table 2.2.2 – Preparation of RT-PCR Master mix per reaction from High 




Component Volume (L)/reaction mix 
1 Nuclease-free H2O 4.2 L 
2 10X RT-PCR Buffer 2.0 L 
3 25X dNTP mix (100 M) 0.8 L 
4 10X RT Random Primers 2.0 L 
5 Multi-ScribeTM Reverse Transcriptase 1.0 L 
6 RNA Sample (50 ng/L) 10.0 L 
 Total per Reaction 20.0 L 
 
Real-Time RT-PCR 
Each reaction mix was added with 12.5 L Power SYBR® Green PCR Master 
Mix (Applied Biosystems), 0.3 ofthe forward and corresponding reverse 
primers (Table 2.1.4.5) together with 5 ng of the cDNA product (diluted to 1 
ng/L in DNase-free H2O) from the RT-PCR step, and diluted to 25 L with 
DNase-free H2O. The reaction mix was prepared in the MicroAmp Fast 96-well 
Reaction Plate (Applied Biosystems) and the plates were sealed with MicroAmp 
96-well optical adhesive covers. The real-time reaction was performed using the 
Applied Biosystems 7500 Real Time PCR System with the following program; 50 
°C for 2 minutes, 95°C for 10 minutes, 95 °C for 15 seconds for 40 cycles 
followed by 60 °C for 1 minute. A final dissociation stage of 95 °C for 15 
seconds, 60 °C for 20 seconds, 95 °C for 15 seconds and 60 °C for 15 seconds 






2.2.4.5 Protein Quantification (BCA assay)  
For protein quantification, 25 μL of the lysates and standards (from the BSA 
Standard Set) were added to a 96-well plate. Following which, 200 μL of freshly 
prepared BCA solution (prepared by mixing ratio of 50 (Reagent A): 1 (Reagent 
B) according to the manufacturer’s instructions) from the BCA Protein Assay Kit 
was added to each well with the samples and the wells containing the standards. 
The plate was then incubated for 30 minutes at 37 °C. Absorbance of the wells 
was measured using the Tecan Infinite F500 Microplate Reader at 562 nm. Using 
the readings of the standards, the protein of the samples were determined and used 
























2.2.5 ANIMAL STUDIES 
2.2.5.1 Animal models 
All animal studies were conducted in accordance with the GSK Policy on the 
Care, Welfare and Treatment of Laboratory Animals and approved protocols were 
reviewed by the Institutional Animal Care and Use Committee of National 
University of Singapore (NUS) and Biological Resource Centre (BRC), 
Singapore. Animals were housed at either NUS or BRC animal facilities. 
Husbandry and maintenance of animals were performed by the staff at the animal 
facilities.  
 
2.2.5.2 C57BL/6J WT mice  
In this study, time-mated pregnant mice of C57BL/6J background provided by 
BRC and CARE were used for primary cultures. Adult WT mice were used for 
intramuscular injections to determine the AAV serotype for efficient transduction 
of motor neurons in the spinal cord. 
 
2.2.5.3 B6.Cg-Tg(SOD1*G93A)1Gur/J transgenic mice 
The G93A SOD1 transgenic mice used in this study were the congenic strain 
(B6.Cg-Tg(SOD1*G93A)1Gur/J, stock number #004435) obtained from Jackson 
Laboratory (Bar Habor, Maine). The G93A SOD1 mice express the G93A mutant 
form of the human SOD1. These mice have been described in previous ALS 
studies (Andreassen et al., 2001; Beers et al., 2008; Bilsland et al., 2010). Adult 
WT and G93A SOD1 male littermates were used for intramuscular injections.  
 
2.2.5.4 Genotyping of transgenic mice 
DNA extraction and PCR 
The DNA from the tail clip samples from the transgenic mice was extracted using 
by addition of 100L of Digestion buffer (67 mM Tris-HCl pH 8.8, 17 mM 
(NH4)2SO4, 67 mM MgCl2, 1% (v/v) -mercaptoethanol, 0.5% (v/v) Triton X-
100) prepared in DNase-free H2O supplemented with 0.5 g/mL Proteinase K, to 
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each tube with the sample followed by shaking incubation at 55 oC overnight. 
After which, samples were vortexed well and heated at 95 °C for 10 minutes to 
inactivate the Proteinase K. The samples were then vortexed again and spun at 
full speed for 5 minutes. The tissue supernatant (eluted DNA) was collected and 
stored at 4 °C until further use.  
 
PCR was carried out in a 25 L reaction mixture, containing the following 
mastermix components 1.5 mM MgCl2, 0.02 U/L Go Taq Flexi DNA 
polymerase, 0.2 mM Deoxyribonucleotide triphosphate (dNTP), 2% (v/v) DMSO, 
1X Colorless GoTaq® Flexi Buffer1, 1X Loading Dye prepared in miliQ H2O 
and added with 0.2 M of the forward and corresponding reverse primers (Table 
2.1.5.1) together with 0.5 L of the eluted DNA from the tissue supernatant in 
PCR tubes. The following program was used in the Biometra, T3000 
Thermocycler and/or Bio-Rad T100 Thermo Cycler for the PCR cycle; 95 °C for 
2 minutes, repeat for 35 cycles: 95 °C for 30 seconds, 55 °C for 30 seconds and 
72 °C for 1 minute, followed by 72 °C for 4 minutes and final holding at 10 °C. 
 
Samples from the completed PCR cycle were separated by gel electrophoresis on 
a 1.5% (w/v) agarose gel prepared with TAE buffer (40mM Tris-acetate and 1mM 
EDTA), supplemented with 1XGelRed Nucleic Acid Gel Stain (Biotium, CA 
USA) which was used to stain DNA for visualization of the DNA bands under 
UV light. The electrophoresis was performed in 1X TAE running buffer at 120 V 
for 60 minutes. The 100 bp DNA ladder (Promega) was loaded next to the 
samples to determine the DNA band sizes. WT band was viewed at approximately 
324 bp and transgene band at 236 bp. 
 
2.2.5.5 Intramuscular injections 
WT and G93A SOD1 male mice were used in the intramuscular injections of 
AAV to prevent potential issues related to hormone levels. Gender hormonal 
differences have been shown to have a negative effect on the AAV-mediated 
protein expression (Dodge et al., 2005). 
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Administration of AAV vectors  
Male WT mice at 8-weeks old were anesthetized by inhalation of isoflurane and 
injected intramuscularly with saline or AAV-tagged with GFP at 5x10e11 to 
2x1012 particles per injection at one or two sites; the left and/or right quadriceps 
muscle of the hindlimbs. The mice were housed up to 3 months from 
intramuscular injections to determine AAV transduction efficiency and stability 
by immunostaining the perfused spinal cord. 
 
Administration of AAV9-Control shRNA and AAV9-Pin1 shRNA  
WT and G93A SOD1 male mice at pre-disease stage (50-55 days old) were 
anesthetized by isoflurane inhalation and received a single dose of 2x1012 
particles of AAV9 (Control shRNA or Pin1 shRNA) via intramuscular injection at 
two sites (one each at the left and right quadriceps muscle of the hindlimbs). Five 
treatment groups were investigated in this study; WT treated with saline, G93A 
SOD1 treated with saline, WT treated with Pin1 shRNA, G93A SOD1 treated with 
AAV9-Control shRNA and G93A SOD1 treated with AAV9-Pin1 shRNA. Saline 
injected mice (80 L per site of injection) were used as the control in these 
studies. The five treatments were investigated for three end time-points: 90, 120 
and 150 days, during which motor behavioural studies were performed. At the end 
time-point, mice were cardiac perfused to collect histological samples for 
immunohistochemistry. 
 
2.2.5.6 Cardiac perfusion 
Mice were anesthetized by inhalation of isoflurane and sufficient anaesthesia 
was determined by pinch-response method. The thoracic cavity was opened by 
an incision through the chest, to expose the heart and visualize the aorta. The 
needle and syringe containing saline solution (0.9% NaCl) was inserted 
through the left ventricle, followed by an incision on the right atrium. Mice 
were then transcardially perfused first with the saline solution to ensure 
complete blood drainage, after which mice were perfused with ice-cold 4% 
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PFA. The spinal cord of the mice were then carefully dissected and placed into 
the 4% PFA solution. 
 
2.2.5.7 Motor Function Studies 
Rotarod 
The Mouse Rota-Rod 47600 (Ugo Basile, Comerio VA, Italy) was used to 
measure the motor coordination and muscle weakness by measuring the latency of 
the mice to fall. The Mouse Rota-Rod 47600 provided five 3 cm diameter 
cylinders, which are divided by dividers into five lanes, each 57 mm wide. The 
rotarod test was conducted at different time-points based on a previously 
described procedure for ALS mice (Steinacker et al., 2010; Kim et al., 2010). All 
mice were pre-trained on the rotarod apparatus at least 1-2 days prior to the final 
test run. The training session included two runs at 4 rpm for 300 seconds as well 
as a test trial, where the initial speed is at 4 rpm which then continuously 
accelerates up to 40 rpm with 300 seconds as the arbitrary cut-off-time. The final 
test run was performed as per the parameters in the test trial (during the training 
session). The longest latency to fall (sec) of the mice was recorded from the 
average of three consecutive test runs for each mouse. Events during which the 
paw of the mouse slips causing the mouse to fall onto the counter trip plates were 
excluded from the analysis. 
 
Grip strength 
Mice were accessed for grip strength performance using the Animal Grip Strength 
System (San Diego Instruments, San Diego, CA, USA) to evaluate the forelimb 
and hindlimb muscle strength. For measurement of the forelimb grip strength, the 
mouse was allowed to grip the grid platform by only its front paws and then 
steadily pulled away horizontal to the grid platform by the base of its tail until the 
grip was detached completely from the grid. The mouse would hold onto the grid 
until it is unable to resist the increasing force and releases the grid. The 
forelimb/hindlimb measurements were taken by allowing the mouse to grip the 
grid platform by all four paws. The mouse was pulled steadily away horizontally 
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by the base of the tail until all four paws released the grid platform. The grip 
strength recorded the values of the maximum force applied as the peak tension (in 
grams) once the grip was released. The average of three consecutive trials was 
taken for the forelimb and forelimb/hindlimb grip strength. 
 
Gait analysis 
The RunwayScan apparatus (CleverSys Inc., Reston, VA, USA) allows capture of 
the voluntary gait patterns in rodent models. The mice were placed, one at a time 
at one end of the RunwayScan apparatus and were allowed to walk across a clear 
glass runway to the other side of the runway. As the mouse crosses the runway, 
the light reflected by the paw contact area on the glass is captured by a high-speed 
digital video camera placed below the runway. The paw prints and positions were 
then visualized and analyzed using the GaitScan software, which performs 
automated calculation of the gait parameters from the movements of the limbs. 
The average of three successful runs was obtained for the gait parameters: stride 
length and time. 
 
2.2.6 STATISTICAL ANALYSIS AND PRESENTATION OF DATA 
All experiments were done at least three times and graphs depict average values 
of at least three experiments. Representative immunostaining images and western 
blot figures from one experiment were presented. All numerical data are 
expressed as mean ± standard deviation or standard error of the mean (SEM). 
Data was analyzed using either Student’s t-test or One-Way analysis of variance 
(ANOVA) with post hoc, Tukey’s honestly significant difference (HSD) test. 












 Previously it has been shown that Pin1 associates with p-NF-H in neurons and 
co-localizes with p-NF-H aggregates in ALS-affected spinal cords (Kesavapany et 
al., 2007). Upon in vitro inhibition of Pin1 expression in neurotoxic-induced 
neuronal cells, there was reduced p-NF-H accumulation and rescue of neuronal 
cell death (Kesavapany et al., 2007; Rudrabhatla et al., 2008; Rudrabhatla et al., 
2009). The main objective of this study is to modulate p-NF-H accumulations in 
an ALS paradigm by reducing Pin1 expression. To achieve this, the use of the 
Pin1 shRNA construct has to be validated as the strategy most suited in this study. 
In this chapter the Pin1 expression knockdown efficiency was validated by 
transient transfections of Pin1 shRNA in vitro in neuronal cells and in the 
mammalian, HEK 293T/17 cells.  
 
Upon validation of Pin1 knockdown using the construct, the use of AAV vector 
expressing Pin1 shRNA was required as the gene delivery tool. This is to facilitate 
efficient transport of the Pin1 shRNA into the spinal motor neurons of the ALS 
mouse. Transduction experiments were performed using AAV2-Pin1 shRNA in 
HEK 293T/17 cells and primary neurons, and the results showed good 
transduction efficiency and long-term stability of the Pin1 silencing. Use of 
AAV2, would facilitate delivery of Pin1 shRNA to the spinal cord of the ALS 
mouse and enable the study of the effect of Pin1 knockdown on the accumulations 









3.2.1 Production of Pin1 shRNA and Control shRNA plasmid DNA 
RNA interference technology using shRNA was used to knockdown Pin1 
expression. The Pin1 shRNA and Control shRNA plasmids (Figure 2.1.1.1) were 
produced and cloned into the AAV vector (Appendix Figure 1) by Vector 
Biolabs, PA USA. The purity of the plasmid DNA was determined by measuring 
the ratio of absorbance at 260 and 280 nm (A260/280 > 1.8).  
 
3.2.2 Validation of Pin1 knockdown by transient transfections of the Pin1 
shRNA construct  
HEK 293T/17 cells were seeded at 1x105 cells per 15 mm glass coverslip that was 
placed in 12-well plates for immunocytochemistry experiments and at 2.5x105 
cells per well in 6-well plates for Western blot and Real time RT-PCR studies. 
E15 primary cortical neurons seeded at 1x105 cells per 15 mm glass coverslip that 
was placed in 12-well plates. The HEK 293T/17 cells were transfected on the 
following day after seeding and the cortical neurons were transiently transfected 
at 4-5 DIC with Pin1 shRNA and Control shRNA using Lipofectamine 2000. The 
samples from various time-points of 1, 3, 5 and 7 days post-transfection were 
collected and processed for immunocytochemistry (HEK 293T/17 cells and 
cortical neurons) and Western Blotting (HEK 293T/17 cells). 
 
3.2.3 Immunocytochemistry to validate knockdown of Pin1 expression 
Transfected HEK 293T/17 cells and cortical neurons were fixed 3 days post-
transfection and processed for immunofluorescence. The Pin1 shRNA and 
Control shRNA expressing cells were GFP positive (green) and were 
immunostained with the monoclonal anti-Pin1 antibody (Santa Cruz). The 
secondary antibody used was Alexa Fluor 594 goat anti-mouse IgG (H+L). The 
nuclei were counterstained with DAPI. Fluorescent images were captured with a 




3.2.4 SDS-PAGE and Western Blot to quantify knockdown of Pin1 protein 
levels 
HEK 293T/17 cells were harvested with Lysis Buffer followed by collection of 
the supernatant and quantification of the amount of protein. 20 g of the HEK 
293T/17 lysates was resolved on the self-casted discontinuous SDS-PAGE gels 
(5% stacking and 15% resolving). The cortical neuron samples were scraped 
directly into 2X SDS sample buffer followed by loading of 20 L of the lysate 
into each well of the SDS-PAGE gels. After completion of the run, the proteins 
were transferred onto nitrocellulose membrane and immunoprobed with the 
polyclonal anti-Pin1 antibody (Cell Signalling Technology), after which the blots 
were stripped and re-probed with monoclonal anti-tubulin antibody (Sigma 
Aldrich) to ensure equal loading. The quantification of the immunoblots was 
performed by densitometric scanning of the immunoblots and normalization of 
the Pin1 bands mean density to the respective tubulin bands for each sample. The 
Pin1/tubulin mean density of the Pin1 shRNA samples were then normalized to 
the respective Control shRNA samples and calculated as a percentage difference. 
 
3.2.5 Real-time RT-PCR to determine reduction of Pin1 RNA levels 
RNA levels of the HEK 293T/17 cells were measured by Real-time RT-PCR. 
Total RNA was extracted following which Reverse Transcription PCR was 
performed to obtain the cDNA product. The ∆Ct values were obtained by 
normalization of the Pin1 Ct to that of the housekeeping gene, GAPDH. The 
relative expression was determined by raising 2 to the power of the negative ∆Ct 
values, following which the Pin1 shRNA was normalized to that of the Control 
shRNA and calculated as a percentage difference. 
 
3.2.6 Stable Pin1 knockdown using AAV as the gene delivery tool 
The rAAV stocks of AAV2-Pin1 shRNA and AAV2-Control shRNA prepared in-
house using the AAV Helper Free System, were used to transduce into 
mammalian cells, HEK 293T/17 and primary cortical neurons. HEK 293T/17 
cells were seeded at 1x105 cells per 15 mm glass coverslip that was placed in 12-
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well plates for immunocytochemistry experiments and at 7x104 cells per well in 
6-well plates for Western blot and Real-time RT-PCR studies. The HEK 293T/17 
cells were transduced on the following day after seeding. E15 primary cortical 
neurons were seeded at 1x105 cells per 15 mm glass coverslip that was placed in 
12-well plates and were transduced at 4-5 DIC. The HEK 293T/17 cells and 
cortical neurons samples from various time-points of 5, 8, 11 and 14 days post-
transduction were collected and processed for immunocytochemistry, Western 



























3.3.1 Validation of Pin1 knockdown by transient transfections of the Pin1 
shRNA construct into HEK 293T/17 and primary cortical neurons. 
 
The efficiency of the knockdown of Pin1 levels by the Pin1 shRNA construct in 
vitro in mammalian, HEK 293T/17 cells was firstly examined. The Control 
shRNA and Pin1 shRNA plasmids were transiently transfected into the cells and 
samples were collected for immunofluorescence (at 3 days post-transfection), 
Western Blot and Real-time RT-PCR studies (at 1, 3, 5 and 7 days post-
transfection) (Figure 3.3.1). When the fixed cells were immunostained with anti-
Pin1 antibody (Figure 3.3.1A), it was observed that the Pin1 shRNA transfected 
cells (GFP positive; representative cells shown by arrowheads) had markedly 
reduced Pin1 expression compared to neighbouring non-transfected cells (GFP 
negative; representative cells shown by arrows) as shown in panels e-h. The 
Control shRNA construct was a missense shRNA control, where the transfected 
cells (GFP positive; representative cells shown by arrowheads) showed no 
difference in Pin1 levels compared to the neighbouring non-transfected cells (GFP 
negative; representative cells shown by arrows) (panels a-d). To quantify the 
reduction in the Pin1 expression when Pin1 shRNA was transfected in HEK 
293T/17 cells, the samples were collected for Western blot analyses at various 
time-points of 1, 3, 5 and 7 days (Figure 3.3.1B). Based on the representative blot 
shown in Figure 3.3.1B and the quantification of the immunoblots in Figure 
3.3.1C, there was no significant reduction in the Pin1 levels in the HEK 293T/17 
cells at 1 and 3 days post-transfection with the Pin1 shRNA compared to the 
Control shRNA. However at days 5 and 7 post-transfection, the Pin1 protein 
levels of the Pin1 shRNA transfected samples were significantly reduced to 35% - 
60% of the Control shRNA samples (*p-value < 0.05, **p-value < 0.01, Student’s 
t-test). To confirm the Pin1 shRNA knockdown on RNA levels, the samples were 
collected and processed for Real-time RT-PCR (Figure 3.3.1D). The data 
collected showed that the percentage of Pin1 RNA levels of the Pin1 shRNA 
samples (post-transfection days 1, 3, 5 and 7) were significantly reduced to 30% - 
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55% of the respective Control shRNA samples (**p-value < 0.01, ***p-value < 
0.001, Student’s t-test). Mean values and SEM for the graphs in Figure 3.3.1 are 









Figure 3.3.1 Validation of Pin1 shRNA construct by transfection into HEK 
293/T17 cells A. HEK 293/T17 cells transfected with GFP-tagged Control 
shRNA (a-d) and Pin1 shRNA (e-h) were immunostained at 3 days post-
transfection with Pin1 antibody (red). Arrows indicate non-transfected cells and 
arrowheads indicate transfected cells. Nuclear counterstaining was performed 
using DAPI (blue). Scale bar represents 20 m. B. Representative immunoblot of 
HEK 293/T17 cell lysates transfected with GFP-tagged Control shRNA (C) and 
Pin1 shRNA (S) collected at various time-points (1, 3, 5 and 7 days post-
transfection) resolved together with the non-transfected sample (NT). The 
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immunoblot was probed with anti-Pin1 and anti-GFP antibodies. Equal loading of 
samples was shown by reprobing the membrane with anti-tubulin antibody C. 
Quantification of the immunoblot analyses in B by densitometric scanning and 
normalization of Pin1 mean density of Pin1 shRNA (red bars) to the respective 
Control shRNA (value=100%) D. Relative quantification Pin1 mRNA levels of 
Pin1 shRNA samples (blue bars) normalized to the respective Control shRNA 
samples (value=100%) from the extracted RNA of transfected HEK 293/T17 cells 
across various time-points (1, 3, 5 and 7 days post-transfection). Error bars 
represent SEM from n=3 experiments performed in triplicates (*p-value < 0.05, 
**p-value < 0.01, ***p-value < 0.001, ns = non significant).  
 
After establishing the efficiency of the Pin1 knockdown using the Pin1 shRNA 
construct in HEK 293T/17 cells, the Pin1 shRNA was transfected into E15 mouse 
cortical neurons at 4-5 DIC. Immunostaining of the transfected neurons at 3 days 
post-transfection with anti-Pin1 antibody indicates that there was reduction of the 
Pin1 levels in the Pin1 shRNA transfected neurons (GFP positive; representative 
cells shown by arrowheads) compared to the neighbouring non-transfected cells 
(GFP negative; representative cells shown by arrows) as shown in panels e-h 
(Figure 3.3.2). The Control shRNA transfected cells (GFP positive; representative 
cells shown by arrowheads) showed no difference in Pin1 levels as compared to 
the neighbouring non-transfected cells (GFP negative; representative cells shown 
by arrows) (panels a-d). Due to the low transfection efficiency of the cortical 
neurons using Lipofectamine 2000, Pin1 knockdown by Pin1 shRNA could not be 





Figure 3.3.2 Transfection of Pin1 shRNA construct into primary cortical 
neurons. E15 primary cortical neurons were transfected with GFP-tagged Control 
shRNA (a-d) and Pin1 shRNA (e-h) at 5 DIC and immunostained at 3 days post-
transfection with Pin1 antibody (red). Arrows indicate non-transfected cells and 
arrowheads indicate transfected cells. Nuclear counterstaining was performed 
using DAPI (blue). Scale bar represents 20 m. 
 
 
3.3.2 Production of AAV2-Pin1 shRNA and AAV2- Control shRNA for 
efficient transduction of HEK 293T/17 and primary cortical neurons. 
 
For in vivo experiments, AAV was used in this study for gene delivery into the 
spinal motor neurons. For preparation of the recombinant AAV serotype 2 
containing the Pin1 shRNA and Control shRNA plasmids, the AAV Helper Free 
System was used in-house to produce the AAV2-Pin1 shRNA and AAV2-Control 
shRNA. The transduction efficiency of the AAV2-Pin1 shRNA and AAV2-
Control shRNA was evaluated in HEK 293T/17 cells and the samples were 
collected and processed for immunofluorescence, Western Blot and Real-time 
RT-PCR studies (at 5, 8, 11 and 14 days post-transduction). The HEK 293T/17 
cells were fixed at 3 days post-transduction and immunostained with the anti-Pin1 
antibody (Figure 3.3.3A). AAV2-Control shRNA transduced cells (GFP positive; 
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representative cells shown by arrowheads) did not show any change in the Pin1 
expression compared to the neighbouring non-transduced cells (GFP negative; 
representative cells shown by arrows) as shown in panels a-d. However Pin1 
knockdown was observed in the AAV2-Pin1 shRNA transduced cells (GFP 
positive; representative cells shown by arrowheads) as compared to the 
neighbouring non-transduced cells (GFP negative; representative cells shown by 
arrows) as shown in panels e-h. Figures 3.3.3B and C respectively show the 
representative Western blot of the AAV2-Pin1 shRNA and AAV2-Control 
shRNA transduced HEK 293/T17 samples collected at days 5, 8, 11 and 14 days 
post-transduction as well as the densitometric quantification of the immunoblots. 
Based on the representative blot shown in Figure 3.3.3B and the quantification of 
the immunoblots in Figure 3.3.3C, there was significant reduction in the Pin1 
levels of AAV2-Pin1 shRNA samples to 50% - 55% of the AAV2-Control 
shRNA samples at post-transduction days 5, 8 and 11 (*p-value < 0.05, Student’s 
t-test). However the Pin1 reduction in the AAV2-Pin1 shRNA samples was 
observed to be non-significant compared to the AAV2-Control shRNA samples at 
day 14. To study the effect of the AAV2-Pin1 shRNA on Pin1 RNA levels in the 
HEK 293T/17, samples were collected (post-transduction days 5, 8, 11 and 14) 
and processed for Real-time RT-PCR (Figure 3.3.3D). There was a significant 
Pin1 reduction (up to 40% - 65% of the respective AAV2-Control shRNA 
samples) across the AAV2-Pin1 shRNA samples at the various time-points (*p-
value < 0.05, **p-value < 0.01, ***p-value < 0.001, Student’s t-test). Mean 











Figure 3.3.3 Pin1 knockdown in HEK 293/T17 cells using AAV2-Pin1 shRNA. 
A. HEK 293/T17 cells transduced with GFP-tagged AAV2-Control shRNA (a-d) 
and Pin1 shRNA (e-h) were immunostained at 3 days post-transduction with Pin1 
antibody (red). Arrows indicate non-transduced cells and arrowheads indicate 
transduced cells. Nuclear counterstaining was performed using DAPI (blue). 
Scale bar represents 20 m. B. Representative immunoblot of HEK 293/T17 cell 
lysates transduced with GFP-tagged AAV2-Control shRNA (C) and Pin1 shRNA 
(S) collected at various time-points (5, 8, 11 and 14 days post-transduction) 
resolved together with the non-transduced sample (NT). Immunoblot was probed 
with anti-Pin1 and anti-GFP antibodies. Equal loading of samples was shown by 
reprobing the membrane with anti-tubulin antibody. C. Quantification of the 
immunoblot analyses in B by densitometric scanning and normalization of Pin1 
mean density to tubulin of the AAV2-Pin1 shRNA samples (red bars) to the 
respective AAV2-Control shRNA samples (value=100%). D. Relative 
quantification Pin1 mRNA levels of AAV2-Pin1 shRNA samples normalized to 
the respective AAV2-Control shRNA (value=1) from extracted RNA of 
transduced HEK 293/T17 cells across various time-points (5, 8, 11 and 14 days 
post-transduction). Error bars represent SEM from n=3 experiments performed in 
triplicates (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001, ns = non 
significant).  
 
The AAV2-Control shRNA and AAV2-Pin1 shRNA were produced for efficient 
transduction in vivo into the motor neurons of the mouse spinal cord. In order to 
investigate the transduction efficiency of the AAV2-Control shRNA and AAV2-
Pin1 shRNA in primary neurons, E15 mouse cortical neurons were transduced at 
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4-5 DIC. The cortical neurons were then fixed and immunostained at 3 days post-
transduction with anti-Pin1 antibody. Figure 3.3.4A shows that in contrast to the 
GFP-tagged AAV2-Control shRNA transduced neurons represented in panels a-d 
(GFP positive; representative cells shown by arrowheads), there was reduction of 
Pin1 levels in the AAV2-Pin1 shRNA transduced neurons represented in panels e-
h (GFP positive; representative cells shown by arrowheads) compared to the 
neighbouring non-transduced cells (GFP negative; representative cells shown by 
arrows). Quantification of the percentage of transduced AAV2-Control shRNA 
and AAV2-Pin1 shRNA neurons over total number of cortical neurons shown in 
Figure 3.3.4B indicated that approximately 20 to 50% of the cortical neurons were 
transduced by AAV2-Control shRNA and AAV2-Pin1 shRNA. The percentage of 
the transduced cells increased with longer time-points (day 5, 8, 11 and 14 post-
transduction) likely due to increased GFP-tagged AAV2-Pin1 shRNA protein 
expression. Mean values and SEM for the graph in Figure 3.3.4B are shown in 
Appendix Table 3. Given the observed high transduced number of neurons in the 
culture, the samples collected at various time-points of 5, 8, 11 and 14 days post-
transduction were processed for Western blot and Real-time RT-PCR to quantify 
the knockdown of Pin1 expression in the AAV2-Pin1 shRNA transduced cells. 
The representative immunoblot shown in Figure 3.3.4C and the quantification of 
the immunoblots in Figure 3.3.4D, indicates that the Pin1 levels in the cortical 
neurons transduced with AAV2-Pin1 shRNA was significantly reduced to 45% - 
70% of the AAV2-Control shRNA at the various collected time-points (**p-value 
< 0.01, ***p-value < 0.001, Student’s t-test). Pin1 RNA expression in the AAV2-
Pin1 shRNA transduced neurons was significantly reduced to 30% - 55% of the 
the AAV2-Control shRNA samples across the collected time-points of 5, 8, 11 
and 14 days post-transduction (Figure 3.3.4E) (**p-value < 0.01, ***p-value < 
0.001, Student’s t-test). The Pin1 RNA levels of the AAV2-Pin1 shRNA samples 
collected at 11 days post-transduction was not significantly different compared to 
the AAV2-Pin1 shRNA samples collected at 5 and 8 days post-transduction. 
However, there was significant reduction in the Pin1 RNA levels of the AAV2-
Pin1 shRNA samples at day 14 compared to day 11 post-transduction. Mean 
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Figure 3.3.4 Pin1 knockdown efficiency of AAV2-Pin1 shRNA in primary 
cortical neurons A. 5 DIC cortical neurons transduced with GFP-tagged AAV2-
Control shRNA (a-d) and AAV2-Pin1 shRNA (e-h) were immunostained at 8 
DIC with Pin1 antibody (red). Arrows indicate non-transduced neurons and 
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arrowheads indicate transduced neurons. Nuclear counterstaining was performed 
using DAPI (blue). Scale bar represents 20 m. B. Quantification of the 
percentage of total number of Control shRNA and Pin1 shRNA transduced (GFP 
expressing) cortical neurons over total number of neurons at 5, 8, 11 and 14 days 
post-transduction. C. Representative immunoblot of the cortical neurons lysates 
transduced with GFP-tagged AAV2-Control shRNA (C) and AAV2-Pin1 shRNA 
(S) collected at various time-points (5, 8, 11 and 14 days post-transduction) 
resolved together with the non-transduced sample (NT). Immunoblot was probed 
with anti-Pin1 and anti-GFP antibodies. Equal loading of samples was shown by 
reprobing the membrane with anti-tubulin antibody D. Quantification of the 
immunoblot analyses in C by densitometric scanning and normalization of Pin1 
mean density to tubulin of the AAV2-Pin1 shRNA samples (red bars) to the 
respective AAV2-Control shRNA samples (value=100%) E. Relative 
quantification Pin1 mRNA levels of AAV2-Pin1 shRNA samples (blue bars) 
normalized to the respective AAV2-Control shRNA (value=1) from extracted 
RNA of the transduced cortical neurons across various time-points (5, 8, 11 and 
14 days post-transduction). Error bars represent SEM from n=3 experiments 



















Previous studies have shown that knockdown of Pin1 using the Pin1 inhibitor, 5-
hydroxy-1,4-naphthoquinone (juglone) as well as Pin1 siRNA was able to rescue  
p-NF-H accumulations during induced excitotoxicity in primary neuronal cultures 
(Kesavapany et al., 2007; Rudrabhatla et al., 2008; Rudrabhatla et al., 2009). The 
use of commercially available Pin1 inhibitors such as juglone and diethyl-1,3,6,8- 
tetrahydro- 1,3,6,8- tetraoxobenzol - phenanthroline- 2,7-diacetate (PiB), have 
been shown to elicit other effects that are non-Pin1 specific. For example, the 
mechanism of action of a well known Pin1 inhibitor, juglone, has been shown to 
be responsible for not only the inhibition of Pin1 (Hennig et al., 1998) but also 
other effects such as the inhibition of transcription by RNA polymerases I and III 
(Chao et al., 2001), inhibition of protein kinase C (Frew et al., 1995), stimulation 
of topoisomerase II-mediated DNA damage (Wang et al., 2001) as well as 
disruption of the cell membrane potential by blocking K+ channels (Varga et al., 
1996). Another model of Pin1 silencing is the Pin1-/- mouse, which has been used 
in several studies to investigate the effect of Pin1 silencing on neurodegeneration, 
oncology and cell cycle progression (Fujimori et al., 1999; Ryo et al., 2001; Liou 
et al., 2003). The use of the Pin1-/- mouse however was not suitable in this study, 
since complete inhibition of Pin1 has been shown to have deleterious effects on 
mice, such as progressive age-dependent neuropathy, retinal atrophy as well as 
impairment of cell proliferation (Liou et al., 2002; Liou et al., 2003). This could 
be attributed to the involvement of Pin1 in neuronal development and 
differentiation (Nakamura et al., 2012) as well as the role of Pin1 in other specific 
tissues, such as induced tau hyperphosphorylation, NFT conformation and tau 
filament formation in Pin1-/- brains (Liou et al., 2003). This study requires partial 
gene inhibition, with temporal- and tissue-specific knockdown of Pin1 as a viable 
therapeutic option for ALS. One method of specific and selective target gene 
inhibition is the use of RNAi, which results in the degradation of specific mRNA 
molecules. Pin1 siRNA has been used in previous studies to show knockdown of 
Pin1 expression in vitro in neuronal cultures as well as in mammalian HEK 
293T/17 cells (Kesavapany et al., 2007; Rudrabhatla et al., 2008). The transient 
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nature of siRNA-mediated knockdown however prevents high potency sustainable 
inhibition of target gene expression which may be required for treatment of 
certain medical conditions such as ALS, where there is progressive motor neuron 
toxicity and the disease period is up to 3 to 5 years from symptomatic onset. In 
this study, shRNA was employed as the method of targeted Pin1 expression 
knockdown due to its target specificity, high potency, sustainable effects as well 
as optimization potential for temporal- and tissue-specificity. In this chapter, the 
knockdown expression using the Pin1 shRNA construct was validated in the HEK 
293T/17 cells as well as in primary cortical neurons. Following which, the AAV2-
Pin1 shRNA was produced and shown to have stable, long-term knockdown in 
HEK 293T/17 cells and primary cortical neurons. 
 
To evaluate the knockdown efficiency of the Pin1 shRNA construct, HEK 
293T/17 cells and primary cortical neurons had been transfected with Pin1 
shRNA and Control shRNA. Figures 3.3.1 and 3.3.2 showed Pin1 shRNA reduced 
Pin1 expression in HEK 293T/17 cells and primary cortical neurons. This study 
aims to partially reduce Pin1 levels using the Pin1 shRNA, as shown in Figure 
3.3.1 where the Pin1 shRNA transfected HEK 293T/17 cells were observed to 
have significantly reduced Pin1 levels of 35% - 60% of the Control shRNA 
transfected cells. One study has shown that the 60% reduction of Pin1 expression 
was sufficiently protective against p-NF-H accumulation and was able to reduce 
neuronal cell death to 16% during H2O2 and heat shock stress (Rudrabhatla et al., 
2008). Another study reported that 50% knockdown of Pin1 levels resulted in the 
reduction of aberrant p-NF-H accumulations in neuronal cells when treated with 
glutamate (Kesavapany et al., 2007). Since this was a transient transfection, it was 
expected that the Pin1 knockdown effect would not be sustainable and indeed this 
was observed at day 7 post-transfection, where there was recovery in Pin1 levels 
accompanied by a reduction in the GFP expression observed from the 
immunoblot results. Interestingly, the Pin1 mRNA reduction observed at days 1 
and 3 post-transfection did not correspond with a knockdown of Pin1 protein 
levels. This indicates that despite a reduction in RNA levels, protein turnover was 
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slow and a longer time-point is required for sufficient Pin1 knockdown. Therefore 
transient transfections of the Pin1 shRNA would not be a suitable technique in 
this study.  
 
One method to ensure stable, long-term expression of Pin1 shRNA in vivo was the 
use of a gene delivery tool such as AAV2 vector, which has been shown to 
effectively transport insulin-like growth factor 1 (IGF-1) to the spinal motor 
neurons in the G93A SOD1 ALS mouse, resulting in the delay of disease 
progression and improvement of survival (Kaspar et al., 2003). This has also been 
reported using AAV2-SOD1 siRNA to target the spinal motor neurons and 
alleviate the disease pathology in the G93A SOD1 mice (Miller et al., 2005). 
Therefore AAV2 was chosen to deliver the Control shRNA and Pin1 shRNA; the 
constructs were packaged into the AAV2 vector for transductions in vitro into 
HEK 293T/17 cells and primary cortical neurons to determine the stability and 
efficiency of Pin1 knockdown using AAV2. The results presented in Figures 3.3.3 
and 3.3.4 indicate that the AAV2-Pin1 shRNA had efficiently and stably reduced 
the Pin1 expression in HEK 293T/17 cells and neurons with sufficient 
transduction efficiency to quantify the Pin1 knockdown levels. Using the AAV2-
Pin1 shRNA, knockdown of Pin1 was observed even at day 14 post-transduction 
indicating the stable, long-term expression of Pin1 shRNA. However based on the 
biochemical assays, the knockdown of Pin1 in the HEK 293T/17 cells had 
diminished by day 14 post-transduction which is likely due to the rapidly dividing 
nature of the HEK 293T/17 cells resulting in the loss of the epichromosomal 
genome after cell replication and hence loss of Pin1 shRNA expression. The 
efficient transduction of AAV2-Pin1 shRNA into the neuronal cells could be due 
to the neuronal tropism of AAV2 (Bartlett et al., 1998). Though the receptors 
responsible for the preferential transduction of neurons is unknown, it has been 
largely attributed to the primary receptor, cell surface heparin sulphate 
proteoglycans (HSPGs) (Summerford and Samulski, 1998) that has been found to 
be prevalent on neuronal surfaces, as well as the other co-receptors, av5 
integrins and fibroblast growth factor receptor 1 (FGFR-1) (Qing et al., 1999; 
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Summerford et al., 1999). The AAV2-Pin1 shRNA samples showed significant 
percentage reduction of Pin1 protein and RNA levels in HEK 293T/17 cells and 
cortical neurons to 50% - 65% and 45 - 70% respectively of the AAV2-Control 
shRNA samples up to day 14 post-transduction in vitro. These results indicate that 
the AAV2-Pin1 shRNA can be tested for in vivo use in mouse spinal motor 
neurons for gene therapy studies. Though the transduction results of AAV2 in 
vitro in cortical neurons were promising, it is crucial to determine the transduction 
efficiency of the AAV2-Control shRNA and AAV2-Pin1 shRNA in vivo into the 
spinal motor neurons. In the following chapter, the delivery of AAV2-Control 
shRNA and AAV2-Pin1 shRNA into the spinal cord via intramuscular injections 
was investigated, for the development of an efficient gene delivery method of 





















CHAPTER 4 GENE DELIVERY OF AAV-PIN1 SHRNA INTO THE 
MOTOR NEURONS OF THE SPINAL CORD 
 
4.1 BACKGROUND 
Investigations on the use of AAV2 as an in vivo gene therapy strategy in the ALS 
mouse model have been reported previously (Wang et al., 2002b; Kaspar et al., 
2003; Miller et al., 2005). In these published reports, intramuscular injections of 
AAV2 had transported the transgenes into the spinal motor neurons and had 
shown alleviation of ALS symptoms in the mice. The positive findings in these 
studies indicate the feasibility of retrograde transport AAV2 from the muscle to 
the spinal cord as gene therapy for ALS. The objective of this section is to show 
in vivo gene delivery of Pin1 shRNA into the spinal motor neurons using AAV as 
the gene delivery tool in this study. In the previous chapter, we had validated the 
gene knockdown efficiency of the AAV2-Pin1 shRNA in vitro in primary cortical 
neurons and HEK 293T/17 cells; subsequently in this section we investigated 
AAV2-Pin1 shRNA transduction in vivo in WT mice through intramuscular 
injections. Data in this chapter shows that there was successful transductions in 
the motor neurons of the spinal cord with prolonged expression. By effectively 
expressing Pin1 shRNA into the spinal motor neurons, we could develop a 
therapeutic method of tissue-specific Pin1 knockdown that can be used in the 














4.2.1 Production and purification of AAV2-Control shRNA and AAV2-Pin1 
shRNA 
The AAV2 stocks were prepared in our laboratory using the AAV Helper Free 
System provided by Stratagene. 
 
4.2.2 Production and purification of AAV serotypes from Vector Core Lab 
The AAV vectors serotype 2/1, 2, 2/5, 2/6, 2/8 and 2/9 (referred to as AAV1, 2, 5, 
6, 8 and 9 in this study) used in the in vitro studies and in vivo gene delivery into 
the mouse spinal cord, were purchased from Vector Core Lab. 
 
4.2.3 Validation of transduction efficiency of various AAV serotypes in vitro 
in primary cortical neurons 
E15 primary cortical neurons were cultured and seeded at 1 x 105 cells per 15 mm 
glass coverslip that was placed in 12-well plates for immunocytochemistry. The 
cortical neurons were transduced at 4-5 DIC with 1x1011 particles of the GFP-
tagged AAV serotypes produced by Vector Core Lab. The transduction 
efficiencies (GFP expression) of the cells were monitored at days 5, 8, 11 and 14 
days post-transduction. The GFP positive cells were fixed and immunostained for 
anti-MAP2 (Sigma Aldrich). The secondary antibodies used were Alexa Fluor 
594 goat anti-mouse IgG (H+L). Fluorescent images were captured with the Carl 
Zeiss LSM-510 laser-scanning confocal microscope. 
 
4.2.4 Intramuscular injections of AAV 
WT male mice were anesthetized by isoflurane and intramuscularly injected with 
GFP-tagged AAV into the left and/or right gastrocnemius muscle of the 
hindlimbs. Volumes of injection of the AAV2-Pin1 shRNA and AAV2-Control 
shRNA were 100 L per site of injection. For AAV stocks produced by Vector 
Core Lab, AAV particles of 5x1011 to 2x1012 were used for the intramuscular 
injections. Saline injected mice were used as the negative control in these studies. 
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After the time-points, the mice were perfused to collect histological samples for 
immunohistochemistry. 
 
4.2.5 Immunohistochemistry to validate transduction efficiency and Pin1 
knockdown in spinal motor neurons 
The spinal cords collected were processed for immunohistochemistry and 
immunostained with the following antibodies; anti-GFP antibody (monoclonal 
from Roche Diagnostics and polyclonal from Invitrogen), polyclonal anti-ChAT 
antibody (Millipore) and polyclonal anti-Pin1 (Enogene). The secondary 
antibodies used were Alexa Fluor 488 goat anti-mouse/rabbit IgG (H+L) and 
Alexa Fluor 594 goat anti-rabbit IgG (H+L). The nuclei were counterstained with 
DAPI. Fluorescent images were captured with the Olympus BX61 fluorescence 






















4.3.1 Delivery of AAV2-Control shRNA and AAV2-Pin1 shRNA into the 
mouse spinal cord 
The AAV2-Control shRNA and AAV2-Pin1 shRNA, which were purified and 
produced using the AAV Helper Free System, were administered into WT mice 
via intramuscular injections. One month after the injections, the spinal cords of 
the mice were collected and divided into the four regions: sacral, lumbar, thoracic 
and cervical for immunostaining with anti-GFP antibody (Figure 4.3.1). From the 
immunostaining results shown in Figure 4.3.1, there were no detectable GFP 
positive cells in any region of the spinal cords of the AAV2-Control shRNA 
(panels a-h) and AAV2-Pin1 shRNA (panels i-p) injected mice. This indicates 
that the AAV2 is not suitable to be used in this study for the gene transfer of Pin1 






Figure 4.3.1 Delivery of AAV2-Control shRNA and AAV2-Pin1 shRNA into 
the spinal cord via intramuscular route of administration. AAV2-Control 
shRNA (panels a-h) and AAV2-Pin1 shRNA (panels i-p) were administered to 
WT mice by intramuscular injections. NT represents control spinal cord images 
from saline injected mice (panels q and r). Nuclear counterstaining was performed 
using DAPI (blue). Scale bar represents 200 m. 
 
4.3.2 Evaluation of the transduction efficiency of various AAV serotypes. 
Since there was no transduction of AAV2-Control shRNA and AAV2-Pin1 
shRNA into the spinal cord, the gene delivery of AAV into the spinal cord had to 
be optimized using various other GFP-tagged AAV serotypes. The AAV 
serotypes 1, 2, 5, 6, 8 and 9 were produced and purified by Vector Core Lab and 
compared for transduction efficiency by in vitro transductions. Vector Core Lab 
purified AAV2 was used to ensure that the low transduction efficiency of the 
AAV2-Pin1 shRNA and AAV2-Control shRNA was not due to differences in the 
production and purification of the vectors. GFP-tagged AAV 1, 2, 5, 6, 8 and 9 
were transduced into E15 mouse cortical neurons and observed for number of 
GFP positive cells following a time course of 5, 8, 11 and 14 days post-
transduction (Figure 4.3.2). Based on the representative images (Figure 4.3.2A) 
and the percentage of GFP positive neurons (total number of GFP positive cells 
over total number of MAP2 positive cells) presented in the graph (Figure 4.3.2B), 
AAV5 had the lowest number of GFP positive cells, followed by AAV2. The 
higher number of GFP positive cells were observed in AAV1, AAV6, AAV8 and 
AAV9 transduced cells. It was observed that the number of GFP positive cells 
increased over the time course (Figure 4.3.2B) indicating that the GFP expression 
was gradual and that the maximum transduction efficiency was more detectable at 
later time points. Mean values and standard deviations for the graph in Figure 





Figure 4.3.2 Transduction efficiency of different AAV serotypes for gene 
delivery. A. 4-5 DIC cortical neurons were transduced with 1x1011 particles of 
GFP-tagged (green) AAV 1, 2, 5, 6, 8 and 9. Representative images show 
transduction efficiency of the neurons (number of GFP positive cells) 
immunostained at 14 days post-transduction with neuronal marker, anti-MAP2 
antibody (red). Scale bar represents 100 m. B. Graphs represent the transduction 
efficiency (percentage of GFP positive neurons) of the GFP-tagged AAV 1, 2, 5, 
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6, 8 and 9 observed at various time-points of 5, 8, 11 and 14 post-transduction. 
Error bars represent standard deviation. 
 
The selected AAV serotypes 1, 6, 8, and 9 were then evaluated for their gene 
delivery ability in vivo into the mouse spinal cord via intramuscular injections (1 
x 1012 virus particles administered per injection site) into two sites: left and right 
gastrocnemius muscle of the hindlimbs. After one month, the spinal cords were 
collected and the four regions: sacral (panels a and b), lumbar (panels c and d), 
thoracic (panels e and f) and cervical (panels g and h) of each spinal cord were 
immunostained with anti-GFP antibody (Figure 4.3.3). There was observed GFP 
expression (as indicated by the red circles) in the cells found in the ventral horn of 
the lumbar region from the AAV1 (Figure 4.3.3A) and AAV9 (Figure 4.3.3D) 
injected mice. There was no observable GFP expression in the spinal cords of the 











Figure 4.3.3 Determination of the GFP-tagged AAV serotypes 1, 6, 8 and 9 for 
gene delivery in vivo into the motor neurons of the spinal cord. AAV1-GFP 
(A), AAV6-GFP (B), AAV8-GFP (C) and AAV9-GFP (D) were intramuscularly 
injected into WT mice (1 x 1012 particles per injection) and GFP expression was 
determined by anti-GFP antibody (green) immunostaining of sacral (panels a and 
b), lumbar (panels c and d), thoracic (panels e and f) and cervical (panels g and h) 
sections of the spinal cord. Red circles indicate transduced cells in the ventral 
horn region of the spinal cord. Nuclear counterstaining was performed using 
DAPI (blue). Scale bar represents 200 m.  
 
 
4.3.3 Validation of stable gene expression of AAV into the spinal motor 
neurons in mice. 
We next evaluated the stability of the transgene expression in the spinal cord of 
the mice to ensure that there was long-term expression of the gene. The mice were 
injected with GFP-tagged AAV1 (panels a-f) and AAV9 (panels g-l) as 
previously described, and the spinal cords were collected at one and three months 
post-injection for imunostaining with anti-GFP antibody (Figure 4.3.4A). The 
results show that GFP expression could be detected even up to three months post-
administration of AAV1 and AAV9, indicating that transgene expression was 
stable using the AAV1 and AAV9 for gene delivery. It is crucial for stable, long-
term gene expression using AAV due to the required gene delivery of Pin1 
shRNA prior to ALS disease onset and the sustained gene expression up to end-
stage of the disease for this study. To determine whether the transgene delivery 
was targeted to the motor neurons of the spinal cord, the lumbar regions of the 
spinal cord were double labeled with anti-GFP antibody and anti-ChAT antibody, 
as the motor neuron marker (Figure 4.3.4B).  There was co-localization of the 
GFP expression in the ChAT positive cells (representative cells indicated by 
white arrows), indicating that the gene delivery of AAV1 and AAV9 via the 
intramuscular route targeted the spinal motor neurons. Based on the results, we 
decided to produce AAV1 and AAV9 containing the Pin1 shRNA construct to 








Figure 4.3.4 Stable transduction of AAV1 and AAV9 in the spinal motor neurons. A. Representative images of the ventral horn 
region of the lumbar spinal cord from mice injected with 1 x 1012 particles per injection of GFP-tagged AAV1 (panels a-f) and AAV9 
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(panels g-l). Spinal cords were collected at 1 month (panels a-c and g-i) and 3 
months (panels d-f and j-l) post-injection. Transduced cells were determined by 
anti-GFP antibody (green) immunostaining of the lumbar spinal cord sections. 
Saline-injected WT mouse (NT) serves as a control (panels m-o). Nuclear 
counterstaining was performed using DAPI (blue). Scale bar represents 200 m. 
B. Representative images of lumbar sections of the spinal cord from WT mice that 
were intramuscularly injected with 1 x 1012 particles per injection of GFP-tagged 
AAV1 (panels a-d) and AAV9 (panels e-h). Sections were immunostained with 
anti-GFP (green) and anti-ChAT antibody (red).  White arrows indicate spinal 
motor neurons transduced with AAV1 and AAV9. Saline-injected WT mouse 
(NT) serves as a negative control (panels i-l). Nuclear counterstaining was 
performed using DAPI (blue). Scale bar represents 100 m. 
 
 
4.3.4 Determination of AAV titer and Pin1 knockdown in transduced spinal 
motor neurons. 
The GFP tagged AAV1-Pin1 shRNA and AAV9-Pin1 shRNA were produced by 
Vector Core Lab and titered in vivo by intramuscular administration of 5x1011 to 
2x1012 particles into each injection of the left hindlimbs. The spinal cords were 
collected one month after the injections and fluorescence immunostaining for 
anti-GFP antibody was performed on the lumbar sections (Figure 4.3.5A). To 
determine the appropriate AAV serotype for further studies into the ALS mouse 
model, the average number of transduced (GFP positive) cells observed in the 
ventral horn of the lumbar region was compared between the AAV1-Pin1 shRNA 
and AAV9-Pin1 shRNA as shown in Figure 4.3.5B. The data showed that the 
highest percentage of GFP expressing cells in the lumbar ventral horn was 
observed when administered with 2x1012 particles of AAV9-Pin1 shRNA. Mean 
values and standard deviations for the graph in Figure 4.3.5B are shown in 





            
Figure 4.3.5 Transduction efficiency of AAV1- and AAV9-Pin1 shRNA at 
different virus titers. A. WT mice were injected (5x1011 to 2x1012 particles per 
injection) with GFP-tagged AAV1-Pin1 shRNA and AAV9-Pin1 shRNA. Lumbar 
sections of the spinal cord were collected 1 month post-injection and 
immunostained with anti-GFP antibody (green) to show transduction of Pin1 
shRNA into the spinal motor neurons. Nuclear counterstaining was performed 
using DAPI (blue). Scale bar represents 200 m. B. Quantification of the 
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percentage of GFP positive (+ve) cells in the ventral horn region of the lumbar 
sections from mice injected with 5x1011 to 2x1012 particles of AAV1-Pin1 shRNA 
and AAV9-Pin1 shRNA. The number of cells counted (n) to determine the 
percentage of GFP positive cells is depicted above each bar. Error bars represent 
standard deviation.  
 
The knockdown of Pin1 expression in vivo using the AAV9-Pin1 shRNA was 
investigated by anti-Pin1 antibody immunostaining the spinal cords of the mice 
injected with AAV9-Pin1 shRNA and AAV9-Control shRNA (Figure 4.3.6). The 
results indicate that there was reduction of Pin1 expression in the AAV9-Pin1 
shRNA transduced motor neurons (GFP positive; representative cells shown by 
arrows) as shown in panels e-h, compared to the AAV9-Control shRNA 
transduced motor neurons (GFP positive; representative cells shown by 




Figure 4.3.6 Knockdown of Pin1 in the AAV9-Pin1 shRNA transduced spinal motor neurons. Lumbar sections of WT mice 
injected with 2x1012 GFP-tagged AAV9-Control shRNA and AAV9-Pin1 shRNA immunostained with anti-Pin1 (red) antibody. 
Arrows indicate AAV9-Pin1 shRNA transduced cells and arrowheads indicate AAV9-Control shRNA transduced cells. Nuclear 




The results revealed that there was no gene expression of AAV2 transductions in 
vivo in the spinal motor neurons. To improve the transduction efficiency into the 
spinal cord, preliminary studies were done to examine the transduction efficiency 
of various GFP-tagged AAV serotypes (AAV 1, 2, 5, 6, 8 and 9) in vitro in 
primary cortical neurons. AAV 1, 6, 8 and 9 serotypes were identified to have 
higher transduction efficiency in the neuronal cultures and were administered in 
vivo by intramuscular injections into WT mice. Immunostaining results revealed 
that AAV1 and AAV9 had positive, stable gene expression into the spinal motor 
neurons. Using these two AAV serotypes, the transduction efficiency of Pin1 
shRNA into the spinal cord was examined to determine the gene delivery tool for 
transport of Pin1 shRNA into the spinal motor neurons. AAV9 was determined to 
show better transduction efficiency into the spinal motor neurons and was used to 
show Pin1 knockdown in the spinal motor neurons when AAV9-Pin1 shRNA was 
administered. 
 
Though ALS affects both upper and lower motor neurons, initial symptoms of the 
disease are generally observed in the peripheral muscles and implicate lower 
motor neurons (Fujimura-Kiyono et al., 2011). By targeting the Pin1 knockdown 
treatment in the lower motor neurons prior to disease onset, the symptoms of the 
disease are expected to be alleviated. One method used for gene delivery for 
targeting lower motor neurons is by intramuscular administration of viral vectors. 
Efficient gene transfer into the CNS from a peripheral injection is important in 
therapeutics, to minimize invasive intervention as well as to permit re-
administration of the therapeutics on a long-term basis especially for chronic 
diseases (Dayton et al. 2012). Additionally, there have been several studies that 
have reported successful gene delivery into the spinal motor neurons using AAV 
delivery via intramuscular injections. One such example was shown when AAV2-
GDNF was administered via intramuscular injections in G93A SOD1 mice; there 
was preservation of the motor neurons and their axons that innervate the muscle, 
as well as delay of disease onset and extension of survival (Wang et al., 2002b). A 
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similar study was performed, in which the G93A SOD1 mice were 
intramuscularly injected with AAV2-IGF-1 or AAV2-GDNF to target the motor 
neurons in the spinal cord (Kaspar et al., 2003). Though both IGF-1 and GDNF 
treated ALS mice showed a delay in disease onset and increase in survival, IGF-1 
treated mice had better survival and alleviation of the disease symptoms (Kaspar 
et al., 2003). Retrograde transport of AAV2-SOD1 siRNA into the spinal motor 
neurons by intramuscular injections resulted in preservation of grip strength in the 
ALS mice (Miller et al., 2005). The positive findings in these studies indicate the 
feasibility of retrograde gene transport of AAV2 from the muscle to the spinal 
cord in this study. In fact, AAV serotypes 1, 2, 5, 7 and 8 were injected 
intramuscularly to compare the ability for retrograde transport to the lower motor 
neurons (Pirozzi et al., 2006). The researchers found that AAV2 had the highest 
number of transduced lower motor neurons (Pirozzi et al., 2006). However in this 
study, when AAV2-Control shRNA and AAV2-Pin1 shRNA were 
intramuscularly injected into WT mice, there was no detectable expression of the 
transgene into the spinal motor neurons (Figure 4.3.1). This could be due to 
differences in the production and purification of AAV2 in-house as compared to 
the publications. The different transgene inserted would also account for the 
differences in the transduction efficiency as compared to other published reports. 
There have been previous studies that have reported enhanced transduction of 
particular AAV serotypes based on tissue-specificity. AAV 1, 5 and 8 was 
reported to demonstrate a marked increase in transduction of the dopaminergic 
nigrostriatal neurons compared to AAV2 (McFarland et al., 2009). Another study 
showed that AAV4 and AAV5 have higher affinities for ependymal cells when 
compared to AAV2 (Davidson et al., 2000). Based on these published papers, we 
investigated the transduction efficiencies of several other AAV serotypes (AAV 
1, 5, 6, 8 and 9) into the spinal motor neurons. A preliminary study to confirm the 
favorable tropism of these AAV serotypes to neuronal cells was conducted, where 
primary cortical neurons were transduced in vitro with the AAV serotypes (Figure 
4.3.2) and AAV 1, 6, 8 and 9 were found to have higher transduction efficiency 
into the neurons. These serotypes have been previously reported to show tropisms 
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into neuronal cells (Towne et al., 2010; Mason et al., 2010; McFarland et al., 
2009; Foust et al., 2009). 
 
Based on the results from the in vitro study which identified that AAV 1, 6, 8 and 
9 had marked increase in transduction efficiency, the GFP-tagged serotypes were 
intramuscularly injected into the mice. Figure 4.3.3 showed that only AAV1 and 
AAV9 had effective gene delivery to the spinal cord. AAV gene transfer and 
expression is likely through retrograde transport from the muscles to the spinal 
cord via the peripheral nerve axonal projections (Zheng et al., 2010). We showed 
that the GFP expression was only observable at the ventral horn of the lumbar 
region of the spinal cord, which is likely due to the innervation of gastrocnemius 
muscles to the lumbar region. The ventral horn of the lumbar region contains the 
lower motor neurons that influence lower limb muscles. Accumulations of p-NF-
H in the ventral horn of the lumbar spinal cord region have been found in the 
G93A SOD1 mice (Subramaniam et al., 2002). This indicates that by using the 
AAV, Pin1 shRNA expression can be targeted into the lower motor neurons 
where p-NF-H accumulations have been reported in the ALS mice. Though the 
neuronal tropism shown by the transduction efficiency from the in vitro data 
suggested that AAV6 and AAV8 would be promising for in vivo gene delivery 
into the spinal cord, there was no detectable transgene expression in spinal cord. 
The differences observed between the in vitro and in vivo transduction efficiency 
could be due to factors such as CNS penetration and efficiency of the AAV 
retrograde transport from the muscle to the spinal cord. The differential tissue 
tropism of the AAV serotypes is also due to the receptors used for cell entry that 
differs between serotypes (Buning et al., 2008). For example, AAV serotype 8 has 
been reported to have poor penetration of the CNS through systemic 
administration of the AAV vector, with only several cells positively expressing 
the transgenes within the spinal cord (Foust et al., 2008). By immunostaining the 
lumbar cords for ChAT expression, a well known marker for cholinergic motor 
neurons, this study has shown that AAV targets the lower motor neurons in the 
lumbar region of the spinal cord (Figure 4.3.4B).  
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Administration of the AAV1-Pin1 shRNA and AAV9-Pin1 shRNA into the WT 
mice had not shown any deleterious health effects to the mice, and expression of 
the transgene into the spinal motor neurons was observed in both treatments 
(Figure 4.3.5). However upon quantification of the percentage of transduced cells, 
it was determined that the AAV9-Pin1 shRNA administered with 2x1012 particles 
of the vector, had shown the highest transduction efficiency. Intramuscular 
administration of AAV9 has been shown to result in widespread motor neuron 
transduction in the spinal cord, beyond the motor neurons connected to the axonal 
projections from the injected muscle (Benkhelifa-Ziyyat et al., 2013). AAV9 has 
been demonstrated to surpass the blood-brain barrier and transduce neurons in the 
brain and spinal cord in rodent and non-human primate model (Duque et al., 
2009; Bevan et al., 2011). Comparison of AAV vector serotypes 1, 6, 8, and 9 for 
spinal motor neuron delivery in adult mice, by the intraparenchymal or intrathecal 
route of administration showed that AAV 6 and 9 performed better than the other 
serotypes (Snyder et al., 2011). GFP expression was also found to be sustainable 
up to 3 months from administration (Figure 4.3.4A), which is crucial for a viable 
gene delivery strategy of Pin1 shRNA prior to ALS disease onset and to observe 
sustained gene expression up to end-stage of the disease. These results were 
supported by a previous study, which reported that intramuscular administration 
of AAV-GDNF had resulted in stable transgene expression up to six months in 
the spinal cord (Lu et al., 2003b). The knockdown efficiency of Pin1 in the cells 
transduced with AAV9-Pin1 shRNA as compared to the AAV9-Control shRNA 
was next evaluated. The results presented in Figure 4.3.6 indicated that AAV9-
Pin1 shRNA had reduced the Pin1 expression in the ventral horn lumbar region of 
the spinal cord. In the following chapter, initial investigation into the disease 
progression in the ALS mice was done. This is to determine the appropriate 
timing to administer the Pin1 shRNA into the mice for early prevention of p-NF-
H accumulations. The ALS mice were then injected with AAV9-Pin1 shRNA to 
knockdown Pin1 shRNA in the lower motor neurons of the spinal cord in the ALS 





CHAPTER 5 KNOCKDOWN OF PIN1 AND REDUCTION OF p-NF-H 
ACCUMULATIONS IN THE ALS MOUSE MODEL 
 
5.1 BACKGROUND 
One of the pathological hallmarks of motor neuron death in ALS is the abnormal 
accumulations of neurofilaments in the neuronal cell body of spinal motor 
neurons (Munoz et al., 1988; Mendonca et al., 2005). Previous reports 
demonstrated that accumulations of p-NF-H were found in the perikarya of the 
anterior horn motor neurons in both familial and sporadic ALS patients (Munoz et 
al., 1988; Mendonca et al., 2005). This pathology has also been consistently 
reported in the lumbar cord of the ALS mouse, G93A SOD1 (Subramaniam et al., 
2002; Cleveland and Rothstein, 2001). The previous chapters have discussed that 
the Pin1 expression in vitro and in vivo could be reduced using Pin1 shRNA. As 
previously published, the knockdown of Pin1 levels was able to rescue p-NF-H 
accumulations and neuronal cell death (Kesavapany et al., 2007). Using AAV as 
the gene delivery tool, there was efficient transduction and Pin1 knockdown in the 
spinal motor neurons of the lumbar cord. In this chapter, the disease pathology 
progression in the G93A SOD1 mouse was investigated. Immunostaining and 
behavioural assessments revealed that accumulations of p-NF-H in the spinal 
motor neurons of G93A SOD1 mice were observed prior to motor neuron cell 
death and behavioural deficits. Based on these results, the early prevention of p-
NF-H accumulations by administration of AAV9-Pin1 shRNA prior to the 
observed disease pathology is crucial in alleviating the disease. It is hypothesized 
that the early expression of Pin1 shRNA into the spinal motor neurons would 
prevent the later ALS pathology in the G93A SOD1 mice. The following results 
section describes the validation of the G93A SOD1 model by evaluation of motor 
function and histological examination of the spinal cords, as well as the effect of 







5.2.1 Production and purification of AAV9-Pin1 shRNA and AAV9-Control 
shRNA from Vector Core Lab 
The AAV9-Pin1 shRNA and AAV9-Control shRNA used for in vivo gene 
delivery into the mouse spinal cord were purchased from Vector Core Lab. 
 
5.2.2 Administration of AAV9-Pin1 shRNA into WT and G93A SOD1 mice 
WT and G93A SOD1 male mice were randomly divided into three groups for the 
end time-points investigated in this study: 90, 120 and 150 days old. For each 
time-point, there were five treatment groups: WT treated with saline (WT saline), 
G93A SOD1 treated with saline (G93A SOD1 saline), WT treated with Pin1 
shRNA (WT Pin1 shRNA), G93A SOD1 treated with AAV9-Control shRNA 
(G93A SOD1 Control shRNA) and G93A SOD1 treated with AAV9-Pin1 shRNA 
(G93A SOD1 Pin1 shRNA). For this study, n=3 was used per treatment group per 
time-point with the exception of WT Pin1 shRNA/90 days old (n=2).   
 
The mice were anesthetized by isoflurane and intramuscularly injected with either 
saline, 2x1012 particles of the GFP-tagged AAV9-Pin1 shRNA or AAV9-Control 
shRNA into the left and right gastrocnemius muscle of the hindlimbs. The mice 
were then subjected to motor function studies at a bi-weekly interval. At the end 
time-points of 90, 120 and 150 days old, the mice were perfused to collect 
histological samples for immunohistochemistry.  
 
5.2.3 Motor function studies  
Motor function studies (rotarod, grip strength and gait analysis) were conducted 






5.2.4 Histological analysis of pathological hallmarks in WT and G93A SOD1 
mice 
The spinal cords collected were processed for either fluorescence 
immunohistochemistry or DAB staining. The following antibodies were used: 
anti-GFP antibody (polyclonal from Invitrogen), monoclonal anti-Neurofilament 
(clone RT97) antibody (Vector Laboratories), monoclonal anti-GFAP (Sigma 
Aldrich) and polyclonal anti-ChAT antibody (Millipore). The secondary 
antibodies used were Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 
594 goat anti-mouse IgG (H+L). The nuclei were counter stained with DAPI. The 
DAB staining was performed using the VECTASTAIN® EliteABC Kit-Mouse 
IgG or VECTASTAIN® EliteABC Kit-Rabbit IgG (Vector Laboratories). Images 
were captured with the Olympus BX61 fluorescence microscope and the Carl 






















5.3.1 Evaluation on motor function dysfunction and pathological hallmarks 
in the G93A SOD1 mice  
To determine when Pin1 knockdown would be most effective during the disease 
progression in ALS mice, further understanding into the hallmarks of the disease 
is crucial. This is to allow sufficient timing for the reduction of Pin1 expression 
before onset of the pathological hallmarks, which may be too severe at the later 
stages for any treatment to take effect. Initial studies on the motor performance of 
the G93A SOD1 mice were done by conducting motor function studies (rotarod, 
grip strength and gait analysis) and compared against the WT mice at various ages 
of 60, 90, 120 and 150 days old (*p-value < 0.05, **p-value < 0.01, ***p-value < 
0.001, Student’s t-test) (Figure 5.3.1). The gait analysis results showing forelimb 
and hindlimb stride time and length as an index of motor function indicate that 
significant decline in the stride length and increase in the stride time of the G93A 
SOD1 mice was presented at 150 days (late-stage of the disease in the mice) 
(Figure 5.3.1A). G93A SOD1 mice showed a significant reduction on the rotarod 
performance and grip strength (forelimb and hindlimb) at 120 days old, and motor 
function continued to deteriorate significantly as the disease progressed (Figure 
5.3.1B and C). Figure 5.3.1 indicates that significant reduction in motor function 
in the G93A SOD1 mice was observed at 120 days old as depicted by rotarod and 
grip strength studies, while the gait analysis appears to be not sensitive and was 
able to detect the late-stage symptoms of the disease. Mean values and standard 




Figure 5.3.1 Progressive motor impairment in the G93A SOD1 mice 
compared to WT A. Representative graphs presenting the average stride time 
(left graph) and stride length (right graph) of the WT and G93A SOD1 mice 
analyzed as a function of age (days old) using the gait analysis. B. Average grip 
strength graphical analyses of forelimb paws (left graph) and forelimb/hindlimb 
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paws (right graph) of WT and G93A SOD1 mice analyzed as a function of age 
(days old). C. Representative graph of rotarod performance of WT and G93A 
SOD1 mice analyzed as a function of age (days old). Significant motor movement 
deficit in the G93A SOD1 mice observed from the age of 120 days old. Error bars 
represent standard deviation from mean of n=3 animals per group (*p-value < 
0.05, **p-value < 0.01, ***p-value < 0.001, ns = non-significant). 
 
 
To further understand the pathological hallmarks in the G93A SOD1 mice, the 
lumbar sections of the mice at various stages (60, 90, 120 and 150 days old) were 
collected and immunostained for reactive astrogliosis and motor neuron viability 
(Figure 5.3.2). Sections from the G93A SOD1 mice show progressive increase of 
reactive astrocytes in the gray matter area (Figure 5.3.2A and B) as well as 
significant loss of the large motor neurons (ChAT positive cells larger than 30 
m) in the ventral horn region (Figure 5.3.2 C-E) at 90 days old onwards (**p-
value < 0.01, ***p-value < 0.001, Student’s t-test). Interestingly, astrogliosis and 
motor neuron death was observed at 90 days old, which is prior to the significant 
motor function decline at 120 days old. There was no significant difference 
between WT and G93A SOD1 mice in the motor neuron viability and astrocyte 
activation at 60 days old. Mean values and standard deviations for the graph in 
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Figure 5.3.2 Progressive neurodegeneration in the spinal cord of the ALS 
mice. A-D. Representative spinal cord images from 60, 90, 120 and 150 days old 
(d.o.) WT and G93A SOD1 mice. The spinal cord sections were immunostained 
with anti-GFAP (A-B) and anti-ChAT (C-D) antibodies. B and D are 20X 
magnification representative of images in A and C respectively. Inset black boxes 
delineate ventral horn region containing the large motor neurons. Scale bars 
represent 200 m. E. Quantification of average number of large motor neurons 
(ChAT positive cells larger than 30 m) per section. There is progressive 
astrogliosis and motor neuron loss in the G93A SOD1 mice. Error bars represent 
standard deviation (**p-value < 0.01, ***p-value < 0.001, ns = non-significant). 
 
 
Since the pathological hallmarks of motor neuron loss and astrogliosis were found 
earlier than any motor impairment in the G93A SOD1 mice, the appearance of p-
NF-H in the disease pathology was studied to determine if p-NF-H accumulation 
is an early event during the disease (Figure 5.3.3). Immunostaining of p-NF-H in 
G93A SOD1 mice indicated that the aberrant accumulations of p-NF-H occurred 
from 60 days old, which is prior to the other observed neurodegeneration 
hallmarks. The accumulations of p-NF-H were found mostly within the ventral 
horn region, which is the region that was previously shown in Chapter 4 to be 
targeted by the AAV transductions when intramuscularly injected in the mice. 
Therefore early administration (at the pre-symptomatic stage) of AAV9-Pin1 
shRNA into the G93A SOD1 mice is hypothesized to rescue the accumulations of 
p-NF-H found in the motor neurons of the ventral horn. Mean values and standard 



















Figure 5.3.3 Accumulations of p-NF-H in G93A SOD1 mice observed as an 
early pathology. A. Lumbar sections from WT and G93A SOD1 mice at various 
ages of 60, 90, 120 and 150 days old (d.o.) were immunostained with anti-p-NF-H 
antibody. Scale bar represents 100m. Arrowheads indicate cell bodies with p-
NF-H accumulation in the ventral horn region of the spinal cord. B. 
Quantification of percentage of ventral horn motor neurons with p-NF-H 
accumulation in the cell bodies (*p-value < 0.05, **p-value < 0.01, ***p-value < 
0.001, ns = non-significant). Accumulations of p-NF-H were observed in the 
G93A SOD1 mice from 60 d.o. indicating aberrant accumulations as an early 
pathological hallmark of the disease. 
 
5.3.2 Effect of Pin1 silencing on p-NF-H accumulations and disease pathology 
in the G93A SOD1 mice 
 
Upon administration of the AAV9-Pin1 shRNA into the 50-55 days old WT and 
G93A SOD1 mice, all treated animals were subjected to motor function studies 
(rotarod and grip strength) to analyze the effects of Pin1 knockdown on motor 
performance of the mice (Figure 5.3.4). The statistical significance for the data 
was determined using ANOVA and post hoc, Tukey’s HSD test (*p-value < 0.05, 
**p-value < 0.01, ***p-value < 0.001). From the data presented, there was no 
significant difference in the mean grip strength (hindlimb/forelimb and forelimb) 
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(Figure 5.3.4A and B) and rotarod performance (Figure 5.3.4C) between the 
G93A SOD1 saline mice versus G93A SOD1 Control shRNA and G93A SOD1 
Pin1 shRNA. There was a significant reduction in the grip strength 
(hindlimb/forelimb and forelimb) as well as rotarod performance between the WT 
controls compared to the G93A SOD1 treatment groups (saline, Control shRNA 
and Pin1 shRNA). There was no significant difference in the motor performance 
between the WT saline and WT Pin1 shRNA groups for all motor performance 
parameters analysed. Together, these observations indicate that there was no 
significant change in the disease onset or severity when the ALS mice were 
treated with Pin1 shRNA. Mean values and standard deviations for the graphs in 









Figure 5.3.4 Intramuscular injection of AAV9-Pin1 shRNA does not improve 
motor performance of G93A SOD1 mice.  A-B. Grip strength graphical analyses 
of forelimb paws (A) and forelimb/hindlimb paws (B) of WT and G93A SOD1 
mice treated with saline, Control shRNA and Pin1 shRNA as a function of age 
(days old) C. Representative graph of rotarod performance of WT and G93A 
SOD1 mice treated with saline, Control shRNA and Pin1 shRNA analyzed as a 
function of age (days old). No significant motor improvement was observed in the 
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G93A SOD1 Pin1 shRNA mice from the G93A SOD1 control groups (saline, and 
Control shRNA). Error bars represent standard deviation (*p-value < 0.05, **p-
value < 0.01, ***p-value < 0.001). 
 
To examine if administration of AAV9-Pin1 shRNA has any effect on the 
astrogliosis pathology observed in the G93A SOD1 mice, the lumbar cords of the 
treated mice from the three time-points: 90 (Figure 5.3.5A), 120 (Figure 5.3.5B) 
and 150 days old (Figure 5.3.5C) were collected and immunostained for GFAP. 
Regions with positive transduction of the Control shRNA and Pin1 shRNA were 
shown by GFP immunostaining. There was no obvious difference in the astrocyte 
activation observed in the G93A SOD1 mice treated with Pin1 shRNA (panels q-t) 
compared with the controls; saline (panels e-h) and Control shRNA treated G93A 
SOD1 mice (panels m-p) at the different time-points as shown in Figure 5.3.5. 
WT saline (panels a-d) and WT Pin1 shRNA (panels i-l) sections appeared both to 











Figure 5.3.5 Pin1 knockdown shows no effect on astrocyte activation in the 
G93A SOD1 mice.  WT and G93A SOD1 mice were treated with saline (panels a-
h), GFP-tagged AAV9-Pin1 shRNA (panels i-l, and q-t) and GFP-tagged AAV9-
Control shRNA (panels m-p). Lumbar sections were collected at various ages of 
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90 (A), 120 (B) and 150 (C) days old (d.o.) and co-immunostained with anti-GFP 
(green) and anti-GFAP (red) antibodies. Nuclear counterstaining was performed 
using DAPI (blue). Representative images indicate that there was no obvious 
rescue of the astrogliosis observed in the 90, 120 and 150 d.o G93A SOD1 mice 
treated with AAV9-Pin1 shRNA. Scale bars represent 200 m. 
 
 
Loss of motor neurons is one of the key pathological hallmarks in ALS and rescue 
of the motor neurons is crucial for alleviation of the disease. The total number of 
large motor neurons (cells larger than 30 m) in the ventral horn of the lumbar 
cord for the treatment groups at 90, 120 and 150 days old were calculated based 
on positive ChAT staining (Figure 5.3.6). The statistical significance for the data 
was determined using ANOVA and post hoc, Tukey’s HSD test (*p-value < 0.05, 
**p-value < 0.01, ***p-value < 0.001). Across the three time-points, there was a 
significant reduction of the number of motor neurons in the G93A SOD1 mice 
treated with saline (panels d-f), Control shRNA (panels j-l) and Pin1 shRNA 
(panels m-o) when compared to the mice treated with WT saline (panels a-c) and 
WT Pin1 shRNA (panels g-i). There was no significant difference in the motor 
neuron survival of the mice treated with WT saline and WT Pin1 shRNA. The 
data presented in Figure 5.3.6B indicates that there was no improvement in the 
survival of the motor neurons in the G93A SOD1 mice treated with Pin1 shRNA. 
The loss of motor neurons in the G93A SOD1 mice treated with Pin1 shRNA was 
shown to be similar to that of the saline or Control shRNA treated G93A SOD1 
mice. Mean values and standard deviations for the graph in Figure 5.3.6B are 












Figure 5.3.6 Reduction of Pin1 does not affect motor neuron survival in the 
G93A SOD1 mice. A. Representative images of the lumbar section of WT and 
G93A SOD1 mice treated with saline (panels a-f), AAV9-Pin1 shRNA (panels g-i, 
and m-o) and AAV9-Control shRNA (panels j-l). Samples were collected at 
various ages of 90, 120 and 150 days old (d.o.). for immunostaining with anti-
ChAT antibody. Inset black boxes delineate ventral horn region containing the 
large motor neurons. Scale bars represent 200 m. B. Quantification of the 
surviving large motor neurons (ChAT positive cells larger than 30 m) per 
section across the treatment groups (*p-value < 0.05, **p-value < 0.01, ***p-
value < 0.001, ns = non-significant). Error bars represent standard deviation. 
 
Since Pin1 knockdown has been reported to reduce p-NF-H accumulations under 
excitotoxic conditions, the main hypothesis in this study is to determine if 
reduction of Pin1 expression could rescue the aberrant accumulations of p-NF-H. 
The sections of the lumbar cords from mice in the treatment groups from the three 
time-points: 90, 120 and 150 days old were immunostained for p-NF-H to detect 
the aberrant accumulations in the motor neurons. Positive motor neuron 
transductions were shown by GFP immunostaining (representative cells shown by 
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arrows) while representative non-transduced motor neurons are indicated by 
arrowheads. At 90 days old, the transduced motor neurons in the G93A SOD1 
mice treated with Pin1 shRNA (panels q-t) did not show perikaryal accumulations 
of p-NF-H in comparison to the G93A SOD1 Control shRNA transduced motor 
neurons (panels m-p), and the non-transduced motor neurons in the G93A SOD1 
saline treated mice (panels e-h) (Figure 5.3.7A). Figure 5.3.7B shows that though 
the G93A SOD1 Pin1 shRNA transduced motor neurons (from the 120 days old 
time-point) have reduced p-NF-H accumulations, the neighbouring non-
transduced cells showed p-NF-H accumulations in the neuronal cell bodies 
(panels q-t). The G93A SOD1 Control shRNA transduced motor neurons (panels 
m-p), and the non-transduced motor neurons in the G93A SOD1 saline mice 
(panels e-h) both show aberrant accumulations of p-NF-H in the cell bodies of the 
motor neurons (Figure 5.3.7B). However at 150 days old, (Figure 5.3.7C), the 
aberrant p-NF-H accumulations observed in the GFP positive Pin1 shRNA 
transduced G93A SOD1 motor neurons (panels q-t) was similar to that of the 
G93A SOD1 Control shRNA transduced motor neurons (panels m-p), and the 
non-transduced motor neurons in the G93A SOD1 saline mice (panels e-h). The 
Pin1 shRNA transduced motor neurons in the WT mice (panels i-l), showed no 
perikaryal accumulations of p-NF-H, similar to the WT saline sections (panels a-
d) at 90, 120 and 150 days old.   
 
Quantification of the percentage of transduced cells without any p-NF-H 
accumulations in the WT Pin1 shRNA, G93A SOD1 Control shRNA and G93A 
SOD1 Pin1 shRNA treated mice is shown in Figure 5.3.7D (*p-value < 0.05, **p-
value < 0.01, ***p-value < 0.001, Student’s t-test). The results indicate though 
there were some p-NF-H accumulations in G93A SOD1 Pin1 shRNA and Control 
shRNA transduced motor neurons at 90 days old, the percentage was not 
significant compared to WT Pin1 shRNA transduced motor neurons. 
Additionally, there was a higher (though not significant) percentage of transduced 
motor neurons without perikaryal accumulations of p-NF-H in the G93A SOD1 
Pin1 shRNA treated mice compared to the G93A SOD1 Control shRNA 
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transduced motor neurons. However at 120 days old, there a significant reduction 
in the percentage of motor neurons without any accumulations of p-NF-H (i.e. 
increase in aberrant p-NF-H accumulations) in the G93A SOD1 Pin1 shRNA and 
Control shRNA treated animals compared to the WT Pin1 shRNA mice. At the 
120 days old time-point, the G93A SOD1 motor neurons treated with Pin1 shRNA 
had a significant higher percentage of motor neurons without p-NF-H 
accumulations compared to the Control shRNA. This indicates that Pin1 
knockdown was able to alleviate some of the p-NF-H pathology observed in the 
G93A SOD1 mice. However, at the late-stage of the disease (150 days old time-
point), Pin1 knockdown was unable to prevent further p-NF-H accumulations in 
the cell bodies of the motor neurons as shown in Figure 5.3.7D. The percentage of 
transduced motor neurons without aberrant p-NF-H accumulations in the G93A 
SOD1 Pin1 shRNA treated mice had reduced to a similar percentage as that of the 
G93A SOD1 Control shRNA. Mean values and standard deviations for the graph 














Figure 5.3.7 Expression of AAV9-Pin1 shRNA in G93A SOD1 motor neurons 
partially rescues p-NF-H accumulation in the cell bodies. WT and G93A SOD1 
mice were treated with saline (panels a-h), GFP-tagged AAV9-Pin1 shRNA 
(panels i-l, and q-t) and GFP-tagged AAV9-Control shRNA (panels m-p). The 
lumbar cords at various ages of 90 (A), 120 (B) and 150 (C) days old (d.o.) were 
co-immunostained with anti-GFP (green) and anti-p-NF-H (red) antibodies. 
Arrows indicate transduced motor neurons and arrowheads indicate non-
transduced motor neurons. Nuclear counterstaining was performed using DAPI 
(blue). Representative images indicate that motor neurons expressing Pin1 shRNA 
had reduced accumulations of p-NF-H in the cell bodies. Scale bars represent 200 
m. D. Quantification of the percentage of transduced cells with no p-NF-H 
accumulations in the cell bodies in the WT Pin1 shRNA, G93A SOD1 Control 
shRNA and G93A SOD1 Pin1 shRNA treatment groups (*p-value < 0.05, **p-
value < 0.01, ***p-value < 0.001, ns = non-significant). The total number of cells 
counted (n) to determine the percentage of GFP positive cells without p-NF-H 










In this final chapter, we investigated whether the reduction of Pin1 expression in 
G93A SOD1 mice was able to rescue the disease pathology of aberrant 
accumulations of p-NF-H as well as alleviate the other hallmarks of the disease 
such as motor neuron death, astrogliosis and motor function. The initial 
experiments performed were to establish the onset of ALS pathology in the G93A 
SOD1 mice, in order to determine the therapeutic window in which to administer 
the AAV9-Pin1 shRNA, to have the most effective results in the mice. A previous 
publication described effective mitigation of the disease pathology in G93A SOD1 
mice by intramuscular injection of AAV-IGF1 at pre-symptomatic stage of the 
disease (Kaspar et al., 2003). Another study involving intramuscular injection of 
AAV-GDNF at the pre-symptomatic stage in G93A SOD1 mice also showed 
successful delay of both disease onset and progression of motor dysfunction, as 
well as extension of the life span in the treated ALS mice (Wang et al., 2002b). 
The motor function studies depicted in Figure 5.3.1 revealed that motor 
dysfunction occurs after the 90 day old time-point, whereby at 120 days, the 
G93A SOD1 mice had significantly reduced grip strength and rotarod 
performance. This is consistent with a previously published study that disease 
onset occurs at 111 days in the G93A SOD1 C57BL6/J congenic mice based on 
walk test results and survival percentages (Dobrowolny et al., 2005). However, 
gait analysis of the G93A SOD1 mice could only show motor impairment at 150 
days old, which has been reported as late-stage of the disease (Zhu and Sheng, 
2011). This indicates that in this study, the gait analysis was not sufficiently 
sensitive to detect any difference in the motor function in the earlier stages of the 
disease.  
  
One of the pathological hallmarks of ALS is the death of the large motor neurons 
in the ventral horn and replacement by fibrous astrocytes (Walling, 1999). This 
was shown in Figure 5.3.2, where immunostaining of spinal cord sections of WT 
and G93A SOD1 mice revealed obvious astrogliosis pathology and significant loss 
of the large motor neurons in the G93A SOD1 mice at 90 days old. The large 
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motor neurons have long axons which project from the spinal cord to the distal 
lower limbs and therefore have a high energy demand, necessitating a high level 
of mitochondrial activity which has been proposed to be one of the dysfunctions 
involved in ALS pathology (Shaw and Eggett, 2000). The lack of calcium-binding 
proteins, such as calbindin and parvalbumin, as well as the absence of the calcium 
impermeable GluR2 receptor (motor neurons express calcium-permeable AMPA 
receptors unlike other cells) indicate that motor neurons are more sensitive to 
calcium fluctuations especially during excitotoxicity (Alexianu et al., 1994; 
Williams et al., 1997). Therefore the large motor neurons in the ventral horn are 
more vulnerable to the disease pathology, as shown by the 37% and 55% loss of 
motor neurons at disease onset and late-stage in the G93A SOD1 mice 
respectively (Dobrowolny et al., 2005). Immunostaining of post-mortem spinal 
cord from sALS patients have revealed reactive astrocytes as part of the disease 
pathology (Schiffer et al., 1996). In the mutant ALS transgenic mice, significant 
reactive astrogliosis has also been described at 100 days of age in both the 
cervical and lumbar spinal cord regions (Hall et al., 1998a). This indicates that the 
disease pathology such as motor neuron loss and astrogliosis initiates prior to the 
physical manifestations of the disease. Figure 5.3.3 reveals that accumulations of 
p-NF-H were observed at 60 days old in the G93A SOD1 mice, which occurred 
prior to any of the other hallmarks such as, motor neuron loss or astrogliosis. The 
long axonal projections from the large motor neurons depend on the cytoskeletal 
proteins, such as neurofilaments for the maintenance of cell shape and axonal 
calibre as well as for axonal transport (Shaw and Eggett 2000). Therefore 
disruption of axonal transport by aberrant phosphorylation of neurofilaments 
could be one of the earlier mechanisms that initiate the ALS pathology. There 
have been evidence that support impaired slow axonal transport of neurofilaments 
as the earliest indication of pathology in ALS models (Zhang et al. 1997; 
Williamson and Cleveland 1999). Therefore by reducing the aberrant p-NF-H 
accumulations at pre-symptomatic stage (prior to 60 days old), this might alleviate 




The WT and G93A SOD1 mice were intramuscularly injected with either saline, 
AAV9-Control shRNA or AAV9-Pin1 shRNA at 50-55 days old and were 
divided into three end time-point groups of 90, 120 and 150 days, in order to 
properly characterize the effect of Pin1 knockdown on the ALS pathology at 
different stages of the disease. In most of the groups n=3 was used with exception 
of WT Pin1 shRNA/90 days old (n=2), however one of the Pin1 shRNA treated 
G93A SOD1 mice from the 150 days old group, had a lifespan of 135 days old 
(immunostaining for GFAP and p-NF-H in Supplementary Figure 2). This could 
be a result of individual differences in expression levels of mutant SOD1 in the 
transgenic G93A SOD1 mice or variations in the mutant SOD1 copy number 
which may be due to spontaneous deletions, which would affect disease onset and 
progression (Alexander et al., 2004) One publication had suggested that the 
differences observed in the longevity of these mice could be due to differences in 
the myogenic potential in individual animals that could compensate for the 
neurodegeneration processes, therefore the animals that survived longer may 
exhibit a higher regenerative capacity than the animals that had a shorter lifespan 
(Calvo et al., 2012). As shown in Figure 5.3.1, the gait analysis was less sensitive 
for the detection of early motor function changes in the ALS mice, therefore the 
rotarod and grip strength were the motor function tests used to analyze the effects 
of Pin1 knockdown on motor performance of the mice. There was no significant 
improvement in the motor function of G93A SOD1 Pin1 shRNA mice as 
determined by grip strength and rotarod studies, indicating that Pin1 knockdown 
by AAV9-Pin1 shRNA was not able to alleviate the disease onset or severity in 
the ALS mice (Figure 5.3.4). Furthermore, there was no rescue of the motor 
neuron loss or astrocyte activation observed in the G93A SOD1 mice treated with 
Pin1 shRNA (Figure 5.3.5 and Figure 5.3.6). This indicates that the pathological 
hallmarks in the G93A SOD1 mice could not be mitigated by AAV9-Pin1 shRNA 
treatment in the spinal motor neurons of the mice; therefore there was no motor 
function improvement in the G93A SOD1 Pin1 shRNA mice. However, Pin1 
knockdown was able to reduce the p-NF-H accumulations observed in the motor 
neurons of the G93A SOD1 mice (Figure 5.3.7). Though there was a higher 
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percentage of p-NF-H accumulations observed in the transduced motor neurons of 
the G93A SOD1 treatment groups (Control shRNA and Pin1 shRNA) at 90 days 
(pre-symptomatic stage) compared to the WT Pin1 shRNA mice, Pin1 
knockdown showed a higher percentage of transduced motor neurons without 
aberrant p-NF-H accumulations in the G93A SOD1 mice as compared to the 
Control shRNA treatment. Disease onset observed at 120 days resulted in a 
significant reduction in the number of transduced motor neurons without any p-
NF-H accumulations for the G93A SOD1 Control shRNA and Pin1 shRNA 
treated mice as compared to the WT Pin1 shRNA mice. However, there was still a 
partial rescue of the aberrant p-NF-H accumulations in the Pin1 shRNA 
transduced G93A SOD1 motor neurons, whereby there was a significant 
improvement in the reduction of p-NF-H accumulations in the transduced motor 
neurons as compared to the Control shRNA treated mice. At the late-stage of the 
disease (150 days old), the severity of the p-NF-H accumulations in the motor 
neurons of the G93A SOD1 Pin1 shRNA was similar to that of the G93A SOD1 
Control shRNA indicating that Pin1 knockdown was unable to prevent further p-
NF-H accumulations as the disease progression worsens. Contrary to previously 
published results that the loss of Pin1 in Pin1-/- mice resulted in loss of neurons 
and motor deficits, the results from this study showed that there no significant 
difference between the WT Pin1 shRNA and the WT saline treated mice (Liou et 
al., 2003). This indicates the possibility that temporal and spatial-specific Pin1 
knockdown could be beneficial for certain diseases. 
 
Though Pin1 knockdown was able to reduce p-NF-H accumulations in ALS mice, 
this effect could not rescue the motor neuron loss, activation of astrocytes or 
motor impairment observed in the mice suggesting that the mutant SOD1 gene 
expression resulted in such aggressive pathology, that even p-NF-H reduction was 
not sufficient to drive benefit. The continued progression of the disease and other 
pathologies in the G93A SOD1 mice lead to the eventual increase of the p-NF-H 
accumulations in the G93A SOD1 Pin1 shRNA treated mice at the late-stage of 
the disease. The exact mechanism involved in the neurodegeneration observed in 
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ALS has not been elucidated. In fact multiple pathways have been associated with 
the disease pathology observed in ALS, such as oxidative damage, excitotoxicity, 
mitochondrial dysfunction, intracellular aggregation, ER stress, impaired axonal 
transport and non-cell autonomous glia and microglia signalling (Cleveland and 
Rothstein 2001). Serial analysis of gene expression of mutant human SOD1 
protein on global gene expression in the spinal cord and lower brain stem of pre-
symptomatic G93A SOD1 transgenic mice has shown altered expression of genes 
involved in various biological processes including apoptosis, oxidative stress, 
ATP biosynthesis, myelination, and axonal transport (Guipponi et al., 2010). 
Activation of the mitochondrial-dependent apoptotic pathway and the activation 
of cytochrome c have been reported in mutant SOD1 mice even at pre-
symptomatic stage of 1 to 2 months old (Guegan et al., 2001). Therefore despite 
the observations of early pathological accumulations of p-NF-H in the ALS mice 
at pre-symptomatic stage, there could be other mechanisms involved in the ALS 















CHAPTER 6 CONCLUSION AND FUTURE STUDIES 
 
Accumulations of phosphorylated neurofilaments in the motor neurons of ALS 
patients and rodent models suggest impairment of the axonal transport of 
neurofilaments (Manetto et al., 1988; Munoz et al., 1988; Collard et al., 1995; 
Zhang et al., 1997; Williamson and Cleveland, 1999). Pin1 has been found to 
associate and co-localise with p-NF-H in ALS-affected spinal cord neuronal 
inclusions (Kesavapany et al., 2007). During neurological disorders such as ALS, 
hyperphosphorylated neurofilaments have been found to accumulate in the 
neuronal cell bodies, which otherwise during normal conditions, the 
neurofilament proteins are phosphorylated in the axonal compartment. Pin1 
inhibition during glutamate-mediated toxicity and oxidative stress, has been 
shown to rescue neurons from aberrant NF-H phosphorylation and cell death 
(Kesavapany et al., 2007; Rudrabhatla et al., 2008). This study determined that 
Pin1 knockdown in an ALS disease model using the G93A SOD1 mice was able 
to rescue the disease pathology of aberrant accumulations of p-NF-H.  
 
The initial experiments in this study validated the Pin1 knockdown efficiency of 
the Pin1 shRNA construct in vitro, in HEK 293T/17 cells and neurons. Following 
this, production and transduction efficiency of AAV2-Pin1 shRNA were 
evaluated to ensure sufficient transduction in vitro in neuronal cells and sustained 
expression of Pin1 silencing. Using AAV2-Pin1 shRNA for gene delivery in vivo, 
WT mice were intramuscularly injected and the spinal cords were collected to 
determine transduction efficiency of the AAV2-Pin1 shRNA into the spinal motor 
neurons. However, there was no transduction of AAV2-Pin1 shRNA into the 
spinal cord. Therefore, the transduction efficiencies of AAV serotypes 1, 2, 5, 6, 8 
and 9 in primary cortical neurons were compared to establish the AAV serotype 
with higher neuronal tropism. Intramuscular injections of the selected serotypes 
AAV 1, 6, 8 and 9 in WT mice determined that AAV9 had higher levels of motor 
neuron transduction in vivo with sustainable gene expression detected even at 3 
months post-administration. To determine the therapeutic window in which to 
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administer the AAV9-Pin1 shRNA, motor function studies and immunostaining 
of the pathological hallmarks such as astrogliosis, motor neuron loss and p-NF-H 
accumulations in the G93A SOD1 mice were performed. The results showed that 
p-NF-H accumulations appeared prior to motor function impairment and the onset 
of the other pathological hallmarks, such as astrocyte activation and motor neuron 
loss, therefore indicating that aberrant phosphorylation of neurofilaments is one of 
the earlier mechanisms in the ALS pathology and reducing the aberrant p-NF-H 
accumulations at the pre-symptomatic stage may alleviate the other symptoms 
observed. Intramuscular injections of AAV9-Pin1 shRNA into the G93A SOD1 
mice conferred no significant change in the motor performance and presentation 
of the disease pathological hallmarks (astrogliosis and motor neuron loss) 
compared to the G93A SOD1 controls (saline and Control shRNA). However, 
Pin1 knockdown in the transduced motor neurons of the G93A SOD1 mice 
showed reduced p-NF-H accumulations early in the disease progression indicating 
that Pin1 is crucial in modulating the p-NF-H accumulations in vivo and therefore 
may play an important role in the pathological hallmark formation in ALS. 
 
One drawback of this study was the transduction efficiency of the AAV9-Pin1 
shRNA in the spinal motor neurons. As shown in Chapter 4, the AAV9-Pin1 
shRNA was only able to transduce the spinal motor neurons in the lumbar section 
and it is unlikely that the upper motor neurons in the brain were transduced. 
However degenerative changes have been also reported in the cervical and 
thoracic spinal sections as well as cerebral cortex in the ALS mice (Tu et al., 
1996; Browne et al., 2006; Leichsenring et al., 2006). To properly determine if 
there is a significant benefit in Pin1 knockdown in the ALS pathology, improved 
gene delivery of the Pin1 shRNA into the other regions of the spinal cord and 
perhaps even to the motor cortex, would be crucial. Therefore AAV9-Pin1 
shRNA expression in only the lumbar cord of the G93A SOD1 mice is insufficient 
to elicit a significant benefit to alleviate the other disease pathologies. 
Additionally, immunostaining results of GFP expression in the AAV9 injected 
mice have revealed that a small portion of astrocytes were also transduced 
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together with the motor neuron population in the spinal cord (Appendix Figure 3). 
This has also been reported when AAV9 was administered via systemic and CSF 
delivery in non-human primates and rodents (Foust et al., 2009; Bevan et al., 
2011; Samaranch et al., 2012). The route of administration of AAV could also 
determine the population of cells transduced, whereby during retrograde transport 
of AAV from the muscle to the spinal motor neurons, it could be exposed to other 
cell types such as astrocytes, dorsal root ganglion cells and the gastrocnemius 
muscles. Another challenge encountered during this study was the age in which 
we could inject the AAV9 into the mice, which was limited by the earliest 
delivery age of the G93A SOD1 mice at about 7 weeks old from Jackson 
Laboratories. Due to regulatory limitations at the animal facility where this study 
was conducted, breeding of the G93A SOD1 mice to get an earlier timepoint could 
not be done during the period of this study. Targeting AAV9-Pin1 shRNA 
delivery into the spinal motor neurons at an earlier age could have better rescued 
the aberrant p-NF-H accumulations or even alleviate the other disease 
pathologies. 
 
This study has shown promising results for future experiments to further elucidate 
the role of Pin1 in ALS. By improving the gene delivery efficiency of Pin1 
knockdown in the spinal motor neurons of the G93A SOD1 mice, there could be 
possible rescue of the other disease pathology and improvement in the motor 
function in the ALS mice.  Self-complementary double-stranded AAV vectors 
have been reported to have good transduction efficiencies into the CNS. 
Intravenous delivery of self-complementary AAV9 vectors in adult mice has 
shown up to 28% transduction efficiency in the spinal motor neurons (Duque et 
al., 2009). Previous reports demonstrated successful gene delivery of self-
complementary AAV9 into the spinal motor neurons of spinal muscular atrophy 
(SMA) transgenic mice via facial vein injection at postnatal day 1 (Foust et al., 
2010; Dominguez et al., 2011; Valori et al., 2010). AAV9-survival motor neuron 
(SMN) delivery in SMA pups resulted in improved of motor function, extension 
of life span and rescue of the other disease pathology (Foust et al., 2010; 
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Dominguez et al., 2011; Valori et al., 2010). Another study reported that self-
complementary AAV9 is much more efficient than single stranded AAV9 for 
intravascular CNS delivery (Gray et al., 2011). Additionally, the use of an 
appropriate promoter for improved and sustained AAV gene transfer in the motor 
neurons is critical. As shown in this study, few astrocytes were also transduced by 
the AAV9-Pin1 shRNA. To eliminate this problem, a promoter region for motor 
neurons, such as the human neurofilament heavy chain or the HB9 promoter, can 
be used to drive the selective expression into motor neurons as has been 
previously demonstrated in a study to over-express mutant TDP-43 in motor 
neurons to produce an ALS rodent model (Huang et al. 2012). Another alternative 
is the production of a conditional Pin1 knockdown transgenic mouse model to 
temporally- and spatially-control the gene expression of Pin1 shRNA. Generation 
of the shRNA transgenic mice has been described previously and its use has been 
reported in the production of a mouse model of reversible insulin resistance 
generated by expression of an insulin receptor-specific shRNA (Seibler et al., 
2007; Hitz et al., 2009). Production of an inducible Hb9-driven Cre/lox-P Pin1 
shRNA transgenic mouse would enable Pin1 knockdown in the spinal motor 
neurons upon administration of an inducing agent (for example; doxycycline, 
tetracycline, RU486, or tamoxifen) at a desired time point. Crossing the 
conditional Pin1 knockdown mice with the G93A SOD1 mice would enable the 
study of Pin1 reduction in the spinal cord of the G93A SOD1 mice at desired time 
points. 
 
Since multiple pathways have been associated with the disease pathology in ALS, 
it would be more feasible to alleviate the disease by targeting multiple pathways 
together with Pin1 knockdown. Targeting p-NF-H accumulation alone might be 
insufficient to rescue the ALS pathology, especially in the G93A SOD1 mice, 
where the overexpression of mutant SOD1 in these transgenic animals is a more 
aggressive model compared to that found in ALS patients. Previous studies 
targeting SOD1 silencing has shown rescue of the disease pathology in the mutant 
SOD1 animals (Ralph et al., 2005; Saito et al., 2005). However, mutant SOD1 
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accounts for only 20% of the fALS patient population. Therefore considerations 
for targeting other and/or multiple pathways may be crucial in developing an 
effective therapy for the rescue of the ALS disease pathology. The use of an in 
vitro ALS model might enable further understanding into the role of Pin1 in the 
accumulations of p-NF-H as well as its effect on the other pathological hallmarks 
observed in ALS. Since this study has shown good transduction efficiencies of 
Pin1 shRNA in vitro, one suggestion would be to reduce Pin1 in vitro in the 
cultured G93A SOD1 spinal motor neurons and determine if there is any rescue of 
the ALS-related motor neuron death. Additionally, previous studies have used 
WT embryonic stem cell-derived motor neurons co-cultured with mutant SOD1 
astrocytes to model the ALS pathology in vitro (Di Giorgio et al., 2008; 
Marchetto et al., 2008).  Future studies using this in vitro ALS system could target 
Pin1 knockdown together with the other treatments such as IGF-1 or inhibition of 
mutant SOD1 to investigate the ALS pathologies especially in terms of p-NF-H 
accumulations.  
 
The production of small molecule Pin1 inhibitors has generated much interest due 
to its role in cancer. However, drug discovery against Pin1 has been rather 
challenging, with the major problem reported as finding verified hits as start 
points (Potter et al 2010). There have been recent publications from 
pharmaceutical companies, such as Pfizer and Vernalis disclosing the series of 
novel Pin1 inhibitors screened and the crystal structures (Guo et al. 2009; Potter et 
al 2010; Moore et al. 2013). For example, Pfizer had screened a million 
compounds against Pin1 and could not confirm any positive hits based on 
orthogonal assays such as nuclear magnetic resonance or isothermal calorimetry 
(Guo et al. 2009). Several problems encountered in the production of small 
molecule inhibitors include non-specific activity, insufficient potency, and 
structural limitations. Development of a confirmation assay to measure Pin1 
activity has also been rather challenging, as Pin1 catalyses a reversible reaction of 
both cis to trans, and trans to cis isomerisation, therefore reaction products of the 
assay are also substrates (Moore and Potter 2013). However, efforts are still 
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ongoing with significant progress made and there is much anticipation for the 
identification of improved inhibitors in the future. The improved design of Pin1 
inhibitors could also be applied into drug discovery for neurodegenerative 
disorders. 
 
This is the first study to uncover the role of Pin1 as a modulator to reduce p-NF-H 
phosphorylation in an ALS model in vivo. The results determined that knockdown 
of Pin1 could rescue the accumulations of p-NF-H in the spinal motor neurons in 
ALS. In AD however, reduction of Pin1 was shown to correlate with tau 
hyperphosphorylation and tangle formation (Holzer et al., 2002; Pastorino et al., 
2006). The difference observed between the two disease models could be due to 
the specific phosphorylated residues that are targeted in the different proteins. For 
example, Pin1 isomerisation of pThr231-Pro motif in tau facilitates its 
dephosphorylation by PP2A (Zhou et al., 2000). Phosphorylation of p-NF-H 
however, was reported to increase by addition of Pin1 as determined in an in vitro 
kinase assay (Rudrabhatla et al., 2008). The data generated here from this study 
has also shown that p-NF-H accumulation is an early pathology that occurs in the 
G93A SOD1 mice, and knockdown of Pin1 in the ALS motor neurons could 
reduce the accumulations of p-NF-H. Future studies with sufficient Pin1 
knockdown in the susceptible motor neurons of the ALS mice could result in 
alleviation of the disease pathology. This is supported by a previous publication 
that showed that deletion of the Ser/Thr-Pro rich tail domain of the NF-H and NF-
M in the mutant SOD1 mice resulted in the delay of disease onset and 
improvement in the survival of the mice (Lobsiger et al., 2005). This study reveals 
the involvement of Pin1 in the neurotoxic accumulations of p-NF-H found in 
ALS, suggesting that it can be used as an avenue to develop new therapies. 
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Appendix Figure 1. Construct backbone of Pin1 shRNA (top) and Control 
shRNA (bottom) indicating restriction digest sites, ampicillin resistance (Amp-R), 




Appendix Figure 2. Immunostaining of lumbar of G93A SOD1 Pin1 shRNA 
treated mouse at 135 days old with anti-GFP (green) and co-stained with anti-
GFAP (A) and anti-p-NF-H antibodies (B). Nuclear counterstaining was 
performed using DAPI (blue). Arrows indicate transduced motor neurons and 




Appendix Figure 3. Small portion of astrocytes were transduced by AAV9 
intramuscular injections into mice. Immunostaining of lumbar of AAV9-Pin1 
shRNA treated G93A SOD1 mouse with anti-GFP (green) and co-stained with 
anti-GFAP (red). Nuclear counterstaining was performed using DAPI (blue). 




Appendix Table 1. Mean values and SEM of immunoblot quantification and 
levels of Pin1 mRNA of Control shRNA and Pin1 shRNA transfected HEK 
293/T17 samples as presented in the graphs in Figure 3.3.1. 
 
Mean values and SEM of percentage Pin1 shRNA/tubulin protein 
levels normalized Control shRNA/tubulin (%) 
Days Mean values SEM 
1 82.5 10.1 
3 79.4 9.0 
5 37.2 3.6 
7 56.9 10.1 
 
Mean values and SEM of percentage Pin1 RNA expression of Pin1 
shRNA/Control shRNA (%) 
Days Mean values SEM 
1 51.7 3.3 
3 54.0 9.4 
5 29.5 1.2 
7 36.4 4.2 
 
 
Appendix Table 2. Mean values and SEM of immunoblot quantification and 
levels of Pin1 mRNA of AAV2-Control shRNA and AAV2-Pin1 shRNA 
transduced HEK 293/T17 samples as presented in the graphs in Figure 3.3.3. 
 
Mean values and SEM of percentage Pin1 shRNA/tubulin protein 
levels normalized Control shRNA/tubulin (%) 
Days Mean values SEM 
5 47.4 14.7 
8 54.2 9.2 
11 48.6 14.2 
14 71.1 16.9 
 
Mean values and SEM of percentage Pin1 RNA expression of Pin1 
shRNA/Control shRNA (%) 
Days Mean values SEM 
5 39.1 6.1 
8 48.8 11.3 
11 59.8 8.7 






Appendix Table 3. Mean values and SEM of percentage number of AAV2-
Control shRNA and AAV2-Pin1 shRNA transduced cortical neurons over total 
number of neurons as presented in the graph in Figure 3.3.4B. 
 
Mean values and SEM of percentage number of transduced Control 
shRNA and Pin1 shRNA cortical neurons over total number of 
neurons (%) 
Days AAV2-Control shRNA AAV2-Pin1 shRNA 
Mean values 
 
SEM Mean values 
 
SEM 
5 36.7 2.6 25.8 0.8 
8 39.4 3.1 28.8 3.3 
11 52.2 2.5 43.0 4.2 
14 48.5 1.5 45.9 2.4 
 
 
Appendix Table 4. Mean values and SEM of immunoblot quantification and 
levels of Pin1 mRNA of AAV2-Control shRNA and AAV2-Pin1 shRNA 
transduced cortical neuron samples as presented in the graphs in Figure 3.3.4D 
and E. 
 
Mean values and SEM of percentage Pin1 shRNA/tubulin protein 
levels normalized Control shRNA/tubulin (%) 
Days Mean values SEM 
5 51.3 8.8 
8 69.0 1.8 
11 50.9 3.8 
14 46.4 5.0 
 
Mean values and SEM of percentage Pin1 RNA expression of Pin1 
shRNA/Control shRNA (%) 
Days Mean values SEM 
5 57.3 6.8 
8 30.4 7.7 
11 52.9 3.6 











Appendix Table 5. Mean values and standard deviation of percentage 
transduction efficiency of different AAV serotypes in vitro in cortical neurons as 
presented in Figure 4.3.2B.   
 
Mean values of percentage transduction efficiency (%) 
Days AAV1 AAV2 AAV5 AAV6 AAV8 AAV9 
5 42.8 12.4 6.4 22.1 36.0 34.9 
8 64.0 21.3 7.8 54.4 49.2 37.1 
11 86.9 33.0 11.7 55.8 71.6 64.9 
14 77.9 51.4 17.6 69.8 80.8 77.2 
 
Standard deviation of percentage transduction efficiency (%) 
Days AAV1 AAV2 AAV5 AAV6 AAV8 AAV9 
5 1.7 3.5 2.5 7.5 5.5 3.9 
8 7.9 8.8 4.9 9.4 3.8 5.5 
11 4.9 0.9 8.2 8.3 5.5 1.8 
14 1.0 7.9 4.8 5.0 2.3 11.0 
 
 
Appendix Table 6. Mean values and standard deviation of percentage 
transduction efficiency of AAV1- and AAV9-Pin1 shRNA at different virus titers 
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Appendix Table 7. Mean values and standard deviation for rotarod, grip strength 
and gait analysis graphs presented in Figure 5.3.1. 
 
Mean values and standard deviation of stride time (ms) from gait analysis 
 
Days old 
WT G93A SOD1 
Mean values Standard 
deviation 
Mean values Standard 
deviation 
60 221 27.5 240 27.3 
90 205 30.6 201 23.9 
120 230 43.5 220 46.5 
150 205 20.0 341 36.5 
 
Mean values and standard deviation of stride length (mm) from gait analysis 
 
Days old 
WT G93A SOD1 
Mean values Standard 
deviation 
Mean values Standard 
deviation 
60 66 2.3 69 4.4 
90 70 7.1 68 4.3 
120 71 11.3 65 6.2 
150 65 11.1 36 6.7 
 
Mean values and standard deviation of grip strength (g) of forelimb 
 
Days old 
WT G93A SOD1 
Mean values Standard 
deviation 
Mean values Standard 
deviation 
60 45 9.2 49 11.7 
90 58 17.6 62 12.9 
120 57 7.9 45 14.9 
150 63 11.3 35 6.5 
 




WT G93A SOD1 
Mean values Standard 
deviation 
Mean values Standard 
deviation 
60 158 24.2 144 25.8 
90 137 24.8 140 27.6 
120 183 11.4 93 11.1 
150 199 36.3 68 10.1 
 
Mean values and standard deviation of latency to fall (sec) from rotarod 
 
Days old 
WT G93A SOD1 
Mean values Standard 
deviation 




60 300 0.0 280 16.1 
90 279 32.2 257 45.6 
120 283 13.5 158 48.7 
150 294 10.2 74 12.4 
 
 
Appendix Table 8. Mean values and standard deviation for quantification of 




WT G93A SOD1 
Mean values Standard 
deviation 
Mean values Standard 
deviation 
60 20 3.7 20 5.0 
90 23 2.9 13 1.4 
120 25 1.0 12 3.5 
150 27 1.0 8 1.5 
 
 
Appendix Table 9. Mean values and standard deviation for quantification of the 
percentage of ventral horn motor neurons with p-NF-H accumulation in the cell 













60 0.0 0.0 6.5 5.5 
90 1.3 2.8 32.0 16.4 
120 2.1 3.6 33.0 8.9 
150 2.5 5.0 37.0 9.3 
 
 
Appendix Table 10. Mean values and standard deviation for rotarod, grip 
strength and gait analysis studies performed in the WT saline, G93A SOD1 saline, 
WT Pin1 shRNA, G93A SOD1 Control shRNA and G93A SOD1 Pin1 shRNA 
treatment groups presented in Figure 5.3.4. 
 
Mean values of grip strength (g) of forelimb 
 
Days old 









60 73 64 62 72 60 
75 77 56 79 58 54 
90 74 61 69 51 59 
105 75 54 59 51 54 
120 76 45 66 51 51 
A8 
 
135 74 35 50 44 30 
150 63 32 61 39 26 
Standard deviation of grip strength (g) of forelimb 
 
Days old 









60 23.3 12.4 17.2 13.6 8.1 
75 13.3 12.1 15.1 8.6 12.8 
90 12.4 12.7 16.3 13.2 14.6 
105 35.0 13.8 18.9 14.8 20.7 
120 4.6 1.2 5.9 2.7 4.9 
135 23.0 6.1 9.1 7.0 10.7 
150 11.3 4.2 2.9 2.9 6.4 
 
Mean values of grip strength (g) of forelimb/hindlimb 
 
Days old 









60 232 183 225 177 182 
75 234 198 223 192 186 
90 248 203 243 181 201 
105 257 176 234 176 178 
120 293 148 269 160 160 
135 288 119 287 139 109 
150 295 90 282 111 91 
Standard deviation of grip strength (g) of forelimb/hindlimb 
 
Days old 









60 47.4 7.0 48.6 8.2 17.6 
75 35.2 2.8 24.5 8.5 13.8 
90 34.9 6.9 17.4 10.2 3.2 
105 33.2 22.1 15.1 22.0 9.3 
120 34.0 18.9 25.6 14.3 13.1 
135 27.1 3.0 44.1 11.9 41.2 
150 56.0 5.8 30.6 11.3 2.9 
 
Mean values of latency to fall (sec) from rotarod 
 
Days old 









60 291 287 290 288 285 
75 295 275 292 272 279 
90 291 265 279 247 271 
105 286 257 286 243 263 
A9 
 
120 280 197 275 200 196 
135 285 92 270 140 106 
150 264 29 263 78 8 
Standard deviation of latency to fall (sec) from rotarod 
 
Days old 









60 14.1 15.4 11.8 11.8 10.2 
75 7.7 25.0 17.1 6.7 11.6 
90 10.6 30.5 25.5 19.5 22.8 
105 19.0 32.7 25.9 42.7 18.0 
120 17.8 41.3 27.8 65.2 40.7 
135 11.9 25.5 36.9 10.6 35.4 
150 13.8 20.5 29.2 28.0 8.7 
 
 
Appendix Table 11. Mean values and standard deviation for quantification of 
average number of large motor neurons per section in the WT saline, G93A SOD1 
saline, WT Pin1 shRNA, G93A SOD1 Control shRNA and G93A SOD1 Pin1 
shRNA treatment groups presented in Figure 5.3.6B. 
 
Mean values of number of large motor neurons per section 
 
Days old 









90 20 11 22 13 11 
120 17 9 22 5 6 
150 20 6 22 8 7 
Standard deviation of number of large motor neurons per section 
 
Days old 









90 2.3 2.1 4.0 3.6 1.2 
120 2.5 4.1 7.6 2.2 2.1 











Appendix Table 12. Mean values and standard deviation for percentage of 
transduced cells with no p-NF-H accumulations in the cell bodies in the WT Pin1 
shRNA, G93A SOD1 Control shRNA and G93A SOD1 Pin1 shRNA treatment 
groups presented in Figure 5.3.7D. 
 
Mean percentage of transduced cells without perikaryal p-NF-H 
accumulations (%) 






90 90 77 86 
120 96 48 68 
150 97 49 54 
Standard deviation of the percentage of transduced cells without perikaryal 
p-NF-H accumulations (%) 






90 12.3 17.4 20.5 
120 6.7 11.8 9.7 
150 7.3 6.8 16.9 
 
